[go: up one dir, main page]

WO1993003012A1 - Indole derivatives - Google Patents

Indole derivatives Download PDF

Info

Publication number
WO1993003012A1
WO1993003012A1 PCT/JP1992/000981 JP9200981W WO9303012A1 WO 1993003012 A1 WO1993003012 A1 WO 1993003012A1 JP 9200981 W JP9200981 W JP 9200981W WO 9303012 A1 WO9303012 A1 WO 9303012A1
Authority
WO
WIPO (PCT)
Prior art keywords
salt
compound
formula
alkyl
defined above
Prior art date
Application number
PCT/JP1992/000981
Other languages
French (fr)
Inventor
Satoshi Okada
Kozo Sawada
Natsuko Kayakiri
Yuki Sawada
Hirokazu Tanaka
Masashi Hashimoto
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Priority to EP92916519A priority Critical patent/EP0600084A1/en
Priority to JP5503471A priority patent/JPH06511238A/en
Publication of WO1993003012A1 publication Critical patent/WO1993003012A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom

Definitions

  • the present invention relates to novel indole
  • novel indole derivatives and a pharmaceutically acceptable salt thereof which have pharmacological activities such as inhibitory activity on testosteron 5 ⁇ -reductase and the like, to process for preparation thereof, to a pharmaceutical composition comprising the same and to a use of the same as a medicament.
  • one object of the present invention is to provide novel indole derivatives and a
  • Another object of the present invention is to provide process for preparation of said indole derivatives or a salt thereof.
  • a further object of the present invention is to provide a pharmaceutical composition comprising, as an active ingredient, said indole derivatives or a
  • Still further object of the present invention is to provide a use of said indole derivatives or a
  • testosteron 5 ⁇ -reductase inhibitor useful for treating or preventing testosteron 5 ⁇ -reductase mediated diseases such as alopecia, acnes, prostatism, and the like in human being or animals.
  • testosteron 5 ⁇ -reductase inhibitor useful for treating or preventing testosteron 5 ⁇ -reductase mediated diseases such as alopecia, acnes, prostatism, and the like in human being or animals.
  • the indole derivatives of the present invention are novel and can be represented by the formula (I) :
  • R 1 is carboxy or protected carboxy
  • R 2 is hydrogen, lower alkyl or halogen
  • R 3 is aryl or ar( lower) alkyl, each of which may have suitable substituent(s), or a group of the formula : in which - is heterocyclic group
  • n 0 or 1
  • A is lower alkylene which may be substituted by oxo or lower alkenylene
  • Q is carbonyl, sulfonyl or lower alkylene
  • R 4 is hydrogen or lower alkyl
  • R 5 is hydrogen, lower alkyl or
  • Y is bond or lower alkylene
  • Z is bond, lower alkylene, lower alkenylene, -O-,
  • R 6 is lower alkyl, ar( lower) alkyl which may have suitable
  • X-Y-Z-R is 6H-dibenzo[b,d]pyranyl which may have suitable substituent(s).
  • the object compound (I) and a salt thereof can be prepared by the following processes.
  • R 1 , R 2 , R 3 , R 4 , R 5 , A, Q, X, Y and Z are each as defined above,
  • ar(lower)alkyl which may have suitable substituent(s) or a group of the formula :
  • R 7 is aryl which may have suitable substituent(s)
  • R 8 is carboxy protective group
  • R 9 is amino which may have suitable substituent(s)
  • W 1 , W 2 , W 3 and W 4 are each acid residue.
  • Y 1 is lower alkylene
  • Z 1 is -O-, -S- or
  • Z 2 is -O-, -S- or
  • Suitable salts of the compounds (I) are conventional non-toxic, pharmaceutically acceptable salt and may
  • a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g. sodium salt, potassium salt, cesium salt, etc.), an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g.
  • an inorganic acid addition salt e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.
  • an organic carboxylic or sulfonic acid addition salt e.g. formate, acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, etc.
  • a salt with a basic or acidic amino acid e.g.
  • lower is intended to mean 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, unless otherwise indicated.
  • Suitable “lower alkyl” may include straight or branched one, having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl,
  • halogen means fluoro, chloro, bromo and iodo.
  • Suitable "lower alkylene” means straight or branched bivalent lower alkane such as methylene, ethylene,
  • trimethylene tetramethylene, pentamethylene
  • Suitable "acid residue” may include halogen (e.g.
  • acyloxy e.g. acetoxy, tosyloxy, mesyloxy, etc.
  • aryloxy e.g. phenoxy, etc.
  • Suitable "lower alkenylene” may include one having 2 to 6 carbon atoms such as vinylene, propenylene, and the like.
  • substituent(s) may include a conventional group such as aryl (e.g. phenyl, naphthyl, etc.), substituted aryl, for example, lower alkylaryl (e.g. tolyl, xylyl, mesityl, cumenyl, isobutylphenyl, isopentylphenyl, etc.), haloaryl (e.g. chlorophenyl, bromophenyl, dichlorophenyl, etc.), lower alkoxyaryl (e.g. isopropoxyphenyl, etc.), lower alkylcarbamoylaryl (e.g. t-butylcarbamoylphenyl, etc.), and the like.
  • aryl e.g. phenyl, naphthyl, etc.
  • substituted aryl for example, lower alkylaryl (e.g. tolyl, xylyl, mesityl, cumenyl, iso
  • Suitable "ar(lower)alkyl which may have suitable substituent(s)” may include a conventional group such as ar(lower)alkyl (e.g. trityl, benzhydryl, benzyl,
  • ar(lower) alkyl for example, ar(lower) alkyl substituted by one or more substituents such as lower alkyl as mentioned above, halogen as mentioned above, cyano, carboxy, protected carboxy as mentioned below, aryl which may have suitable substituent(s) as mentioned above, amidated carboxy as mentioned below and oxo.
  • substituents such as lower alkyl as mentioned above, halogen as mentioned above, cyano, carboxy, protected carboxy as mentioned below, aryl which may have suitable substituent(s) as mentioned above, amidated carboxy as mentioned below and oxo.
  • aromatic(lower)alkyl which may have suitable substituents may be methylbenzyl, propylbenzyl,
  • Suitable "amino protective group” may be a
  • conventional protective group which is used in the field of organic chemistry, that is, may include acyl such as lower alkanoyl (e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, etc.), lower alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl,
  • acyl such as lower alkanoyl (e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, etc.), lower alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl,
  • Suitable "protected carboxy” may include an
  • esterified carboxy may be the ones such as lower alkyl ester (e.g. methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, tert-butyl ester, pentyl ester, hexyl ester, 1-cyclopropylethyl ester, etc.) which may have at least one suitable lower alkyl ester (e.g. methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, tert-butyl ester, pentyl ester, hexyl ester, 1-cyclopropylethyl ester, etc.) which may have at least one suitable
  • substituent(s) for example, lower alkanoyloxy(lower)alkyl ester (e.g. acetoxymethyl ester, propionyloxymethyl ester, butyryloxymethyl ester, valeryloxymethyl ester,
  • lower alkanoyloxy(lower)alkyl ester e.g. acetoxymethyl ester, propionyloxymethyl ester, butyryloxymethyl ester, valeryloxymethyl ester
  • alkanesulfonyl(lower) alkyl ester e.g. 2-mesylethyl ester, etc.
  • mono( or di or tri)-halo(lower)alkyl ester e.g.
  • alkyl-2-oxo-1,3-dioxol-4-yl) (lower)alkyl ester e.g.
  • lower alkenyl ester e.g. vinyl ester, allyl ester, etc.
  • lower alkynyl ester e.g. ethynyl ester, propynyl ester, etc.
  • ar(lower)alkyl ester which may have at least one suitable substituent(s) (e.g. benzyl ester,
  • substituent(s) e.g. phenyl ester, 4-chlorophenyl ester, tolyl ester, tert-butylphenyl ester, xylyl ester, mesityl ester, cumenyl ester, etc.
  • substituent(s) e.g. phenyl ester, 4-chlorophenyl ester, tolyl ester, tert-butylphenyl ester, xylyl ester, mesityl ester, cumenyl ester, etc.
  • phthalidyl ester e.g. phenyl ester, 4-chlorophenyl ester, tolyl ester, tert-butylphenyl ester, xylyl ester, mesityl ester, cumenyl ester, etc.
  • esterified carboxy as mentioned above may include lower alkoxycarbonyl (e.g.
  • Suitable “carboxy protective group” may be the ester moiety of the above defined “protected carboxy” and may include lower alkyl (e.g. methyl, ethyl, etc.),
  • ar(lower)alkyl e.g. benzyl, etc.
  • ar(lower)alkyl e.g. benzyl, etc.
  • pharmaceutical field may include amino, mono or
  • di(lower)alkylamino e.g. methylamino, dimethylamino, ethylamino, diethylamino, butylamino, t-butylamino, etc.
  • arylamino e.g. phenylamino, etc.
  • lower alkylarylamino e.g. isobutylphenylamino, etc.
  • Suitable "heterocyclic group containing nitrogen atom” may include saturated or unsaturated monocyclic or polycyclic heterocyclic group containing at least one nitrogen atom.
  • Especially preferable heterocyclic group may be 5- or 6- membered aliphatic heteromonocyclic group (e.g. morpholinyl, pyrrolidinyl, imidazolidinyl,
  • piperidyl, piperazinyl, etc. unsaturated condensed heterocyclic group such as dibenzo[6 or 7-membered unsaturated]heteromonocyclic group (e.g. phenoxazinyl, phenothiazinyl, 10,11-dihydro-5H-dibenzoazepinyl, etc.), and the like.
  • unsaturated condensed heterocyclic group such as dibenzo[6 or 7-membered unsaturated]heteromonocyclic group (e.g. phenoxazinyl, phenothiazinyl, 10,11-dihydro-5H-dibenzoazepinyl, etc.), and the like.
  • Suitable "amidated carboxy” may carbamoyl which may have suitable substituent( s) and may include carbamoyl, mono or di( lower)alkylcarbamoyl (e.g. methylcarbamoyl, dimethylcarbamoyl, ethylcarbamoyl diethylcarbamoyl, butylcarbamoyl, t-butylcarbamoyl, etc.), lower alkylaryl- carbamoyl (e.g. isobutylphenylcarbamoyl, etc.), and the like.
  • lower alkylaryl- carbamoyl e.g. isobutylphenylcarbamoyl, etc.
  • Suitable "6H-dibenzo[b,d]pyranyl which may have suitable substituent(s)" may include
  • 6H-dibenzo[b,d]pyranyl substituted by lower alkyl as mentioned above e.g. 8-isobutyl-3,4,6,6-tetramethyl-6H- dibenzo[b,d]pyranyl, etc., and the like.
  • R 1 , R 2 , R 3 , A, Q, X, Y and Z are as follows.
  • R 1 is carboxy;
  • alkoxycarbonyl e.g. methoxycarbonyl, ethoxycarbonyl, etc.
  • ar(lower)alkoxycarbonyl more preferably mono- or di- or triphenyl(C 1 -C 4 )alkoxycarbonyl (e.g.
  • R 2 is hydrogen
  • lower alkyl more preferably C 1 -C 4 alkyl (e.g.
  • R 3 is aryl which may be substituted by one to three substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, halogen and lower
  • alkylcarbamoyl more preferably phenyl which may be substituted by one to three substituent(s) selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halogen and C 1 -C 4 alkylcarbamoyl (e.g.
  • ar(lower) alkyl which may be substituted by one to three substituents selected from the group consisting of lower alkyl, halogen, cyano, carboxy, protected carboxy, amidated carboxy, and oxo, more preferably mono- or di- or triphenyK lower)alkyl which may be substituted by one or two the groups selected from lower alkyl, halogen, cyano, carboxy, phenyl(lower)- alkoxycarbonyl, mono or di(lower)alkylcarbamoyl, phenylcarbamoyl and lower alkylphenylcarbamoyl, most preferably mono- or di- or triphenyl(C 1 -C 6 )alkyl which may be substituted by the group selected from (C 1 -C 4 )alkyl, halogen, cyano, carboxy,
  • (C 1 -C 4 )alkylphenylcarbamoyl and oxo e.g. benzyl, propylbenzyl, isobutylbenzyl, isobutylphenylethyl, isobutylphenylpropyl, isobutylphenylpentyl,
  • A is lower alkylene which may be substituted by oxo, more preferably C 1 -C 4 alkylene which may be substituted by oxo (e.g. ethylene, trimethylene, oxotrimethylene, etc.); or
  • lower alkylene more preferably C 1 -C 4 alkylene (e.g. methylene, etc.),
  • R 4 is hydrogen; or lower alkyl, more
  • C 1 -C 4 alkyl e.g. methyl, etc.
  • R 5 is hydrogen; lower alkyl, more preferably C 1 -C 4 alkyl (e.g. methyl, etc.); or ar(lower)alkylamino which may be
  • alkylbenzylamino e.g.
  • Y is bond
  • lower alkylene more preferably C 1 -C 4 alkylene (e.g. methylene, etc.), and
  • lower alkylene more preferably C 1 -C 4 alkylene (e.g. methylene, etc.);
  • alkenylene more preferably C 2 -C 4 alkenylene (e.g. propenylene, etc.),
  • R 6 is lower alkyl, preferably
  • C 1 -C 4 alkyl e.g. methyl, ethyl, etc.
  • lower alkoxycarbonyl preferably C 1 -C 4 alkoxycarbonyl (e.g. t-butoxycarbonyl, etc.);
  • ar(lower)alkyl which may be substituted by lower alkyl, more preferably mono- or di- or triphenyKlower)alkyl which may be substituted by lower alkyl, most
  • triphenyl(C 1 -C 6 ) alkyl which may be
  • C 1 -C 4 alkyl e.g. benzyl, isobutylbenzyl, etc.
  • X-Y-Z-R 3 is 6H-dibenzo[b,d]pyranyl which may be substituted by lower alkyl, more preferably 6H-dibenzo[b,d]pyranyl
  • the object compound (I-a) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the compound (III) or a salt thereof.
  • This reaction is usually carried out in a solvent such as alcohol [e.g. methanol, ethanol, etc.],
  • the reaction may be carried out in the presence of an inorganic or an organic base such as an alkali metal hydroxide [e.g. sodium hydroxide, potassium hydroxide, etc.], an alkali metal carbonate [e.g. sodium carbonate, potassium carbonate, etc.], an alkali metal bicarbonate [e.g. sodium bicarbonate, potassium bicarbonate, etc.], alkali metal hydride (e.g. sodium hydride, potassium hydride, etc.), tri(lower)alkylamine [e.g. trimethylamine, triethylamine, diisopropylethylamine, etc.], pyridine or its derivative [e.g. picoline, lutidine,
  • an alkali metal hydroxide e.g. sodium hydroxide, potassium hydroxide, etc.
  • an alkali metal carbonate e.g. sodium carbonate, potassium carbonate, etc.
  • an alkali metal bicarbonate e.g. sodium bicarbonate, potassium bicarbonate
  • the base to be used is liquid, it can also be used as a solvent.
  • the reaction temperature is not critical, and the reaction can be carried out under cooling, at room
  • the object compound (I) or a salt thereof can be prepared by reacting the compound (IV) or a salt thereof with the compound (V) or a salt thereof.
  • reaction can be carried out in substantially the same manner as Process 1, and therefore the reaction mode and reaction conditions [e.g. solvents, reaction
  • the object compound (I-b) or a salt thereof can be prepared by reacting the compound (VI) or a salt thereof with the compound (VII) or a salt thereof.
  • reaction can be carried out in substantially the same manner as Process 1, and therefore the reaction mode and reaction conditions [e.g. solvents, reaction
  • the object compound (I-c) or a salt thereof can be prepared by reacting the compound (VII) or a salt thereof with the compound (III) or a salt thereof.
  • reaction can be carried out in substantially the same manner as Process 1, and therefore the reaction mode and reaction conditions [e.g. solvents, reaction
  • the present reaction includes, within its scope, the case that when R is carboxy, it is protected during the reacting or at the post-treating step of the present process.
  • the object compound (I-e) or a salt thereof can be prepared by subjecting the compound (I-d) or a salt thereof to elimination reaction of the carboxy protective group.
  • hydrolysis is preferably carried out in the presence of a base or an acid.
  • Suitable base may include, for example, an inorganic base such as alkali metal hydroxide (e.g. sodium bicarbonate), sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium
  • alkaline earth metal hydroxide e.g. magnesium hydroxide, calcium
  • alkali metal carbonate e.g. sodium carbonate, potassium carbonate, etc.
  • alkaline earth metal carbonate e.g. magnesium carbonate, calcium
  • alkali metal bicarbonate e.g. sodium bicarbonate, potassium bicarbonate, etc.
  • alkali metal acetate e.g. sodium acetate, potassium acetate, etc.
  • alkaline earth metal phosphate e.g. magnesium phosphate, calcium phosphate, etc.
  • alkali metal hydrogen phosphate e.g. disodium hydrogen phosphate, dipotassium hydrogen phosphate, etc.
  • an organic base such as trialkylamine (e.g. trimethylamine, triethylamine, etc.), picoline-, N-methylpyrrolidine, N-methylmorpholine,
  • the hydrolysis using a base is often carried out in water or a hydrophilic organic solvent or a mixed solvent thereof.
  • Suitable acid may include an organic acid (e.g.
  • formic acid acetic acid, propionic acid, etc.
  • an inorganic acid e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, etc.
  • the present hydrolysis is usually carried out in an organic solvent, water or a mixed solvent thereof.
  • the reaction temperature is not critical, and it may suitable be selected in accordance with the kind of the carboxy protective group and the elimination method.
  • the elimination using Lewis acid is preferable to eliminate substituted or unsubstituted ar(lower)alkyl ester and carried out by reacting the compound (Ig) or a salt thereof with Lewis acid such as boron trihalide (e.g. boron trichloride, boron trifluoride, etc.), titanium tetrahalide (e.g. titanium tetrachloride, titanium
  • tetrabromide e.g. tin
  • tetrachloride tin tetrabromide, etc.
  • aluminum halide e.g. aluminum chloride, aluminum bromide, etc.
  • trihaloacetic acid e.g. trichloroacetic acid
  • This elimination reaction is preferably carried out in the presence of cation trapping agents (e.g. anisole, phenol, etc.) and is usually carried out in a solvent such as nitroalkane (e.g. nitromethane, nitroethane, etc.), alkylene halide (e.g. methylene chloride, ethylene chloride, etc.), diethyl ether, carbon disulfide or any other solvent which does not adversely affect the reaction. These solvents may be used as a mixture thereof.
  • the reduction elimination can be applied preferably for elimination of the protective group such as
  • halo(lower)alkyl e.g. 2-iodoethyl, 2,2,2-trichloroethyl, etc.
  • ar(lower)alkyl e.g. benzyl, etc.
  • the reduction method applicable for the elimination reaction may include, for example, reduction by using a combination of a metal (e.g. zinc, zinc amalgam, etc.) or a salt of chromium compound (e.g. chromous chloride, chromous acetate, etc.) and an organic or an inorganic acid (e.g. acetic acid, propionic acid, hydrochloric acid, etc.); and conventional catalytic reduction in the
  • the reaction temperature is not critical, and the reaction is usually carried out under cooling, at ambient temperature or under warming.
  • the object compound (I-g) or a salt thereof can be prepared by subjecting the compound (I-f) or a salt thereof to elimination reaction of the carboxy protective group.
  • reaction can be carried out in substantially the same manner as Process 5, and therefore the reaction mode and reaction conditions [e.g. bases, acids, reducing agents, catalysts, solvents, reaction temperature, etc.] of this reaction are to be referred to those as explained in Process 5.
  • reaction mode and reaction conditions e.g. bases, acids, reducing agents, catalysts, solvents, reaction temperature, etc.
  • the object compound (I-h) or a salt thereof can be prepared by reacting a compound (I-g) or its reactive derivative at the carboxy group or a salt thereof with a compound (IX) or its reactive derivative at the amino group or a salt thereof.
  • Suitable reactive derivative at the amino group of the compound (IX) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (IX) wit a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (IX) with a silyl compound such as bis(trimethylsilyl)acetamide,
  • Suitable reactive derivative at the carboxy group of the compound (I-g) may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like.
  • Suitable examples of the reactive derivatives may be an acid chloride; an acid azide; a mixed acid anhydride within acid such as substituted phosphoric acid [e.g.
  • halogenated phosphoric acid, etc. dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid [e.g. methanesulfonic acid, etc.], aliphatic carboxylic acid [e.g. acetic acid, propionic acid, butyric acid, is ⁇ butyric acid, pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.] or aromatic carboxylic acid [e.g. benzoic acid, etc.]; a symmetrical acid anhydride; an activated amide with imidazole, 4-substituted imidazole,
  • dimethylpyrazole, triazole or tetrazole or an activated ester
  • N-hydroxy compound e.g. N,N-dimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridone, N-hydroxysuccinimide,
  • N-hydroxyphthalimide 1-hydroxy-1H-benzotriazole, etc.]
  • These reactive derivatives can optionally be selected from them according to the kind of the
  • the reaction is usually carried out in a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, dioxane, acetonitrile, chloroform,
  • a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, dioxane, acetonitrile, chloroform,
  • a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide;
  • N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide;
  • triphenylphosphine 2-ethyl-7-hydroxybenzisoxazolium salt
  • reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal bicarbonate, tri(lower)alkylamine, pyridine,
  • N-(lower)alkylmorpholine N,N-di(lower)alkylbenzylamine, or the like.
  • the reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.
  • the object compound (I-i) or a salt thereof can be prepared by reacting the compound (X) or a salt thereof with the compound (XI) or a salt thereof.
  • reaction can be carried out in substantially the same manner as Process 1, and therefore the reaction mode and reaction conditions [e.g. solvents, reaction
  • the present reaction includes, within its scope, the case that when R 1 is carboxy, it is protected during the reaction or at the post-treating step of the present process.
  • the object compound (I-d) or a salt thereof can be prepared by subjecting the compound (I-e) or a salt thereof to introduction reaction of the carboxy protective group.
  • reaction can be carried out in substantially the same manner as Process 1, and therefore the reaction mode and reaction conditions [e.g. solvent,s reaction
  • the starting compounds (II), (IV) and (VI) can be prepared by the details of which are shown in Preparations mentioned below, or a conventional manner.
  • the object compound (I) of the present invention can be isolated and purified in a conventional manner, for example, extraction, precipitation, fractional
  • the object compound (I) of the present invention is useful as a testosteron 5 ⁇ -reductase inhibitor and
  • testosteron 5 ⁇ -reductase mediated diseases such as prostatism, prostatic hypertrophy, prostatic cancer, alopecia, hirsutism (e.g. female hirsutism, etc.), androgenic alopecia (or male-pattern baldness), acne (e.g. acne vulgarism, pimple etc.), other hyperandrogenism, and the like.
  • Test Compound (1) 4-[1-[3-(3-Isobutylphenoxymethyl)benzoyl]indol-3-yl]- butyric acid
  • 1,2,6,7- 3 H-Testosterone (85-105 Ci/mmol) is a mixture of 1,2,6,7- 3 H-testosterone and testosterone which includes 85-105 Ci of 1,2,6,7- 3 H-testosterone per mmol of testosterone and is purchased from New
  • the reaction solution contains 1 mM dithiothreitol, 40 mM sodium phosphate pH 6.5, 50 ⁇ M NADPH,
  • the object compound (I) of the present invention are used in the form of conventional pharmaceutical preparation which contains said compound as an active ingredient, in admixture with pharmaceutically acceptable carriers such as an organic or inorganic solid or liquid excipient which is suitable for oral, parenteral and external
  • the pharmaceutical preparation may be in solid form such as tablet, granule, powder, capsule, or liquid form such as solution, suspension, syrup, emulsion, lemonade, lotion and the like.
  • auxiliary substances such as lactose, citric acid, tartaric acid, stearic acid,
  • magnesium stearate magnesium stearate, terra alba, sucrose, corn starch, talc, gelatin, agar, pectin, peanut oil, olive oil, cacao butter, ethylene glycol, and the like.
  • While the dosage of the compound (I) may vary from and also depend upon the age, conditions of the patient, a kind of diseases or conditions, a kind of the compound (I) to be applied, etc. In general amounts between 0.01 mg and about 500 mg or even more per day may be administered to a patient. An average single dose of about 0.05 mg, 0.1 mg, 0.25 mg, 0.5 mg, 1 mg, 20 mg, 50 rag, 100 mg of the object compound (I) of the present invention may be used in treating diseases.
  • dichloromethane 300 ml was added a solution of bromine (8.20 ml) in dichloromethane (20 ml) at -20°C. After stirred for 1.5 hours, the mixture was washed with water. The solution was dried over magnesium sulfate and the solvent was removed in vacuo. The residue was
  • Triphenylphosphine (7.23 g) was added to a mixture of 3-bromo-4,5-dimethylbenzyl alcohol (3.95 g) and carbon tetrabromide (9.14 g) in ether (100 ml) at 0°C, and the mixture was allowed to warm up to 25°C. The reaction mixture was stirred at 25°C for 2 hours, and then the precipitates were filtered off. The filtrate was washed with water and brine, and dried over magnesium sulfate. After evaporation of the solvent, the residue was
  • 1,4-cyclohexanedione mono-ethylene acetal (10.0 g) in tetrahydrofuran (100 ml). The mixture was stirred at room temperature for 3 days and partitioned between diethyl ether and water. The organic layer was washed with water, dried over magnesium sulfate and evaporated. The residue was purified by chromatography on silica gel (300 g) using a mixture of n-hexane and 5% ethyl acetate as the eluent. Appropriate fractions were combined and evaporated to give 4-(2-methyl-1-propylidene)cyclohexan ⁇ ne ethylene acetal (12.16 g) as a colorless oil.
  • tetrahydrofuran (30 ml) was added a solution of potassium tert-butoxide (1.67 g) in tetrahydrofuran (20 ml). The mixture was stirred at room temperature for 1 hour. To the mixture was added a solution of 3-bromobenzaldehyde (1.6 ml) in tetrahydrofuran (10 ml). The mixture was stirred at room temperature for 3 hours, and portioned between ethyl acetate and water. The organic layer was washed with water, dried over magnesium sulfate and then a solution of 4-isobutylcyclohexanone (2.0 g) in tetrahydrofuran (30 ml) was added at 25°C.
  • reaction mixture was poured into a mixture of ether and 1N hydrochloric acid. The organic layer was separated, washed with water and brine, and dried over magnesium sulfate.
  • triphenylphosphonium iodide (5.82 g) in tetrahydrofuran (50 ml) at 0°C.
  • the reaction mixture was allowed to warm up to 25°C and stirred at the same temperature for 1 hour .
  • a solution of methyl 3- ( 3-formylphenoxymethyl)benzoate (2.8 g) in tetrahydrofuran (20 ml) was added to the mixture at 0°C.
  • the reaction mixture was stirred at 0°C for 30 minutes and the solvent was evaporated off.
  • the residue was quenched with 1N hydrochloric acid and the mixture was extracted with ether.
  • the extract was washed with water and brine, and dried over magnesium sulfate. After evaporation of the solvent, the residue was
  • n-Butyl lithium (1.6 M solution in hexane) (6 ml) was added to a solution of bis(4-isobutylphenyl)methane (2.25 g) in tetrahydrofuran (20 ml). The mixture was stirred at room temperature for 5 hours and cooled at 0°C. To the mixture was added a solution of 4-bromobenzylbromide (2.0 g) in tetrahydrofuran (10 ml). The mixture was stirred at 0°C for 30 minutes and partitioned between ethyl acetate and water. The organic layer was washed with water, dried over magnesium sulfate and evaporated.
  • Acetic anhydride (20 ml) was added to a solution of bis (4-isobutylphenyl)methanol (11.07 g) in pyridine (40 ml). The mixture was stirred at room temperature for 5 hours and partitioned between ethyl acetate and water.
  • Acetyl chloride (0.94 ml) was added to a suspension of aluminum chloride (1.76 g) in dichloromethane (15 ml) at 3°C. The mixture was stirred at 3°C for 15 minutes. To the mixture was added a solution of 4-isobutylphenyl phenyl ether (2.67 g) in dichloromethane (15 ml). The mixture was stirred at 0°C for 1 hour and poured into 7% hydrochloric acid. The organic layer was washed with water, dried over magnesium sulfate and evaporated to give 4-(4-isobutylphenoxy)acetophenone (3.30 g) as a colourless oil.
  • Trifluoroacetic acid (10 ml) was added to a solution of methyl 3-[N-t-butoxycarbonyl-N-'(4-isobutylphenyl)- aminomethyl]benzoate (1.5 g) in dichloromethane (10 ml). The mixture was stirred at room temperature for 2 hours and evaporated. The residue was dissolved in
  • 6-chloroindole (3.0 g) in dichloromethane (20 ml) at 25°C.
  • the reaction mixture was stirred at 25°C for.1 hour, and poured into a mixture of ice and 1N hydrochloric acid.
  • reaction mixture was stirred at 25°C for 15 minutes and poured into a mixture of ethyl acetate and 1N hydrochloric acid.
  • the organic layer was separated, washed with water and brine, and dried over magnesium sulfate. After evaporation of the solvent, the residue was purified by column chromatography on silica gel (50 g) eluting with
  • Methyl 4-(6-chloroindol-3-yl)butyrate (1.2 g) was hydrolyzed with 1N aqueous solution of sodium hydroxide (12 ml) and the crude product was recrystallized from a mixture of ethyl acetate and hexane to give 4-(6- chloroindol-3-yl)butyric acid (1.09 g) as colorless crystals.
  • N,N-dimethylformamide (20 ml) was added to a suspension of sodium hydride (60% dispersion in mineral oil, 1.05 g) in N,N-dimethylformamide (30 ml) at 25°C over 15 minutes. The mixture was stirred at 25°C for 1.5 hours and cooled to -40°C. A solution of phenyl 3-(methoxymethoxy)benzoate (3.07 g) in tetrahydrofuran (40 ml) was added at -40°C over 30 minutes, and the mixture was stirred at the same temperature for 30 minutes.
  • Benzyl 4-[1-[4-(methoxymethoxy)benzoyl]indol-3-yl]- butyrate was dissolved in trifluoroacetic acid (12 ml) at 25°C and the mixture was stirred at the same temperature for 15 minutes. After evaporation of the solvent, the residue was dissolved with ethyl acetate, washed with aqueous sodium bicarbonate solution and brine, dried over magnesium sulfate, and evaporated.
  • Chloromethyl methyl ether (0.17 ml) was added to a mixture of 4-[1-[4-(4'-benzyloxycarbonyl)biphenylcarbonyl]indol-3-yl]butyric acid (0.55 g) and potassium carbonate (0.21 g) in dimethylformamide (10 ml). The mixture was stirred at room temperature for 5 hours and partitioned between ethyl acetate and water. The organic layer was washed with water, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (40 g) using a mixture of n-hexane and ethyl acetate (5:1) as an eluent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Indole derivatives of formula (I), or a salt thereof, which are useful as a testosteron 5α-reductase inhibitor.

Description

DESCRIPTION
INDOLE DERIVATIVES
The present invention relates to novel indole
derivatives and a pharmaceutically acceptable salt
thereof. More particularly, it relates to novel indole derivatives and a pharmaceutically acceptable salt thereof which have pharmacological activities such as inhibitory activity on testosteron 5α-reductase and the like, to process for preparation thereof, to a pharmaceutical composition comprising the same and to a use of the same as a medicament.
Accordingly, one object of the present invention is to provide novel indole derivatives and a
pharmaceutically acceptable salt thereof, which are useful as a testosteron 5α-reductase inhibitor.
Another object of the present invention is to provide process for preparation of said indole derivatives or a salt thereof.
A further object of the present invention is to provide a pharmaceutical composition comprising, as an active ingredient, said indole derivatives or a
pharmaceutically acceptable salt thereof.
Still further object of the present invention is to provide a use of said indole derivatives or a
pharmaceutically acceptable salt thereof as a medicament such as testosteron 5α-reductase inhibitor useful for treating or preventing testosteron 5α-reductase mediated diseases such as alopecia, acnes, prostatism, and the like in human being or animals. The indole derivatives of the present invention are novel and can be represented by the formula (I) :
Figure imgf000004_0001
wherein R1 is carboxy or protected carboxy,
R2 is hydrogen, lower alkyl or halogen, R3 is aryl or ar( lower) alkyl, each of which may have suitable substituent(s), or a group of the formula :
Figure imgf000004_0002
in which - is heterocyclic group
Figure imgf000004_0004
containing nitrogen atom, and n is 0 or 1,
A is lower alkylene which may be substituted by oxo or lower alkenylene,
Q is carbonyl, sulfonyl or lower alkylene,
Figure imgf000004_0003
in which R4 is hydrogen or lower alkyl, and
R5 is hydrogen, lower alkyl or
Y-Z-R3, Y is bond or lower alkylene,
Z is bond, lower alkylene, lower alkenylene, -O-,
Figure imgf000005_0002
in which R6 is lower alkyl, ar( lower) alkyl which may have suitable
substituent( s) or amino
protective group; or
3
X-Y-Z-R is 6H-dibenzo[b,d]pyranyl which may have suitable substituent(s).
According to the present invention, the object compound (I) and a salt thereof can be prepared by the following processes.
Process 1
Figure imgf000005_0001
or a salt thereof or a salt thereof
Figure imgf000006_0001
(I-a)
or a salt thereof
Process 2
Figure imgf000006_0002
(V)
(IV) or a salt thereof or a salt thereof
Figure imgf000006_0003
(I)
or a salt thereof Process 3
Figure imgf000007_0001
(VI) (VII) or a salt thereof or a salt thereof
Figure imgf000007_0002
(I-b)
or a salt thereof
Process 4
Figure imgf000007_0003
(VIII) (III) or a salt thereof or a salt thereof
Figure imgf000008_0001
(I-C)
or a salt thereof
Process 5
Elimination of the carboxy protective group
Figure imgf000008_0003
Figure imgf000008_0002
(I-d)
or a salt thereof
Figure imgf000008_0004
(I-e)
or a salt thereof Process 6
Elimination of the carboxy protective group
Figure imgf000009_0002
Figure imgf000009_0001
(I-f)
or a salt thereof
Figure imgf000009_0003
(I-g)
or a salt thereof
Process 7
+ H - R9
(VII) or its reactive
Figure imgf000009_0004
derivative at the amino group
(I-g) or a salt thereof or its reactive derivative
at the carboxy group
or a salt thereof
Figure imgf000010_0001
(I-h)
or a salt thereof
Process 8
Figure imgf000010_0002
(X) (XI) or a salt thereof or a salt thereof
Figure imgf000010_0003
(I-i)
or a salt thereof Process 9
Introduction of the carboxy
protective group
Figure imgf000011_0003
Figure imgf000011_0002
(I-e)
or a salt thereof
Figure imgf000011_0001
(I-d)
or a salt thereof wherein R 1, R2, R3, R4, R5, A, Q, X, Y and Z are each as defined above,
is protected carboxy,
is ar(lower)alkyl which may have suitable
Figure imgf000011_0006
substituent(s) or a group of the formula :
Figure imgf000011_0004
in which - and n are each as defined
Figure imgf000011_0005
above,
is lower alkyl,
Figure imgf000011_0007
ar(lower)alkyl which may have suitable substituent(s) or amino protective group, R7 is aryl which may have suitable substituent(s), R8 is carboxy protective group. R9 is amino which may have suitable substituent(s),
W 1, W2, W3 and W4 are each acid residue.
Y1 is lower alkylene,
Z1 is -O-, -S- or
Figure imgf000012_0001
in which is lower alkyl or amino
Figure imgf000012_0003
protective group, and Z2 is -O-, -S- or
Figure imgf000012_0002
in which R6 is as defined above.
Suitable salts of the compounds (I) are conventional non-toxic, pharmaceutically acceptable salt and may
include a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g. sodium salt, potassium salt, cesium salt, etc.), an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g.
triethylamine salt, pyridine salt, picoline salt,
ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.), etc.;
an inorganic acid addition salt (e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.);
an organic carboxylic or sulfonic acid addition salt (e.g. formate, acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, etc.); a salt with a basic or acidic amino acid (e.g.
arginine, aspartic acid, glutamic acid, etc.);
and the like, and the preferable example thereof is an acid addition salt.
With respect to the salt of the compounds (I-a) to (I-i), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X) and (XI) in Processes 1 to 9, the suitable examples of the salts of these compounds are to be referred to those as exemplified for the object compound (I).
In the above and subsequent descriptions of the present specification, suitable examples and illustrations of the various definitions which the present invention include within the scope thereof are explained in detail as follows.
The term "lower" is intended to mean 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, unless otherwise indicated.
Suitable "lower alkyl" may include straight or branched one, having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl,
t-butyl, pentyl, hexyl, and the like, preferably one having 1 to 4 carbon atoms.
The term "halogen" means fluoro, chloro, bromo and iodo.
Suitable "lower alkylene" means straight or branched bivalent lower alkane such as methylene, ethylene,
trimethylene, tetramethylene, pentamethylene,
hexamethylene, propylene, and the like, which may be substituted by oxo.
Suitable "acid residue" may include halogen (e.g.
fluoro, chloro, bromo, iodo), acyloxy (e.g. acetoxy, tosyloxy, mesyloxy, etc.), aryloxy (e.g. phenoxy, etc.) and the like.
Suitable "lower alkenylene" may include one having 2 to 6 carbon atoms such as vinylene, propenylene, and the like.
Suitable "aryl which may have suitable
substituent(s)" may include a conventional group such as aryl (e.g. phenyl, naphthyl, etc.), substituted aryl, for example, lower alkylaryl (e.g. tolyl, xylyl, mesityl, cumenyl, isobutylphenyl, isopentylphenyl, etc.), haloaryl (e.g. chlorophenyl, bromophenyl, dichlorophenyl, etc.), lower alkoxyaryl (e.g. isopropoxyphenyl, etc.), lower alkylcarbamoylaryl (e.g. t-butylcarbamoylphenyl, etc.), and the like.
Suitable "ar(lower)alkyl which may have suitable substituent(s)" may include a conventional group such as ar(lower)alkyl (e.g. trityl, benzhydryl, benzyl,
phenethyl, naphthylmethyl, etc.), substituted
ar(lower) alkyl, for example, ar(lower) alkyl substituted by one or more substituents such as lower alkyl as mentioned above, halogen as mentioned above, cyano, carboxy, protected carboxy as mentioned below, aryl which may have suitable substituent(s) as mentioned above, amidated carboxy as mentioned below and oxo. Specific examples of thus defined "ar(lower)alkyl which may have suitable substituents" may be methylbenzyl, propylbenzyl,
isobutylbenzyl, methylphenylethyl, isobutylphenylethyl, methylphenylpropyl, isobutylphenylpropyl,
methylphenylpentyl, isobutylphenylpentyl,
bis (methylphenyl)methyl, bis(propylphenyl)methyl,
bis(butylphenyl)methyl, bis (isobutylphenyl)methyl,
bis(chlorophenyl)methyl, (cyano)(isobutylphenyl)methyl, (carboxy)(isobutylphenyl)methyl,
(benzyloxycarbonyl) (isobutylphenyl)methyl,
(N,N-diethylcarbamoyl) (isobutylphenyl)methyl,
(t-butylcarbamoyl) (isobutylphenyl)ήiethyl,
(phenylcarbamoyl) (isobutylphenyl)methyl,
(isobutylphenylcarbamoyl) (isobutylphenyl)methyl, etc.], benzoyl, isobutylbenzoyl, and the like.
Suitable "amino protective group" may be a
conventional protective group, which is used in the field of organic chemistry, that is, may include acyl such as lower alkanoyl (e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, etc.), lower alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl,
t-butoxycarbonyl, etc.), and the like.
Suitable "protected carboxy" may include an
esterified carboxy group.
Suitable examples of the ester moiety of an
"esterified carboxy" may be the ones such as lower alkyl ester (e.g. methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, tert-butyl ester, pentyl ester, hexyl ester, 1-cyclopropylethyl ester, etc.) which may have at least one suitable
substituent(s), for example, lower alkanoyloxy(lower)alkyl ester (e.g. acetoxymethyl ester, propionyloxymethyl ester, butyryloxymethyl ester, valeryloxymethyl ester,
pivaloyloxymethyl ester, hexanoyloxymethyl ester, 1(or
2)-acetoxyethyl ester, 1(or 2 or 3)-acetoxypropyl ester,
1(or 2 or 3 or 4)-acetoxybutyl ester,1(or
2)-propionyloxyethyl ester, 1(or 2 or
3)-propionyloxypropyl ester, 1(or 2)-butyryloxyethyl ester, 1(or 2)-isobutyryloxyethyl ester, 1(or
2)-pivaloyloxyethyl ester, 1(or 2)-hexanoyloxyethyl ester, isobutyryloxymethyl ester, 2-ethylbutyryloxymethyl ester, 3,3-dimethylbutyryloxymethyl ester, 1(or
2)-pentanoyloxyethyl ester, etc.) lower
alkanesulfonyl(lower) alkyl ester (e.g. 2-mesylethyl ester, etc.), mono( or di or tri)-halo(lower)alkyl ester (e.g.
2-iodoethyl ester, 2,2,2-trichloroethyl ester, etc.), lower alkoxycarbonyloxy(lower)alkyl ester (e.g.
methoxycarbonyloxymethyl ester, ethoxycarbonyloxymethyl ester, 2-methoxycarbonyloxyethyl ester,
1-ethoxycarbonyloxyethyl ester,
1-isopropoxycarbonyloxyethyl ester, etc.),
phtahlidylidene(lower)alkyl ester, or (5-lower
alkyl-2-oxo-1,3-dioxol-4-yl) (lower)alkyl ester (e.g.
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester. (5-ethyl-2-oxo-1,3-dioxol-4-yl)methyl ester,
(5-propyl-2-oxo-1,3-dioxol-4-yl)ethyl ester, etc.;
lower alkenyl ester (e.g. vinyl ester, allyl ester, etc.); lower alkynyl ester (e.g. ethynyl ester, propynyl ester, etc.); ar(lower)alkyl ester which may have at least one suitable substituent(s) (e.g. benzyl ester,
4-methoxybenzyl ester, 4-nitrobenzyl ester, phenethyl ester, trityl ester, benzhydryl ester,
bis(methoxyphenyl)methyl ester, 3,4-dimethoxybenzyl ester, 4-hydroxy-3,5-di-tert-butylbenzyl ester, etc.);
aryl ester which may have at least one suitable
substituent(s) (e.g. phenyl ester, 4-chlorophenyl ester, tolyl ester, tert-butylphenyl ester, xylyl ester, mesityl ester, cumenyl ester, etc.); phthalidyl ester; and the like.
Preferable examples of the esterified carboxy as mentioned above may include lower alkoxycarbonyl (e.g.
methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,
isopropoxycarbonyl butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl,
tert-pentyloxycarbonyl, hexyloxycarbonyl,
1-cyclopropylethoxycarbonyl, etc.).
Suitable "carboxy protective group" may be the ester moiety of the above defined "protected carboxy" and may include lower alkyl (e.g. methyl, ethyl, etc.),
ar(lower)alkyl (e.g. benzyl, etc.), and the like.
Suitable "amino which may have suitable
substituent(s)" is conventional one used in a
pharmaceutical field and may include amino, mono or
di(lower)alkylamino (e.g. methylamino, dimethylamino, ethylamino, diethylamino, butylamino, t-butylamino, etc.), arylamino (e.g. phenylamino, etc.), lower alkylarylamino (e.g. isobutylphenylamino, etc.), and the like.
Suitable "heterocyclic group containing nitrogen atom" may include saturated or unsaturated monocyclic or polycyclic heterocyclic group containing at least one nitrogen atom. Especially preferable heterocyclic group may be 5- or 6- membered aliphatic heteromonocyclic group (e.g. morpholinyl, pyrrolidinyl, imidazolidinyl,
piperidyl, piperazinyl, etc.), unsaturated condensed heterocyclic group such as dibenzo[6 or 7-membered unsaturated]heteromonocyclic group (e.g. phenoxazinyl, phenothiazinyl, 10,11-dihydro-5H-dibenzoazepinyl, etc.), and the like.
Suitable "amidated carboxy" may carbamoyl which may have suitable substituent( s) and may include carbamoyl, mono or di( lower)alkylcarbamoyl (e.g. methylcarbamoyl, dimethylcarbamoyl, ethylcarbamoyl diethylcarbamoyl, butylcarbamoyl, t-butylcarbamoyl, etc.), lower alkylaryl- carbamoyl (e.g. isobutylphenylcarbamoyl, etc.), and the like.
Suitable "6H-dibenzo[b,d]pyranyl which may have suitable substituent(s)" may include
6H-dibenzo[b,d]pyranyl substituted by lower alkyl as mentioned above (e.g. 8-isobutyl-3,4,6,6-tetramethyl-6H- dibenzo[b,d]pyranyl, etc.), and the like.
Particularly, the preferred embodiments of
R 1, R2, R3, A, Q, X, Y and Z are as follows. R1 is carboxy;
lower alkoxycarbonyl, more preferably C1-C4
alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, etc.); or
ar(lower)alkoxycarbonyl, more preferably mono- or di- or triphenyl(C1-C4)alkoxycarbonyl (e.g.
benzyloxycarbonyl, etc.),
R2 is hydrogen;
lower alkyl, more preferably C1-C4 alkyl (e.g.
methyl, etc.); or
halogen (e.g. chloro, etc.), R3 is aryl which may be substituted by one to three substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, halogen and lower
alkylcarbamoyl more preferably phenyl which may be substituted by one to three substituent(s) selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halogen and C1-C4 alkylcarbamoyl (e.g.
phenyl, isobutylphenyl, isopentylphenyl,
isopropoxyphenyl, bromophenyl, dichlorophenyl, t-butylcarbamoylphenyl, etc.);
ar(lower) alkyl which may be substituted by one to three substituents selected from the group consisting of lower alkyl, halogen, cyano, carboxy, protected carboxy, amidated carboxy, and oxo, more preferably mono- or di- or triphenyK lower)alkyl which may be substituted by one or two the groups selected from lower alkyl, halogen, cyano, carboxy, phenyl(lower)- alkoxycarbonyl, mono or di(lower)alkylcarbamoyl, phenylcarbamoyl and lower alkylphenylcarbamoyl, most preferably mono- or di- or triphenyl(C1-C6)alkyl which may be substituted by the group selected from (C1-C4)alkyl, halogen, cyano, carboxy,
phenyl(C1-C4)alkoxycarbonyl, mono or
di(C1-C4)alkylcarbamoyl, phenylcarbamoyl,
(C1-C4)alkylphenylcarbamoyl and oxo (e.g. benzyl, propylbenzyl, isobutylbenzyl, isobutylphenylethyl, isobutylphenylpropyl, isobutylphenylpentyl,
bis(isobutylphenyl)methyl, dichlorobenzyl,
bis(chlorophenyl)methyl,
(cyano) (isobutylphenyl)methyl,
(carboxy) (isobutylphenyl)methyl, (benzyloxycarbonyl)- (isobutylphenyl)methyl, (N,N-diethylcarbamoyl)- ( isobutylphenyl)methyl, (t-butylcarbamoy1)- (isobutylphenyl)methyl, (phenylcarbamoyl)- (isobutylphenyl)methyl, (isobutylphenylcarbamoyl)- (isobutylphenyl)methyl, benzoyl, isobutylbenzoyl, etc.);
5- or 6- membered aliphatic heteromonocycliccarbonyl
(e.g. piperidylcarbonyl, etc.); or
unsaturated condensed heterocyclic group (e.g.
phenoxazinyl, phenothiazinyl, 10,11-dihydro-5H- dibenzo[b,f]azepinyl, etc.),
A is lower alkylene which may be substituted by oxo, more preferably C1-C4 alkylene which may be substituted by oxo (e.g. ethylene, trimethylene, oxotrimethylene, etc.); or
lower alkenylene, more preferably C2-C4 alkenylene
(e.g. propenylene, etc.),
Q is carbonyl;
sulfonyl; or
lower alkylene, more preferably C1-C4 alkylene (e.g. methylene, etc.),
X is
Figure imgf000019_0001
in which R4 is hydrogen; or lower alkyl, more
preferably C1-C4 alkyl (e.g. methyl, etc.),
R5 is hydrogen; lower alkyl, more preferably C1-C4 alkyl (e.g. methyl, etc.); or ar(lower)alkylamino which may be
substituted by the group(s) selected from lower alkyl or lower alkoxycarbonyl, more preferably C1-C4 alkylbenzylamino or N-C1-C4 alkoxycarbonyl-N-C1-C4
alkylbenzylamino (e.g.
isobutylbenzylamino, N-t-butoxycarbonyl-N-isobutylbenzylamino, etc.),
Y is bond; or
lower alkylene, more preferably C1-C4 alkylene (e.g. methylene, etc.), and
Z is bond;
lower alkylene, more preferably C1-C4 alkylene (e.g. methylene, etc.);
lower alkenylene, more preferably C2-C4alkenylene (e.g. propenylene, etc.),
O ;
S; or
N-R6
in which R6 is lower alkyl, preferably
C1-C4 alkyl (e.g. methyl, ethyl, etc.); lower alkoxycarbonyl, preferably C1-C4 alkoxycarbonyl (e.g. t-butoxycarbonyl, etc.);
ar(lower)alkyl which may be substituted by lower alkyl, more preferably mono- or di- or triphenyKlower)alkyl which may be substituted by lower alkyl, most
preferably mono- or di- or
triphenyl(C1-C6) alkyl which may be
substituted by C1-C4 alkyl (e.g. benzyl, isobutylbenzyl, etc.); or
X-Y-Z-R3 is 6H-dibenzo[b,d]pyranyl which may be substituted by lower alkyl, more preferably 6H-dibenzo[b,d]pyranyl
substituted by C1-C4 alkyl (e. g.
8-isobutyl-3,4,6,6-tetramethyl-6H- dibenzo[b,d]pyranyl, etc.).
The processes 1 to 9 for preparing the object
compound (I) of the present invention are explained in detail in the fo llowing. Process 1
The object compound (I-a) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the compound (III) or a salt thereof.
This reaction is usually carried out in a solvent such as alcohol [e.g. methanol, ethanol, etc.],
dichloromethane, benzene, N,N-dimethylformamide,
tetrahydrofuran, diethyl ether or any other solvent which does not adversely affect the reaction.
The reaction may be carried out in the presence of an inorganic or an organic base such as an alkali metal hydroxide [e.g. sodium hydroxide, potassium hydroxide, etc.], an alkali metal carbonate [e.g. sodium carbonate, potassium carbonate, etc.], an alkali metal bicarbonate [e.g. sodium bicarbonate, potassium bicarbonate, etc.], alkali metal hydride (e.g. sodium hydride, potassium hydride, etc.), tri(lower)alkylamine [e.g. trimethylamine, triethylamine, diisopropylethylamine, etc.], pyridine or its derivative [e.g. picoline, lutidine,
4-dimethylaminopyridine, etc.], or the like. In case that the base to be used is liquid, it can also be used as a solvent.
The reaction temperature is not critical, and the reaction can be carried out under cooling, at room
temperature or under warming or heating.
Process 2
The object compound (I) or a salt thereof can be prepared by reacting the compound (IV) or a salt thereof with the compound (V) or a salt thereof.
This reaction can be carried out in substantially the same manner as Process 1, and therefore the reaction mode and reaction conditions [e.g. solvents, reaction
temperature, etc.] of this reaction are to be referred to those as explained in Process 1. Process 3
The object compound (I-b) or a salt thereof can be prepared by reacting the compound (VI) or a salt thereof with the compound (VII) or a salt thereof.
This reaction can be carried out in substantially the same manner as Process 1, and therefore the reaction mode and reaction conditions [e.g. solvents, reaction
temperature, etc.] of this reaction are to be referred to those as explained in Process 1.
Process 4
The object compound (I-c) or a salt thereof can be prepared by reacting the compound (VII) or a salt thereof with the compound (III) or a salt thereof.
This reaction can be carried out in substantially the same manner as Process 1, and therefore the reaction mode and reaction conditions [e.g. solvents, reaction
temperature, etc.] of this reaction are to be referred to those as explained in Process 1.
The present reaction includes, within its scope, the case that when R is carboxy, it is protected during the reacting or at the post-treating step of the present process. Process 5
The object compound (I-e) or a salt thereof can be prepared by subjecting the compound (I-d) or a salt thereof to elimination reaction of the carboxy protective group.
in the present elimination reaction, all conventional methods used in the elimination reaction of the carboxy protective group, for example, hydrolysis, reduction, elimination using Lewis acid, etc. are applicable. When the carboxy protective group is an ester, it can be
eliminated by hydrolysis or elimination using Lewis acid. The hydrolysis is preferably carried out in the presence of a base or an acid.
Suitable base may include, for example, an inorganic base such as alkali metal hydroxide (e.g. sodium
hydroxide, potassium hydroxide, etc.), alkaline earth metal hydroxide (e.g. magnesium hydroxide, calcium
hydroxide, etc.), alkali metal carbonate (e.g. sodium carbonate, potassium carbonate, etc.), alkaline earth metal carbonate (e.g. magnesium carbonate, calcium
carbonate, etc.), alkali metal bicarbonate (e.g. sodium bicarbonate, potassium bicarbonate, etc.), alkali metal acetate (e.g. sodium acetate, potassium acetate, etc.), alkaline earth metal phosphate (e.g. magnesium phosphate, calcium phosphate, etc.), alkali metal hydrogen phosphate (e.g. disodium hydrogen phosphate, dipotassium hydrogen phosphate, etc.), or the like, and an organic base such as trialkylamine (e.g. trimethylamine, triethylamine, etc.), picoline-, N-methylpyrrolidine, N-methylmorpholine,
1,5-diazabicyclo[4.3.0]non-5-one,
1,4-diazabicyclo[2.2.2]octane,
1,5-diazabicyclo[5.4.0]undecene-5 or the like.
The hydrolysis using a base is often carried out in water or a hydrophilic organic solvent or a mixed solvent thereof.
Suitable acid may include an organic acid (e.g.
formic acid, acetic acid, propionic acid, etc.) and an inorganic acid (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, etc.).
The present hydrolysis is usually carried out in an organic solvent, water or a mixed solvent thereof.
The reaction temperature is not critical, and it may suitable be selected in accordance with the kind of the carboxy protective group and the elimination method. The elimination using Lewis acid is preferable to eliminate substituted or unsubstituted ar(lower)alkyl ester and carried out by reacting the compound (Ig) or a salt thereof with Lewis acid such as boron trihalide (e.g. boron trichloride, boron trifluoride, etc.), titanium tetrahalide (e.g. titanium tetrachloride, titanium
tetrabromide, etc.), tin tetrahalide (e.g. tin
tetrachloride, tin tetrabromide, etc.), aluminum halide (e.g. aluminum chloride, aluminum bromide, etc.),
trihaloacetic acid (e.g. trichloroacetic acid,
trifluoroacetic acid, etc.) or the like. This elimination reaction is preferably carried out in the presence of cation trapping agents (e.g. anisole, phenol, etc.) and is usually carried out in a solvent such as nitroalkane (e.g. nitromethane, nitroethane, etc.), alkylene halide (e.g. methylene chloride, ethylene chloride, etc.), diethyl ether, carbon disulfide or any other solvent which does not adversely affect the reaction. These solvents may be used as a mixture thereof.
The reduction elimination can be applied preferably for elimination of the protective group such as
halo(lower)alkyl (e.g. 2-iodoethyl, 2,2,2-trichloroethyl, etc.) ester, ar(lower)alkyl (e.g. benzyl, etc.) ester or the like.
The reduction method applicable for the elimination reaction may include, for example, reduction by using a combination of a metal (e.g. zinc, zinc amalgam, etc.) or a salt of chromium compound (e.g. chromous chloride, chromous acetate, etc.) and an organic or an inorganic acid (e.g. acetic acid, propionic acid, hydrochloric acid, etc.); and conventional catalytic reduction in the
pressure of a conventional metallic catalyst (e.g.
palladium carbon, Raney nickel, etc.).
The reaction temperature is not critical, and the reaction is usually carried out under cooling, at ambient temperature or under warming.
Process 6
The object compound (I-g) or a salt thereof can be prepared by subjecting the compound (I-f) or a salt thereof to elimination reaction of the carboxy protective group.
This reaction can be carried out in substantially the same manner as Process 5, and therefore the reaction mode and reaction conditions [e.g. bases, acids, reducing agents, catalysts, solvents, reaction temperature, etc.] of this reaction are to be referred to those as explained in Process 5. Process 7
The object compound (I-h) or a salt thereof can be prepared by reacting a compound (I-g) or its reactive derivative at the carboxy group or a salt thereof with a compound (IX) or its reactive derivative at the amino group or a salt thereof.
Suitable reactive derivative at the amino group of the compound (IX) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (IX) wit a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (IX) with a silyl compound such as bis(trimethylsilyl)acetamide,
mono(trimethylsilyl)acetamide, bis(trimethylsilyl)urea or the like; a derivative formed by reaction of the compound (IX) with phosphorus trichloride or phosgene, and the like.
Suitable reactive derivative at the carboxy group of the compound (I-g) may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like. Suitable examples of the reactive derivatives may be an acid chloride; an acid azide; a mixed acid anhydride within acid such as substituted phosphoric acid [e.g.
dialkylphosphoric acid, phenylphosphoric acid,
diphenylphosphoric acid, dibenzylphosphoric acid,
halogenated phosphoric acid, etc.], dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid [e.g. methanesulfonic acid, etc.], aliphatic carboxylic acid [e.g. acetic acid, propionic acid, butyric acid, isαbutyric acid, pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.] or aromatic carboxylic acid [e.g. benzoic acid, etc.]; a symmetrical acid anhydride; an activated amide with imidazole, 4-substituted imidazole,
dimethylpyrazole, triazole or tetrazole; or an activated ester [e.g. cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl [(CH3)2
Figure imgf000026_0001
=CH-] ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2, 4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenyl
thioester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.], or an ester with a N-hydroxy compound [e.g. N,N-dimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridone, N-hydroxysuccinimide,
N-hydroxyphthalimide, 1-hydroxy-1H-benzotriazole, etc.], and the like. These reactive derivatives can optionally be selected from them according to the kind of the
compound (I-g) to be used.
The reaction is usually carried out in a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, dioxane, acetonitrile, chloroform,
methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction. These conventional solvent may also be used in a mixture with water.
In this reaction, when the compound (I-g) is used in a free acid form or its salt form, the reaction is
preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide;
N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide; N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide;
N,N'-carbonylbis-(2-methylimidazole);
pentamethyleneketene-N-cyclohexylimine;
diphenylketene-N-cyclohexylimine; ethoxyacetylene;
1-alkoxy-1-chloroethylene; trialkyl phosphite; ethyl polyphosphate; isopropyl polyphosphate; phosphorus
oxychloride (phosphoryl chloride); phosphorus trichloride; diphenyl phosphorylazide; thionyl chloride; oxalyl
chloride; lower alkyl haloformate [e.g. ethyl
chloroformate, isopropyl chloroformate, etc.];
triphenylphosphine; 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5-(m-sulfophenyl)isoxazolium hydroxide
intramolecular salt; 1-(p-chlorobenzenesulfonyloxy)-6- chloro-1H-benzotriazole; so-called vilsmeier reagent prepared by the reaction of N,N-dimethylformamide with thionyl chloride, phosgene, trichloromethyl chloroformate, phosphorus oxychloride, etc.; or the like.
The reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal bicarbonate, tri(lower)alkylamine, pyridine,
N-(lower)alkylmorpholine, N,N-di(lower)alkylbenzylamine, or the like.
The reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.
Process 8
The object compound (I-i) or a salt thereof can be prepared by reacting the compound (X) or a salt thereof with the compound (XI) or a salt thereof.
This reaction can be carried out in substantially the same manner as Process 1, and therefore the reaction mode and reaction conditions [e.g. solvents, reaction
temperature, etc.] of this reaction are to be referred to those as explained in Process 1.
The present reaction includes, within its scope, the case that when R1 is carboxy, it is protected during the reaction or at the post-treating step of the present process.
Process 9
The object compound (I-d) or a salt thereof can be prepared by subjecting the compound (I-e) or a salt thereof to introduction reaction of the carboxy protective group.
The reaction can be carried out in substantially the same manner as Process 1, and therefore the reaction mode and reaction conditions [e.g. solvent,s reaction
temperature, etc.] of this reaction are to be referred to those as explained in Process 1.
The starting compounds (II), (IV) and (VI) can be prepared by the details of which are shown in Preparations mentioned below, or a conventional manner.
The object compound (I) of the present invention can be isolated and purified in a conventional manner, for example, extraction, precipitation, fractional
crystallization, recrystallization, chromatography, and the like.
The object compound (I) thus obtained can be
converted to its salt by a conventional method.
The object compound (I) of the present invention is useful as a testosteron 5α-reductase inhibitor and
effective to testosteron 5α-reductase mediated diseases such as prostatism, prostatic hypertrophy, prostatic cancer, alopecia, hirsutism (e.g. female hirsutism, etc.), androgenic alopecia (or male-pattern baldness), acne (e.g. acne vulgarism, pimple etc.), other hyperandrogenism, and the like.
In order to illustrate the usefulness of the object compounds (I), pharmacological activity of representative compounds of the present invention is shown below.
[l] Test Compound : (1) 4-[1-[3-(3-Isobutylphenoxymethyl)benzoyl]indol-3-yl]- butyric acid
(2) 4-[1-[4-(4-Isobutylbenzyloxy)benzyl]indol-3-yl]- butyric acid
(3) 4-[1-[4,5-Dimethyl-3-[1-(4-isobutylphenyl)ethoxy]- benzoyl]indol-3-yl]butyric acid
(4) 4-[1-[3-(3-Bromophenoxymethyl)benzoyl]indol-3-yl]- butyric acid
(5) 4-[1-[3-[N-(4-Isobutylbenzoyl)(3-isobutylphenyl)- aminomethyl]benzoyl]indol-3-yl]butyric acid (6) 4-[1-[2,3-Dimethyl-5-(3-isobutylphenoxymethyl)- benzoyl]indol-3-yl]butyric acid
(7) 4-[1-[3-[2-(4-Isobutylphenyl)vinyl]benzoyl]indol-3- yl]butyric acid (8) 4-[1-[4-[Bis(4-isobutylphenyl)methoxy]benzoyl]- indol-3-yl]butyric acid
(9) 4-[1-[4-[2-(4-Isobutylphenyl)propyl]benzoyl]-indol- 3-yl]butyric acid
[2] Inhibitory activity on testosterone 5α-reductase in rats : Test Methods
i) Materials
1,2,6,7-3H-Testosterone (85-105 Ci/mmol) :
1,2,6,7-3H-Testosterone (85-105 Ci/mmol) is a mixture of 1,2,6,7-3H-testosterone and testosterone which includes 85-105 Ci of 1,2,6,7-3H-testosterone per mmol of testosterone and is purchased from New
England Nuclear, Boston, Mass., U.S.A.. Aquazol-2 (Aguazol-2- Universal LSC Cocktail) :
trademark, purchased from New England Nuclear,
Boston, Mass., U.S.A. ii) Preparation of prostatic testosterone 5α-reductase
Mature Sprague-Dawley male rats (7-8 weeks old) were sacrificed by diethyl ether. The ventral prostates were dissected to be free of their capsules and their combined volume was measured by displacement in several milliliters of ice-cold medium A (0.32 M sucrose, 0.1 mM
dithiothreitol and 20 mM sodium phosphate, pH 6.5).
Unless specified, all the following procedures were carried out at 0-4°C. The prostates were drained, minced, and then homogenized in 3-4 tissue volumes of medium A with Pyrex-glass homogenizer. The homogenate was fractions by differential centrifugations at 3,000 g for 15 minutes. The resulting pellets were resuspended in medium A. The suspension (20-30 mg protein/ml) was stored at -80°C. iii) Testosterone 5α-reductase assay
The reaction solution contains 1 mM dithiothreitol, 40 mM sodium phosphate pH 6.5, 50 μM NADPH,
1,2,6,7-3H-testosterone/testosterone (2.2 x 10-9 M) and the suspension prepared above (0.8 mg of protein) in a total volume of 565 μl. Test Compound was added in 10 μl of 10% ethanol whereas control tubes received the same volume of 10% ethanol. The reaction was started with the addition of the enzyme suspension. After incubation at 37°C for 30 minutes, the reaction was extracted with 1 ml of ethyl acetate. Fifty μl of ethyl acetate phase was chromatographed on a Merck silica plastic sheet Kieselgel 60 F254, using ethyl acetate :
cyclohexane (1:1) as the developing solvent system. The plastic sheet was air dried and cut the testosterone and the 5α-dihydrotestosterone areas. The radioactivity was counted in 5 ml of Aquazol-2 in Packard scintillation counter (PACKARD TRI - CARB 4530), and an inhibitory ratio was calculated.
[3] Test Results :
Figure imgf000031_0001
Figure imgf000032_0001
For therapeutic or preventive administration, the object compound (I) of the present invention are used in the form of conventional pharmaceutical preparation which contains said compound as an active ingredient, in admixture with pharmaceutically acceptable carriers such as an organic or inorganic solid or liquid excipient which is suitable for oral, parenteral and external
administration. The pharmaceutical preparation may be in solid form such as tablet, granule, powder, capsule, or liquid form such as solution, suspension, syrup, emulsion, lemonade, lotion and the like.
If needed, there may be included in the above
preparations auxiliary substances, stabilizing agents, wetting agents and other commonly used additives such as lactose, citric acid, tartaric acid, stearic acid,
magnesium stearate, terra alba, sucrose, corn starch, talc, gelatin, agar, pectin, peanut oil, olive oil, cacao butter, ethylene glycol, and the like.
While the dosage of the compound (I) may vary from and also depend upon the age, conditions of the patient, a kind of diseases or conditions, a kind of the compound (I) to be applied, etc. In general amounts between 0.01 mg and about 500 mg or even more per day may be administered to a patient. An average single dose of about 0.05 mg, 0.1 mg, 0.25 mg, 0.5 mg, 1 mg, 20 mg, 50 rag, 100 mg of the object compound (I) of the present invention may be used in treating diseases.
The following Preparations and Example are given for the purpose of illustrating the present invention. Preparation 1
To a solution of 2,3-xylenol (19.45 g) in
dichloromethane (300 ml) was added a solution of bromine (8.20 ml) in dichloromethane (20 ml) at -20°C. After stirred for 1.5 hours, the mixture was washed with water. The solution was dried over magnesium sulfate and the solvent was removed in vacuo. The residue was
crystallized with n-hexane to give a white solid of
4-bromo-2,3-dimethylphenol (16.8 g).
mp : 87-88°C
IR (CDCl3, δ) : 2.23 (3H, s), 2.37 (3H, s), 4.75 (1H, br s), 6.52 (1H, d, J=9Hz), 7.24 (1H, d, J=9Hz ) Preparation 2
To a solution of 3,4-dimethylbenzoic acid (10.0 g) in acetic acid (300 ml) were added nitric acid (47 ml), water (33 ml) and bromine (11.7 g) at 25°C. A solution of silver nitrate (14.7 g) in water (70 ml) was added
dropwise to the mixture at 25°C over 1 hour. The reaction mixture was poured into a mixture of ethyl acetate (1 l) and water (1.5 l). The organic layer was separated, washed with water and brine, and dried over magnesium sulfate. After evaporation at the solvent, the residue was purified by recrystallization from ethanol to give 3-bromo-4,5-dimethylbenzoic acid (6.16 g) as yellow crystals.
NMR (CDCl3, δ) : 2.40 (3H, s), 2.46 (3H, s), 7.82
(1H, d, J=1Hz), 8.28 (1H, d, J=1Hz)
Preparation 3
Triphenylphosphine (7.23 g) was added to a mixture of 3-bromo-4,5-dimethylbenzyl alcohol (3.95 g) and carbon tetrabromide (9.14 g) in ether (100 ml) at 0°C, and the mixture was allowed to warm up to 25°C. The reaction mixture was stirred at 25°C for 2 hours, and then the precipitates were filtered off. The filtrate was washed with water and brine, and dried over magnesium sulfate. After evaporation of the solvent, the residue was
chromatographed on silica gel (100 g) eluting with chloroform to give 3-bromo-4,5-dimethylbenzyl bromide (4.15 g) as colorless crystals.
NMR (CDCl3, δ) : 2.32 (3H, s), 2.46 (3H, s),
4.38 (2H, s), 7.12 (1H, d, J=1Hz),
7.45 (1H, d, J=7Hz)
Preparation 4
The following compound was obtained according to a similar manner to that of Preparation 3.
1-(4-Isobutylphenyl)ethyl bromide
bp : 77-80°C/0.2 mmHg
NMR (CDCl3, δ) : 0.90 (6H, d, J=7.5Hz), 1.86 (1H, m), 2.05 (3H, d, J=7.5Hz), 2.46 (2H, d,
J=7.5Hz), 5.23 (1H, q, J=7.5Hz), 7.11 (2H, d,
J=8Hz), 7.34 (2H, d, J=8Hz)
Preparation 5
To a solution of 4-isobutylacetophenone (100 g) in isopropyl alcohol (500 ml) was added sodium borohydride (25.76 g). The mixture was stirred for 16 hours at room temperature. To the mixture was added water (500 ml) and diluted hydrochloric acid (600 ml). The organic layer was extracted with ethyl acetate (300 ml) and washed with water. The solution was dried over magnesium sulfate.
The solvent was removed in vacuo to give colorless oil of 1-(4-isobutylphenyl)ethanol (101.1 g).
NMR (CDCl3, δ) : 0.90 ( 6H, d, J=7.5Hz), 1.49 (3H, d, J=6Hz), 1.86 (1H, m), 2.47 (2H, d, J=7.5Hz), 4.88 (1H, q, J=6Hz), 7.13 (2H, d, J=8Hz), 7.28
(2H, d, J=8Hz) Preparation 6
To a solution of isobutyltriphenylphosphonium bromide (48.8 g) in tetrahydrofuran (600 ml) was added a solution of potassium t-butoxide (13.57 g) in tetrahydrofuran (230 ml). The mixture was stirred at room temperature for 1 hour. To the mixture was added a solution of
1,4-cyclohexanedione mono-ethylene acetal (10.0 g) in tetrahydrofuran (100 ml). The mixture was stirred at room temperature for 3 days and partitioned between diethyl ether and water. The organic layer was washed with water, dried over magnesium sulfate and evaporated. The residue was purified by chromatography on silica gel (300 g) using a mixture of n-hexane and 5% ethyl acetate as the eluent. Appropriate fractions were combined and evaporated to give 4-(2-methyl-1-propylidene)cyclohexanσne ethylene acetal (12.16 g) as a colorless oil.
NMR (CDCl3, δ) : 0.94 (6H, d, J=7Hz), 1.6-1.8 (4H, m), 2.1-2.3 (4H, m), 2.4-2.6 (1H, m), 3.97 (4H, s), 4.98 (1H, d, J=9Hz)
Preparation 7
6N-Hydrochloric acid (35 ml) was added to a solution of 4-(2-methyl-1-propylidene)cyclohexanone ethylene acetal (12.16 g) in 1,4-dioxane (70 ml) and methanol (35 ml).
The mixture was stirred at room temperature for 20 hours and partitioned between ethyl acetate and water. The organic layer was washed with brine and dried over
magnesium sulfate. The solvent was removed in vacuo to give 4-(2-methyl-1-propylidene)cyclohexane (9.43 g) as a colorless oil.
NMR (CDCl3, δ) : 0.98 (6H, d, J=7Hz), 2.3-2.7 (9H, m), 5.18 (1H, d, J=9Hz)
Preparation 8
To a solution of 4-(2-methyl-1-propylidene)- cyclohexanone (1.0 g) in acetic acid (20 ml) was added 10% palladium on carbon (0.2 g). The mixture was hydrogenated for 19 hours at room temperature. The catalyst was filtered off and the filtrate was partitioned between ethyl acetate and water. The organic layer was washed with saturated sodium bicarbonate aqueous solution and water and dried over magnesium sulfate. The solvent was removed in vacuo to give 4-isobutylcyclohexane (1.01 g) as a colorless oil.
NMR (CDCl3, δ) : 0.90 (3H, d, J=7Hz), 1.16 ( 2H, t,
J=7.5Hz), 1.2-1.5 (2H, m), 1.6-1.9 (2H, m),
1.9-2.1 (2H, m), 2.3-2.4 (4H, m)
Preparation 9
To a solution of diethyl carbonate (6.19 g) and potassium tert-butoxide (4.31 g) in tetrahydrofuran (50 ml) was added a solution of 4-isobutylcyclohexanαne (2.48 g) in tetrahydrofuran (35 ml). The mixture was allowed to reflux for 1 hour and partitioned between ethyl acetate and water. The organic layer was washed with water, dried over magnesium sulfate and evaporated. The residue was distilled at reduced pressure to give 2-ethoxycarbonyl-4- isobutylcyclohexanone (2.99 g) as a colourless oil.
bp : 92ºC/0.4 mmHg
NMR(CDCl3, δ) : 0.8-1.0 (1H, m), 0.89 ( 6H, d,
J=6Hz), 1.1-1.4 (3H, m), 1.31 (3H, t, J=7Hz), 1.4-1.9 (5H, m), 2.2-2.3 (2H, m), 4.22 (2H, q, J=7Hz) Preparation 10
1M solution of borane in tetrahydrofuran (40.5 ml) was added to a solution of 3-bromo-4,5-dimethylbenzoic acid (4.22 g) in tetrahydrofuran (20 ml) at 0°C, and then the mixture was allowed to warm up to 25°C. The reaction mixture was stirred at 25°C for 2 hours and poured into a mixture of ether and 1N hydrochloric acid. The organic layer was separated, washed with water and brine, and dried over magnesium sulfate. Evaporation of the solvent gave 3-bromo-4,5-dimethylbenzyl alcohol (4.00g) as an oil.
NMR (CDCl3, δ) : 2.33 (3H, s), 2.36 (3H, s), 4.60
(2H, s), 7.09 (1H, d, J=1Hz), 7.42 (1H, d,
J=1Hz)
Preparation 11
A mixture of 1-bromo-1-(4-isobutylphenyl)ethane (8.70 g) and triphenylphosphine (9.47 g) in xylene (100 ml) was refluxed for 10 hours. After evaporation of the solvent, the residue was washed with hexane to give
1-(4-isobutylphenyl)ethyltriphenylphosphonium bromide (12.69 g) as powder.
NMR (CDCl3, δ) : 6.65 (1H, q, J=6Hz)
Preparation 12
4-lsobutylbenzoyl chloride (1.32 g) was added to a solution of 4-isobutylaniline (1.0 g) and triethylamine (0.68 g) in dichloromethane (20 ml). The mixture was stirred at 0°C for 1 hour and poured into ice water. The organic layer was washed with water, dried over magnesium sulfate, and evaporated. The residue was washed with n-hexane to give N-(4-isobutylbenzoyl)-4-isobutylaniline (1.82 g) as a white powder,
mp : 162°C
NMR (CDCl3, δ) : 0.91 (6H, d, J=7Hz), 0.92 (6H, d, J=7Hz), 1.8-2.0 (2H, m), 2.46 (2H, d, J=7Hz), 2.54 (2H, d, J=7HZ), 7.14 (2H, d, J=8Hz), 7.25
(2H, d, J=8Hz), 7.54 (2H, d, J=8Hz), 7.78 (2H, d, J=8Hz)
Preparation 13
The following compounds were obtained according to a similar manner to that of Preparation 12.
(1) N-Benzoyl-4-isobutylaniline
mp : 128°C
NMR (CDCl3, δ) : 0.90 (6H, d, J=7Hz), 1.85 (1H, m),
2.46 (2H, d, J=7Hz), 7.15 (2H, d, J=8Hz),
7.4-7.6 (5H, m). 7.7-7.9 (3H, m)
( 2) Methyl 3-[N-(4-isobutylphenyl)carbamoyl]benzoate
mp : 116°C
NMR (CDCl3, δ) : 0.91 (6H, d, J=7Hz), 1.86 (1H, m),
2.47 (2H, d, J=7Hz), 3.95 (3H, s), 7.15 (2H, d, J=8Hz), 7.56 (1H, t, J=7.5Hz), 7.56 (2H, d, J=8Hz), 7.98 (1H, br s), 8.13 (1H, dt, J=2Hz, 7.5Hz), 8.20 (1H, dt, J=2Hz, 7.5Hz), 8.47 (1H, t, J=7.5Hz)
(3) N-(4-Isobutylbenzoyl)-3-isobutylaniline
mp : 69-70°C
NMR (CDCl3, δ) : 0.92 (12H, d, J=7Hz), 1.8-2.0 (2H, m), 2.48 (2H, d, J=7Hz), 2.54 (2H, d, J=7Hz), 6.94 (1H, d, J=7.5Hz), 7.2-7.4 (4H, m), 7.4-7.5 (2H, m), 7.3-7.4 (3H, m) Preparation 14
To a solution of 1-(4-isobutylphenyl)- ethyltriphenylphosphonium bromide (7.48 g) in
tetrahydrofuran (30 ml) was added a solution of potassium tert-butoxide (1.67 g) in tetrahydrofuran (20 ml). The mixture was stirred at room temperature for 1 hour. To the mixture was added a solution of 3-bromobenzaldehyde (1.6 ml) in tetrahydrofuran (10 ml). The mixture was stirred at room temperature for 3 hours, and portioned between ethyl acetate and water. The organic layer was washed with water, dried over magnesium sulfate and then a solution of 4-isobutylcyclohexanone (2.0 g) in tetrahydrofuran (30 ml) was added at 25°C. After stirred at 25°C for 1 hour, the reaction mixture was quenched with 1N hydrochloric acid and extracted with ethyl acetate. The extract was washed with water and brine, dried over magnesium sulfate, and evaporated. The residue was purified by column chromatography on silica gel (50 g) eluting with a mixture of ethyl acetate and hexane (1:10 to 1:6) to give 4-(1-hydroxy-4-isobutylcyclohexyl)benzyl methyl ether (2.51 g) as an oil.
NMR (CD3OD, δ) : 0.68 (6H, d, J=7.5Hz), 0.80-1.05 (3H, m), 1.35-1.75 (7H, m), 2.05-2.24 (2H, m), 3.20 (3H, s), 4.38 (2H, s), 7.13 (2H, d, J=8Hz), 7.32 (2H, d, J=8Hz)
Preparation 17
To a suspension of sodium hydride (60% dispersion in mineral oil) (0.35 g) in dimethylformamide (15 ml) was added a solution of N-(4-isobutylbenzoyl)-4- isobutylaniline (1.81 g) in dimethylformamide (10 ml).
The mixture was stirred at room temperature for 30 minutes and cooled at 0°C. To the mixture was added a solution of methyl 3-bromomethylbenzoate (1.34 g) in dimethylformamide (5 ml). The mixture was stirred at 0°C for 1 hour and partitioned between ethyl acetate and 7% hydrochloric acid. The organic layer was washed with water, dried over magnesium sulfate and evaporated. The residue was
purified by column chromatography on silica gel (60 g) using a mixture of n-hexane and ethyl acetate (3:1) as the eluent. Appropriate fractions were combined and
evaporated to give methyl 3-[N-(4-isobutylbenzoyl)-N-(4- isobutylphenyl)aminomethyl]benzoate (2.13 g) as a
colourless foam.
NMR (CDCl3, δ) : 0.79 (12H, d, J=7Hz), 1.6-1.9 (2H, m), 2.35 (2H, d, J=7Hz), 2.37 (2H, d, J=7Hz), 3.89 (3H, s), 5.16 (2H, s), 6.78 (2H, d, J=8Hz), 6.92 (2H, d, J=8Hz), 7.23 (2H, d, J=8Hz), 7.38 (1H, t, J=7.5Hz), 7.58 (1H, d, J=7.5Hz), 7.93 (1H, d, J=7.5Hz), 7.95 (1H, s)
Preparation 18
The following compounds were obtained according to a similar manner to that of Preparation 17. (1) Methyl 3-[N-(4-isobutylbenzoyl)-N-(3-isobutylphenyl)- aminomethyl]benzoate
NMR (CDCl3, δ) : 0.66 (6H, d, J=7Hz), 0.82 ( 6H, d,
J=7Hz), 1.52 (1H, m), 1.75 (1H, m), 2.24 (2H, d, J=7Hz), 2.35 (2H, d, J=7Hz), 3.90 (3H, s), 5.17 (2H, s), 6.57 (1H, s), 6.8-7.0 (2H, m), 6.92
(1H, d, J=7.5Hz), 7.08 (1H, t, J=7.5Hz), 7.25 (2H, d, J=8Hz), 7.37 (1H, t, J=7.5Hz), 7.58 (1H, d, J=7.5Hz), 7.93 (1H, d, J=7.5Hz), 7.94 (1H, br s)
(2) Methyl 3-[N-t-butoxycarbonyl-N-(4-isobutylphenyl)- aminomethyl]benzoate
NMR (CDCl3, δ) : 0.87 (6H, d, J=7Hz), 1.49 (9H, s), 1.81 (1H, m), 2.41 (2H, d, J=7Hz), 3.90 (3H, s), 4.84 (2H, s), 7.02 (4H, s), 7.3-7.5 (2H, m),
8.4-8.5 (2H, m)
(3) Methyl 3-[N-benzoyl-N-(4-isobutylphenyl)aminomethyl]- benzoate
NMR (CDCl3, δ) : 0.80 (6H, d, J=7Hz), 1.74 (1H, m),
2.35 (2H, d, J=7Hz), 3.89 (3H, s), 5.17 (2H, s), 6.79 (2H, d, J=8Hz), 6.91 (2H, d, J=8Hz),
7.1-7.3 (3H, m), 7.3-7.5 (3H, m), 7.59 (1H, d, J=7.5Hz), 7.9-8.0 (2H, m) Preparation 19
Sulfuric acid (2 ml) was added to a mixture of
2,3-dimethylphenol (0.81 g) and
2-ethoxycarbonyl-4-isobutylcyclohexanone (1.0 g) at 0°C. The mixture was stirred at room temperature for 16 hours, poured into ice water and partitioned between ethyl acetate and water. The organic layer was washed with saturated aqueous sodium bicarbonate solution and brine, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (50 g) using a mixture of n-hexane and 2.5-10% ethyl acetate as the eluent. Appropriate fractions were combined and evaporated. The residue was crystallized with n-hexane to give 3,4-dimethyl-8-isobutyl-7,8,9,10-tetrahydro-6H- dibenzo[b,d]pyran-6-one (0.66 g) as a colorless solid, mp : 92-93°C
NMR (CDCl3, δ) : 0.92 (6H, d, J=7Hz), 1.3-1.5 (3H, m), 1.7-2.2 (4H, m), 2.37 (6H, s), 2.6-3.1 (3H, m), 7.07 (1H, d, J=8Hz), 7.31 (1H, d, J=8Hz)
Preparation 20
To a solution of 3,4-dimethyl-8-isobutyl-7,8,9,10- tetrahydro-6H-dibenzo[b,d]pyran-6-one (0.22 g) in tetrahydrofuran (10 ml) was added 3M-methylmagnesium bromide in ether (1.5 ml) at 0°C. The mixture was refluxed for 1 hour and acidified with 7% hydrochloric acid at 0°C. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with water and dried over magnesium sulfate. The solvent was removed in vacuo to give 8-isobutyl-7,8,9,10-tetrahydro-3,4,6,6-tetramethyl- 6H-dibenzo[b,d]pyrane (223 mg) as a colorless oil.
NMR (CDCl3, δ) : 0.90 (6H, d, J=7Hz), 1.1-1.4 (3H, m), 1.29 (3H, s), 1.41 (3H, s), 1.6-2.0 (4H, m), 2.0-2.2 (1H, m), 2.12 (3H, s), 2.24 (3H, s), 2.3-2.5 (2H, m), 6.67 (1H, d, J=8Hz), 6.85 (1H, d, J=8Hz) Preparation 21
2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (0.38 g) was added to a solution of 8-isobutyl-7,8,9,10-tetrahydro- 3,4,6,6-tetraraethyl-6H-dibenzo[b,d]pyrane (0.23 g) in toluene (5 ml). After the mixture was stirred at room temperature for 1.5 hours, allowed to stir at 100°C for 1 hour. The mixture was washed with diluted hydrochloric acid, diluted aqueous sodium bicarbonate solution and water. The solution was dried over magnesium sulfate and evaporated. The residue was purified by column
chromatography on silica gel using a mixture of n-hexane and 3% ethyl acetate as the eluent. Appropriate fractions were combined and evaporated to give 8-isobutyl-3,4,6,6- tetramethyl-6H-dibenzo[b,d]pyrane (184 mg) as a colourless solid.
mp : 39-40°C
NMR (CDCl3, δ) : 0.92 (6H, d, J=7Hz), 1.61 (6H, s), 1.87 (1H, m), 2.18 (3H, s), 2.28 (3H, s), 2.49 (2H, d, J=7Hz), 6.81 (1H, d, J=8Hz), 6.98 (1H, d, J=1Hz), 7.10 (1H, dd, J=1Hz, 8Hz), 7.45 (1H, d, J=8Hz), 7.60 (1H, d, J=8Hz)
Preparation 22
To a solution of 8-isobutyl-3,4,6,6-tetramethyl-6H- dibenzo[b,d]pyrane (0.18 g) and dichloromethyl methyl ether (0.11 ml) in benzene (5 ml) was added IM solution of titanium (IV) chloride in dichloromethane (1.2 ml) at 0°C. The mixture was stirred at room temperature for 30 minutes and partitioned between ethyl acetate and water. The organic layer was washed with saturated aqueous sodium bicarbonate solution and brine, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (12 g) using a mixture of n-hexane and 3-5% ethyl acetate as a eluent.
Appropriate fractions were combined and evaporated to give 2-formyl-8-isobutyl-3,4,6,6-tetramethyl-6H-dibenzo[b,d]- pyrane (180 mg) as a colourless oil.
NMR (CDCl3, δ) : 0.94 (6H, d, J=7Hz), 1.66 (6H, s), 1.89 (1H, m), 2.24 (3H, s), 2.51 (2H, d, J=7Hz), 2.62 (3H, s), 7.01 (1H, d, J=1Hz), 7.16 (1H, dd,
J=1Hz, 8Hz), 7.72 (1H, d, J=8Hz), 8.08 (1H, s), 10.27 (1H, s)
Preparation 23
To a solution of 2-formyl-8-isobutyl-3,4,6,6- tetramethyl dibenzo[b,d]pyrane (286 mg) in acetone (2 ml) was added 2N Jone's reagent (2.5 ml) at 0°C. The mixture was stirred at 0°C for 4 hours and partitioned between ethyl acetate and water. The organic layer was washed with water, dried over magnesium sulfate and evaporated. The resulting solid was collected, washed with n-hexane and dried to give 8-isobutyl-3,4,6,6-tetramethyl-6H- dibenzo[b,d]pyrane-2-carboxylic acid (261 mg).
mp : 179-180°C
NMR (CDCl3, δ) : 0.93 (6H, d, J=7Hz), 1.65 (6H, s),
1.7-2.0 (1H, m), 2.26 (3H, s), 2.50 (2H, d, J=7Hz), 2.62 (3H, s), 7.01 (1H, d, J=1Hz), 7.15 (1H, dd, J=1Hz, 8Hz), 7.70 (1H, d, J=8Hz), 8.34 (1H, s)
Preparation 24
A mixture of 3-bromo-4,5-dimethylbenzyl
3-isobutylphenyl ether (2.00 g), magnesium (280 mg) and 1,2-dibromoethane (540 mg) in tetrahydrofuran (20 ml) was refluxed for 2 hours, and then allowed to cool to 25°C.
After addition of dry ice (2 g), the reaction mixture was poured into a mixture of ether and 1N hydrochloric acid. The organic layer was separated, washed with water and brine, and dried over magnesium sulfate. After
evaporation of the solvent, the residue was purified by recrystallization from a mixture of ethyl acetate and hexane to give 2,3-dimethyl-5-(3-isobύtylphenoxymethyl)- benzoic acid (1.56 g) as colorless crystals.
NMR (CDCl3, δ) : 0.90 (6H, d, J=7.5Hz), 1.65-1.98 (1H, m), 2.37 (3H, s), 2.45 (2H, d, J=7.5Hz),
2.55 (3H, s), 5.02 (2H, s), 6.72-6.85 (3H, m), 7.18 (1H, dd, J=6Hz, 8Hz), 7.45 (1H, d, J=1Hz), 7.90 (1H, d, J=1Hz) Preparation 25
The following compounds were obtained according to a similar manner to that of Preparation 24.
(1) 2,3-Dimethyl-4-[1-(4-isobutylphenyl)ethoxy]benzoic acid
mp : 139°C
NMR (CDCl3, δ) : 0.89 (6H, d, J=7Hz), 1.65 (3H, d,
J=6Hz), 1.84 (1H, m), 2.30 (3H, s), 2.45 (2H, d, J=7Hz), 2.57 (3H, s), 5.37 (1H, q, J=6Hz), 6.61 (1H, d, J=10Hz), 7.10 (2H, d, J=8Hz), 7.25 (2H, d, J=8Hz), 7.75 (1H, d, J=10Hz)
(2) 3-[2-(4-Isobutylphenyl)-1-propenyl]benzoic acid
mp : 118-120°C
NMR (CDCl3, δ) : 0.93 (6H, d, J=7Hz), 1.90 (1H, m),
2.29 (3H, d, J=1Hz), 2.50 (2H, d, J=7Hz), 6.86 (1H, d, J=1Hz), 7.17 (2H, d, J=8Hz), 7.46 (2H, d, J=8Hz), 7.4-7.6 (1H, m), 7.60 (1H, d,
J=7.5Hz), 8.00 (1H, d, J=7.5Hz), 8.12 (1H, s)
(3) 3-[2,2-Bis(4-isobutylphenyl)ethyl]benzoic acid
mp : 112-113°C
NMR (CDCl3, δ) : 0.86 (12H, d, J=7Hz), 1.78 (2H, m),
2.36 (4H, d, J=7Hz), 3.20 (2H, d, J=7.5Hz), 4.07 (1H, t, J=7.5Hz), 7.2-6.7 (10H, m), 7.8-7.6 (2H, m) (4) 4-[2,2-Bis(4-isobutylphenyl)ethyl]benzoic acid mp : 181-182°C
NMR (CDCl3, δ) : 0.90 (12H, d, J=7.5Hz), 1.7-2.0 (2H, m), 2.41 (4H, d, J=7.5Hz), 3.39 (2H, d, J=7.5Hz), 4.16 (1H, t, J=7.5Hz), 6.95-7.2 (10H, m), 7.88 (2H, d, J=7.5Hz)
(5) 3-[Bis(4-isobutylphenyl)methylthio]benzoic acid
NMR (CDCl3, δ) : 0.88 (12H, d, J=6Hz), 1.82 (2H, m), 2.42 (4H, d, J=6Hz), 5.52 (1H, s),-7.07 (2H, d,
J=8Hz), 7.15-7.45 (6H, m), 7.82 (1H, d, J=8Hz), 7.95 (1H, s)
(6) 2,3-Dimethyl-5-(4-isobutylphenoxymethyl)benzoic acid NMR (CDCl3, δ) : 0.88 ( 6H, d, J=7.5Hz), 1.68-1.94
(1H, m), 2.37 (3H, s), 2.51 (2H, d, J=7.5Hz), 2.55 (3H, s), 5.00 (2H, s), 6.88 (2H, d, J=8Hz), 7.07 (2H, d, J=8Hz), 7.45 (1H, d, J=1Hz), 7.88 (1H, d, J=1Hz)
Preparation 26
A 1.6N solution of butyl lithium in hexane (9.7 ml) was added to a suspension of isopropyl
triphenylphosphonium iodide (5.82 g) in tetrahydrofuran (50 ml) at 0°C. The reaction mixture was allowed to warm up to 25°C and stirred at the same temperature for 1 hour . A solution of methyl 3- ( 3-formylphenoxymethyl)benzoate (2.8 g) in tetrahydrofuran (20 ml) was added to the mixture at 0°C. The reaction mixture was stirred at 0°C for 30 minutes and the solvent was evaporated off. The residue was quenched with 1N hydrochloric acid and the mixture was extracted with ether. The extract was washed with water and brine, and dried over magnesium sulfate. After evaporation of the solvent, the residue was
chromatographed on silica gel (40 g) eluting with 10% ethyl acetate in hexane to give methyl
3-[3-(2-methyl-1-propenyl)phenoxymethyl]benzoate (2.55 g) as an oil.
NMR (CDCl3, δ) : 1.82 (3H, d, J=1Hz), 1.87 (3H, d, J=1Hz), 3.92 (3H, s), 6.22 (1H, t, J=1Hz),
6.77-6.88 (3H, m), 7.23 (1H, t, J=4Hz), 7.45 (1H, t, J=4Hz), 7.63 (1H, dd, J=1Hz, 4Hz), 8.00 (1H, dd, J=1Hz, 4Hz), 8.11 (1H, d, J=1Hz) Preparation 27
The following compounds were obtained according to a similar manner to that of Preparation 26.
(1) Methyl 3-[4-(3-methyl-1-butenyl)phenoxymethyl]- benzoate
NMR (CDCl3, δ) : 1.06 (6H, d, J=4Hz), 2.89 (1H, m), 3.94 (3H, s), 5.11 (2H, s), 5.39 (1H, dd, J=6Hz, 7Hz), 6.23 (1H, d, J=7Hz), 6.83 (2H, d, J=5Hz), 7.22 (2H, d, J=5Hz), 7.47 (1H, t, J=5Hz), 7.66 (1H, dd, J=1Hz, 5Hz), 8.03 (1H, dd, J=1Hz, 5Hz),
8.13 (1H, t, J=1Hz)
(2) Methyl 3-[2-(2-methyl-1-propenyl)phenoxymethyl]
benzoate
NMR (CDCl3, δ) : 1.82 (3H, d, J=1.5Hz), 1.92 (3H, d,
J=1.5Hz), 3.93 (3H, s), 5.11 (2H, s), 6.93 (1H, s), 6.82-7.00 (2H, m), 7'.10-7.25 (2H, m), 7.44 (1H, t, J=8Hz), 7.63 (1H, d, J=8Hz), 7.99 (1H, d, J=8Hz), 8.10 (1H, s)
Preparation 28
A mixture of methyl 3-[4-(3-methyl-1-butenyl)- phenoxymethyl]benzoate (1.85 g), 10% palladium on
activated carbon (185 mg) in tetrahydrofuran (20 ml) was shaken under hydrogen atmosphere (4 atm) for 1 hour. The mixture was filtered and the filtrate was evaporated in vacuo to give methyl 3-(4-isopentylphenoxymethyl)- benzoate (1.85 g) as an oil.
NMR (CDCl3, δ ) : 0.92 (6H, d, J=4Hz), 1.40-1.70 (3H, m), 2.56 (2H, dd, J=4Hz, 5Hz), 3.92 (3H, s), 5.08 (2H, s), 6.88 (2H, d, J=5Hz), 7.08 (2H, d, J=5Hz), 7.46 (1H, t, J=5Hz), 7.65 (1H, dd,
J=1Hz, 5Hz), 8.00 (1H, dd, J=1Hz, 5Hz), 8.12 (1H, t, J=1Hz)
Preparation 29
The following compounds were obtained according to a similar manner to that of Preparation 28. (1) Methyl 3-(3-isobutylphenoxymethyl)benzoate
NMR (CDCl3, δ) : 0.88 (6H, d, J=4Hz), 1.86 (1H, m),
2.44 (2H, d, J=4Hz), 3.91 (3H, s), 5.08 (2H, s), 6.75-6.80 (3H, m), 7.18 (1H, dd, J=4Hz, 5Hz),
7.45 (1H, t, J=4Hz), 7.63 (1H, dd, J=1Hz, 4Hz), 8.00 (1H, dd, J=1Hz, 4Hz), 8.12 (1H, t, J=1Hz)
(2) 4-Isobutylphenyl phenyl ether
NMR (CDCl3, δ) : 0.92 ( 6H, d, J=7Hz), 1.84 (1H, m),
2.45 (2H, d, J=7Hz), 6.9-7.2 (7H, m), 7.2-7.4 (2H, m)
(3) Methyl 3-(2-isobutylphenoxymethyl)benzoate
NMR (CDCl3, δ) : 0.92 (6H, d, J=7Hz), 1.88-2.10 (1H, m), 2.55 (2H, d, J=7.5Hz), 3.92 (3H, s), 5.10 (2H, s), 6.82-6.98 (2H, m) , 7.08-7.18 (2H, m),
7.46 (1H, t, J=8Hz), 7.64 (1H, d, J=8Hz), 8.00 (1H, d, J=8Hz), 8.12 (1H, s)
Preparation 30
n-Butyl lithium (1.6 M solution in hexane) (6 ml) was added to a solution of bis(4-isobutylphenyl)methane (2.25 g) in tetrahydrofuran (20 ml). The mixture was stirred at room temperature for 5 hours and cooled at 0°C. To the mixture was added a solution of 4-bromobenzylbromide (2.0 g) in tetrahydrofuran (10 ml). The mixture was stirred at 0°C for 30 minutes and partitioned between ethyl acetate and water. The organic layer was washed with water, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (100 g) using n-hexane as the eluent. Appropriate fractions were combined and evaporated to give 1,1-bis(4-isobutylphenyl)- 2-(4-bromophenyl)ethane (1.57 g) as a colourless oil.
NMR (CDCl3, δ) : 0.85 (12H, d, J=7.5Hz), 1.81 (2H, m), 2.41 (4H, d, J=7Hz), 3.25 (2H, d, J=7.5Hz), 4.08 (1H, t, J=7.5Hz), 6.81 (2H, d, J=8Hz), 7.00
(4H, d, J=8Hz), 7.24 (2H, d, J=8Hz), 7.07 (4H, d, J=8Hz)
Preparation 31
The following compound was obtained according to a similar manner to that of Preparation 30.
1,1-Bis(4-isobutylphenyl)-2-(3-bromophenyl)ethane NMR (CDCl3, δ) : 0.88 (12H, d, J=7Hz), 1.82 (2H, m), 2.41 (4H, d, J=7Hz), 3.27 (2H, d, J=7.5Hz), 4.09
(1H, t, J=7.5Hz), 6.85 (1H, d, J=7.5Hz), 7.3-7.0 (11H, m)
Preparation 32
A mixture of bis(4-isobutylphenyl)methyl acetate
(12.64 g) and 10% palladium on carbon (2 g) in acetic acid (100 ml) was shaken under hydrogen atmosphere (3 atm) at room temperature for 21 hours. The catalyst was filtered off and the filtrate was evaporated. The residue was dissolved in ethyl acetate and washed with saturated aqueous sodium bicarbonate solution and water. The solution was dried over magnesium sulfate and evaporated. The residual oil was distillated under reduced pressure to give bis(4-isobutylphenyl)methane (9.97 g) as a colourless oil.
bp : 150-155°C/0.2 mmHg
NMR (CDCl3, δ) : 0.89 (12H, d, J=7Hz), 1.84 (2H, m), 2.43 (4H, d, J=7Hz), 3.92 (2H, s), 7.07 (8H, m) Preparation 33
Acetic anhydride (20 ml) was added to a solution of bis (4-isobutylphenyl)methanol (11.07 g) in pyridine (40 ml). The mixture was stirred at room temperature for 5 hours and partitioned between ethyl acetate and water.
The organic layer was washed with 7% hydrochloric acid, water, saturated aqueous sodium bicarbonate solution and water. The solution was dried over magnesium sulfate and evaporated to give bis(4-isobutylphenyl)methyl acetate (12.64 g) as a colourless oil.
NMR (CDCl3, δ) : 0.89 (12H, d, J=7Hz), 1.84 (2H, m),
2.15 (3H, s), 2.44 (4H, d, J=7Hz), 6.85 (1H, s), 7.23 (4H, d, J=8Hz)
Preparation 34
To a solution of sodium hydroxide (4.71 g) and bromine (2 ml) in water (60 ml) was added a solution of 4-(4-isobutylphenoxy)acetophenone (3.29 g) in 1,4-dioxane (90 ml). The mixture was stirred at 0°C for 2 hours and partitioned between ethyl acetate and 7% hydrochloric acid. The organic layer was washed with water and
saturated aqueous sodium thiosulfate solution, dried over magnesium sulfate and evaporated. The residue was washed with n-hexane to give 4-(4-isobutylphenoxy)benzoic acid (2.60 g) as a white powder.
mp : 128°C NMR (CDCl3, δ ) : 0. 94 ( 6H, d, J=7Hz ) , 1. 87 ( 1H, m) , 2.50 ( 2H, d, J=7Hz ) , 7 . 00 ( 4H, d, J=8Hz ) , 7. 17 ( 2H, d, J=8Hz ) , 8. 06 ( 2H, d, J=8Hz ) Preparation 35
Acetyl chloride (0.94 ml) was added to a suspension of aluminum chloride (1.76 g) in dichloromethane (15 ml) at 3°C. The mixture was stirred at 3°C for 15 minutes. To the mixture was added a solution of 4-isobutylphenyl phenyl ether (2.67 g) in dichloromethane (15 ml). The mixture was stirred at 0°C for 1 hour and poured into 7% hydrochloric acid. The organic layer was washed with water, dried over magnesium sulfate and evaporated to give 4-(4-isobutylphenoxy)acetophenone (3.30 g) as a colourless oil.
NMR (CDCl3, δ) : 0.93 (6H, d, J=7Hz), 1.86 (1H, m), 2.50 (2H, d, J=7Hz), 2.57 (3H, s), 6.98 (4H, d, J=8Hz), 7.16 (2H,, d, J=8Hz), 7.94 (2H, d, J=8Hz)
Preparation 36
To a solution of dibenzyl 4,4'-biphenyldicarboxylate (4.23 g) in 1,4-dioxane (100 ml) was added 0.6N aqueous barium hydroxide solution (17 ml). The mixture was stirred at room temperature for 3 days. The resulting precipitate was collected by filtration and washed with 7% hydrochloric acid to give benzyl hydrogen
4 ,4'-diphenyldicarboxylate (3.21 g) as a white powder.
NMR (DMSO-d6, δ) : 5.40 (2H, s), 7.3-7.6 (5H, m), 7.84 (2H, d, J=9Hz), 7.92 (2H, d, J=9Hz), 8.07
(2H, d, J=9Hz), 8.12 (2H, d, J=9Hz)
Preparation 37
To a suspension of sodium hydride (60% dispersion in mineral oil) (0.13 g) in tetrahydrofuran (10 ml) was added a solution of phenyl 3-(4-isobutylbenzoyl)aminobenzoate (1.0 g) in tetrahydrofuran (10 ml). The mixture was stirred at 0°C for 15 minutes. Methyl iodide (0.95 g) was added to the mixture. The mixture was stirred at 0°C for 45 minutes and partitioned between ethyl acetate and diluted hydrochloric acid. The organic layer was washed with water, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (20 g) using chloroform as the eluent.
Appropriate fractions were combined and evaporated to give phenyl 3-[N-(4-isobutylbenzoyl)-N-methylamino]benzoate (0.51 g) as a colourless foam.
NMR (CDCl3, δ) : 0.82 (6H, d, J=6Hz), 1.7-1.9 (1H, m), 2.42 (2H, d, J=6.5Hz), 3.55 (3H, s), 6.94 (2H, d, J=8.5Hz), 7.1-7.5 (9H, m), 7.9-8.0 (2H, m)
Preparation 38
4-Isobutylbenzoyl chloride (0.20 g) was added to an ice cooling solution of phenyl 3-aminobenzoate (0.21 g) in dichloromethane (10 ml). After pyridine (0.08 g) was added to the mixture, the mixture was allowed to stir at room temperature for 45 minutes. The mixture was poured into diluted hydrochloric acid. The organic layer was washed with water, dried over magnesium sulfate and evaporated. The residue was purified by column
chromatography on silica gel (10 g) using a mixture of n-hexane and ethyl acetate (4:1) as the eluent.
Appropriate fractions were combined and evaporated to give phenyl 3-(4-isobutylbenzoyl)aminobenzoate (0.33 g) as a colourless foam.
NMR (CDCl3, δ) : 0.90 (6H, d, J=6Hz), 1.91 (1H, m), 2.53 (2H, d, J=7Hz), 7.1-7.3 (4H, m), 7.3-7.6 (3H, m), 7.81 (2H, d, J=8Hz), 7.9-8.3 (4H, m) Preparation 39
To a suspension of sodium hydride (60% dispersion in mineral oil) (0.15 g) in tetrahydrofuran (5 ml) was added a solution of methyl 3-[N-(4-isobutylphenyl)carbamoyl]- benzoate (0.75 g) in tetrahydrofuran (10 ml). The mixture was stirred at room temperature for 1 hour. 4-Isobutyl- benzyl chloride (0.53 g) was added to the mixture. The mixture was refluxed for 65 hours and partitioned between ethyl acetate and 7% hydrochloric acid. The organic layer was washed with water, dried over magnesium sulfate and evaporated. The residue was purified by column
chromatography on silica gel (50 g) using a mixture of n-hexane and ethyl acetate (4:1) as the eluent.
Appropriate fractions were combined and evaporated to give methyl 3-[N-(4-isobutylbenzyl)-N-(4-isobutylphenyl)- carbamoyl]benzoate (0.38 g) as a colorless foam.
NMR (CDCl3, δ) : 0.77 (6H, d, J=7Hz), 0.88 (6H, d, J=7Hz), 1.6-2.0 (2H, m), 2.34 (2H, d, J=7Hz), 2.45 (2H, d, J=7Hz), 3.84 (3H, s), 5.08 (2H, s), 6.78 (2H, d, J=8Hz), 6.89 (2H, d, J=8Hz), 7.06
(2H, d, J=8Hz), 7.20 (2H, d, J=8Hz), 7.21 (1H, t, J=7.5Hz), 7.48 (1H, dt, J=2Hz, 7.5Hz), 7.89 (1H, dt, J=2Hz, 7.5Hz), 8.01 (1H, t, J=2Hz) Preparation 40
Trifluoroacetic acid (10 ml) was added to a solution of methyl 3-[N-t-butoxycarbonyl-N-'(4-isobutylphenyl)- aminomethyl]benzoate (1.5 g) in dichloromethane (10 ml). The mixture was stirred at room temperature for 2 hours and evaporated. The residue was dissolved in
dichloromethane (50 ml), washed with saturated aqueous sodium bicarbonate solution, dried over magnesium sulfate and evaporated. The residue was dissolved in
tetrahydrofuran (15 ml). To the solution was added
4-isobutylbenzyl chloride (2.48 g) and potassium tert-butoxide (1.24 g). The mixture was stirred at room temperature for 5 hours, poured into ice water and dissolved in lN-sodium hydroxide aqueous solution. The solution was washed with diethyl ether, acidified with diluted hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (70 g) using a mixture of chloroform and 10% methanol as the eluent. Appropriate fractions were combined- and
evaporated to give 3-[N-(4-isobutylbenzyl)-N- (4-isobutylphenyl)aminomethyl]benzoic acid (116 mg) as a colorless foam.
NMR (CDCl3, δ) : 0.88 (6H, d, J=7Hz), 0.90 (6H, d, J=7Hz), 1.6-2.0 (2H, m), 2.35 (2H, d, J=7Hz),
2.45 (2H, d, J=7Hz), 4.62 (2H, s), 4.64 (2H, s), 6.67 (2H, d, J=8Hz), 6.95 (2H, d, J=8Hz), 7.08 (2H, d, J=8Hz), 7.17 (2H, d, J=8Hz), 7.3-7.6 (2H, m), 7.9-8.1 (2H, m)
Preparation 41
Thionyl chloride (4.5 ml) was added to a solution of 4-(1-hydroxy-4-isobutylcyclohexyl)benzyl methyl ether (2.24 g) in pyridine (45 ml) at 5°C over 20 minutes.
After stirred at 5°C for 2.5 hours, the reaction mixture was quenched with 1N hydrochloric acid and extracted with ethyl acetate. The extract was wa'shed with water and brine, dried over magnesium sulfate, and evaporated. The residue was purified by column chromatography on silica gel (100 g) eluting with a mixture of ethyl acetate and hexane to give 4-(4-isobutyl-1-cyclohexenyl)benzyl methyl ether (1.52 g) as an oil.
NMR (CDCl3, δ) : 0.90 (6H, d, J=7Hz), 1.18 (2H, t, J=7Hz), 1.24-1.44 (1H, m), 1.60-1.98 (4H, m), 2.20-2.50 (3H, m), 3.40 (3H, s), 4.43 (2H, s). 6 . 06-6. 12 ( 1H, m) , 7 . 27 ( 2H, d, J=8Hz ) , 7 . 38 ( 2H, d, J=8Hz )
Preparation 42
A mixture of 4-(4-isobutyl-1-cyclohexenyl)benzyl methyl ether (1.37 g) and 2,3-dichloro-5,6-dicyclo- 1,4-benzoquinone (6.01 g) in toluene (50 ml) was refluxed for 5 hours. The reaction mixture was quenched with 1N hydrochloric acid, and extracted with ethyl acetate. The extract was washed with water and brine, dried over magnesium sulfate, and evaporated. The residue was chromatographed on silica gel (100 g) eluting with a mixture of ethyl acetate and hexane (1:50) to give
4-(4-isobutylphenyl)benzaldehyde (820 mg) as an oil.
NMR (CDCl3, δ) : 0.88 (6H, d, J=7.5Hz), 1.75-1.98
(1H, m), 2.46 (2H, d, J=7.5Hz), 7.20 (2H, d, J=8Hz), 7.48 (2H, d, J=8Hz), 7.68 (2'H, d,
J=8Hz), 7.86 (2H, d, J=8Hz), 9.98 (1H, s) Preparation 43
A solution of 4- (4-isobutylphenyl)benzaldehyde (200 mg) in acetone (2 ml) was added to a solution of 2N Jones reagent ( 0.9 ml ) in acetone ( 5 ml ) at 0 ° C over 10 minutes. The reaction mixture was poured into a mixture of
ice-water and ethyl acetate. The organic layer was separated, washed with water, dried over magnesium
sulfate, and evaporated to give 4-(4-isobutylphenyl)- benzoic acid (195 mg) as an oil.
NMR (CDCl3, δ) : 0.95 (6H, d, J=7.5Hz), 1.80-2.0
(1H, m), 2.54 (2H, d, J=7.5Hz), 7.26 (2H, d,
J=8Hz), 7.57 (2H, d, J=8Hz), 7.70 (2H, d,
J=8Hz), 8.18 (2H, d, J=8Hz)
Preparation 44
A mixture of 3-cyano-4'-isobutylstilbene (875 mg) and 3NHCl (15 ml) in formic acid (50 ml) was heated under reflux with stirring for 3 days. The reaction mixture was evaporated under reduced pressure and extracted with ethyl acetate. The organic layer was washed with water, dried over magnesium sulfate and evaporated under reduced pressure to give a residue which was crystallized from isopropyl ether to afford 4'-isobutylstilbene-3-carboxylic acid (512 mg).
NMR (CDCl3, δ) : 0.92 (6H, d, J=7.5Hz), 1.79 (1H, m), 2.49 (2H, d, J=7.5Hz), 7.05-7.25 (4H, m),
7.39-7.50 (3H, m), 7.70 (1H, m), 7.95 (1H, m), 8.22 (1H, m)
Preparation 45
To a suspension of 3-aminobenzoic acid (1.37 g) and potassium carbonate (7.0 g) in dimethylformamide (50 ml) was added 4-isobutylbenzyl chloride (7.3 g). The mixture was stirred for 4 hours at 50°C and poured into diluted hydrochloric acid (200 ml). The organic layer was
extracted with ethyl acetate (30 ml) and washed with water. The solution was dried over magnesium sulfate and the solvent was removed in vacuo. The residue was
purified by a column chromatography of silica gel to give colorless oil of 4-isobutylbenzyl 3-[bis(4- isobutylbenzyl)amino]benzoate (1.56 g).
NMR (CDCl3, δ) : 0.6-0.8 (18H, m), 1.5-1.8 (3H, m), 2.20 (4H, d, J=7.5Hz), Z.23 (2H, d, J=7.5Hz), 4.37 (4H, s), 5.00 (2H, s), 6.6-6.7 (1H, m), 6.8-7.2 (14H, m), 7.2-7.3 (1H, m)
Preparation 46
To a mixture of methyl 4-hydroxybebzoate (1.52 g) and potassium carbonate (3.0 g) in dimethylformamide (10 ml) was added 4-isobutylbenzyl chloride (2.0 g). After
stirring for 6 hours at 50°C, the mixture was poured into diluted hydrochloric acid (120 ml). The organic layer was extracted with ethyl acetate (50 ml) and washed with water (30 ml x 2). The solution was dried over magnesium sulfate and the solvent was removed in vacuo. The residue was crystallized with n-hexane to give a white solid of methyl 4- (4-isobutylbenzyloxy)benzoate (1.98 g).
NMR (CDCl3, δ) : 0.88 (6H, d, J=7.5Hz), 1.7-2.1 (1H, m), 2.50 (2H, d, J=7.5Hz), 3.87 (3H, s), 5.05 (2H, s), 7.00 (2H, d, J=10Hz), 7.18 (2H, d, J=7.5Hz), 7.33 (2H, d, J=7.5Hz), 8.00 (2H, d,
J=10Hz)
Preparation 47
The following compounds were obtained according to a similar manner to that of Preparation 46.
( 1) 4-Bromo-2,3-dimethylphenyl-1-(4-isobutylphenyl) ethyl ether
NMR (CDCl3, δ) : 0.90 (6H, d, J=7.5Hz), 1.62 (3H, d, J=6Hz), 1.84 (1H, m), 2.29 (3H, s), 2.36 (3H, s), 2.44 (2H, d, J=7.5Hz), 5.22 (1H, q, J=6Hz), 6.45 (1H, d, J=9Hz), 7.09 (2H, d, J=7.5Hz), 7.17 (1H, d, J=9Hz), 7.23 (2H, d, J=7.5Hz) (2) Methyl 3-[1-(4-isobutylphenyl)ethoxy]benzoate
NMR (CDCl3, δ) : 0.88 (6H, d, J=4Hz), 1.64 (3H, d, J=4Hz), 1.82 (1H, m), 2.43 (2H, d, J=4Hz), 3.87 (3H, s), 5.34 (1H, q, J=4Hz), 7.00-7.15 (3H, m), 7.20-7.35 (3H, s), 7.50-7.60 (2H, m)
(3) Methyl 3-(3-formylphenoxymethyl)benzoate
NMR (CDCl3, δ) : 3.92 (3H, s), 5.19 (2H, s), 7.26 (1H, m), 7.2-7.4 (4H, m), 7.64 (1H, dd, J=1Hz, 5Hz), 8.01 (1H, dd, J=1Hz, 5Hz), 8.14 (1H, t, J=1Hz) (4) Methyl 3-(3,4-dichlorophenoxymethyl)benzoate
NMR (CDCl3, δ) : 3.90 (3H, s), 5.05 (2H, s), 7.15 (1H, dd, J=2.5Hz, 8Hz), 7.27 (1H, dd, J=2.5Hz, 8Hz), 7.36 (1H, t, J=8Hz), 7.55 (1H, d,
J=2.5Hz), 7.62 (1H, s), 7.69 (1H, d, J=8Hz)
(5) Methyl 3-(methoxymethoxy)benzoate
NMR (CDCl3, δ) : 3.50 (3H, s), 3.90 (3H, s), 5.22 (2H. s), 7.23 (1H, m), 7.34 (1H, t, J=6Hz), 7.7-7.8 (2H, m)
(6) Bis(4-isobutylphenyl) (3-bromophenylthio)methane
NMR (CDCl3, δ) : 0.88 (12H, d, J=6Hz), 1.84 (2H, m), 2.44 (4H, d, J=6Hz), 5.48 (1H, s), 6.96-7.15 (6H, m), 7.20-7.35 (6H, m)
(7) Methyl 3-(3,4-dichlorobenzyloxy)benzoate
NMR (CDCl3, δ) : 3.90 (3H, s), 5.05 (2H, s), 7.15 (1H, dd, J=2.5Hz, 8Hz), 7.36 (1H, t, J=8Hz), 7.46 (1H, d, J=8Hz), 7.55 (1H, d, J=2.5Hz), 7.62
(1H, broad s), 7.69 (1H, d, J=8Hz)
(8) Methyl 3-(3-bromophenoxymethyl)benzoate
NMR (CDCl3, δ) : 3.92 (3H, s), 5.09 (2H, s),
6.85-6.95 (1H, m), 7.05-7.65 (4H, m), 7.95-8.10
(3H, m)
(9) 3-(Isopropoxy)phenol
NMR (CDCl3, δ) : 1.32 ( 6H, d, J=7.5Hz), 4.40-4.60 (1H, m), 5.18 (1H, s), 6.35-6.55 (3H, m), 7.12
(1H, t, J=8.0Hz)
(10) Methyl 3-[3-(isopropoxy)phenoxymethyl]benzoate
NMR (CDCl3, δ) : 1.35 (6H, d, J=7.5Hz), 3.93 (3H, s), 4.43-4.65 (1H, m), 5.08 (2H, s), 6.45-6.62 (3H, m), 7.10-7.20 (1H, m), 7.45 (1H, t, J=8Hz), 7.65 (1H, d, J=8Hz), 8.01 (1H, d, J=8.0Hz), 8.10 (1H, broad s) (11) Methyl 3-(4-isobutylphenoxymethyl)benzoate
NMR (CDCl3, δ) : 0.90 (6H, d, J=7Hz), 1.70-1.94 (1H, m), 2.41 (2H, d, J=8Hz), 3.92 (3H, s), 5.08 (2H, s), 6.90 (2H, d, J=8Hz), 7.08 (2H, d, J=8Hz), 7.46 (1H, t, J=8Hz), 7.66 (1H, dd, J=1Hz, 8Hz), 8.00 (1H, dd, J=1Hz, 8Hz), 8.12 (1H, t, J=1Hz)
(12) Methyl 4-(4-propylphenoxymethyl)benzoate
NMR (CDCl3, δ) : 0.92 (3H, t, J=7.5Hz), 1.50-1.70 (2H, m), 2.53 (2H, t, J=7.5Hz), 3.92 (3H, s), 5.12 (2H, s), 6.88 (2H, d, J=8Hz), 7.08 (2H, d,
J=8Hz), 7.50 (2H, d, J=8Hz), 8.06 (2H, d, J=8Hz)
(13) 3-Bromo-4,5-dimethylbenzyl 3-isobutylphenyl ether
NMR (CDCl3, δ) : 0.90 (6H, d, J=7.5Hz), 1.75-1.98 (1H, m), 2.33 (3H, s), 2.37 (3H, s), 2.44 (2H, d, J=7.5Hz), 4.93 (2H, s), 6.72-6.84 (3H, m), 7.14-7.24 (2H, m), 7.50 (1H, d, J=1Hz)
(14) 3-Bromo-4,5-dimethylbenzyl 4-isobutylphenyl ether
NMR (CDCl3, δ) : 0.88 (6H, d, J=7.5Hz), 1.70-1.94 (1H, m), 2.34 (3H, s), 2.36 (3H, s), 2.41 (2H, d, J=7.5Hz), 4.92 (2H, s'), 6.88 (2H, d, J=8Hz), 7.06 (2H, d, J=8Hz), 7.15 (1H, d, J=1Hz), 7.48 (1H, d, J=1Hz)
(15) Methyl 3-(2-formylphenoxymethyl)benzoate
NMR (CDCl3, δ) : 3.93 (3H, s), 5.22 (2H, s),
6.98-7.12 (2H, m), 7.43-7.72 (3H, m), 7.88 (1H, dd, J=2.5Hz, 8Hz), 8.05 (1H, d, J=8Hz), 8.12 (1H, broad s), 10.58 (1H, s) Preparation 48
To a solution of methyl 4-(4-isobutylbenzyloxy)- benzoate (1.90 g) in 1,4-dioxane (10 ml) was added
1N-sodium hydroxide (10 ml). The mixture was stirred for 3 hours and poured into diluted hydrochloric acid (110 ml). The organic layer was extracted with ethyl acetate (30 ml) and washed with water (30 ml x 3). The solution was dried over magnesium sulfate and the solvent was removed in vacuo. The residue was crystallized with n-hexane to give a white solid of
4-(4-isobutylbenzyloxy)benzoic acid (1.78 g).
NMR (CDCl3, δ) : 0.90 (6H, d, J-7.5Hz), 1.70-2.0 (1H, m), 2.50 (2H, d, J=7.5Hz), 5.08 (2H, s), 7.02 (2H, d, J=10Hz), 7.18 (2H, d, J=7.5Hz), 7.35 (2H, d, J=7.5Hz), 8.06 (2H, d, J=10Hz)
Preparation 49
The following compounds were obtained according to a similar manner to that of Preparation 48.
(1) 3-[Bis(4-isobutylbenzyl)amino]benzoic acid
NMR (CDCl3, δ) : 0.90 (12H, d, J=7.5Hz), 1.7-2.0 (2H, m), 2.45 (4H, d, J=7.5Hz), 4.65 (4H, s), 6.9-7.0 (1H, m), 7.10 (8H, dd, J=7.5Hz), 7.23 (1H, t, J=7.5Hz), 7.42 (1H, d, J=7.5Hz), 7.53 (1H, s)
(2) 3-[1-(4-Isobutylphenyl)ethoxy]benzoic acid
NMR (CDCl3, δ) : 0.88 (6H, d, J=4Hz), 1.64 (3H, d, J=4Hz), 1.82 (1H, m), 2.43 (2H, d, J=4Hz), 5.34 (1H, q, J=4Hz), 7.00-7.15 (3H, m), 7.20-7.35 (3H, m), 7.50-7.60 (2H, m)
(3) 3-(3-Isobutylphenoxymethyl)benzoic acid
NMR (CDCl3, δ) : 0.90 (6H, d, J=8Hz), 1.76-2.00 (1H, m), 2.46 (2H, d, J=8Hz), 5.10 (2H, s), 6.73-6.85 (3H, m), 7.20 (1H, dd, J=8Hz, 10Hz), 7.50 (1H, t, J=8Hz), 7.72 (1H, dd, J=1Hz, 8Hz), 8.09 (1H, dd, J=l, 8Hz), 8.19 (1H, t, J=1Hz)
(4) 3-(4-Isopentylphenoxymethyl)benzoic acid
NMR (CDCl3, δ) : 0.93 (6H, d, J=4Hz), 1.40-1.70 (3H, m), 2.57 (2H, dd, J=4Hz, 5Hz), 5.12 (2H, s), 6.90 (2H, d, J=5Hz), 7.12 (2H, d, J=5Hz), 7.51 (1H, t, J=5Hz), 7.72 (1H, dd, J=1Hz, 5Hz), 8.08 (1H, dd, J=1Hz, 5Hz), 8.19 (1H, t, J=1Hz)
(5) 4,5-Dimethyl-3-[1-(4-isobutylphenyl)ethoxy]benzoic acid
NMR (CDCl3, δ) : 0.80 (6H, d, J=7.5Hz), 1.54 (3H, d,
J=7.5Hz), 1.62-1.92 (1H, m), 2.20 (3H, s), 2.22 (3H, s), 2.38 (2H, d, J=7.5Hz), 5.30 (1H, q, J=7.5Hz), 7.02 (2H, d, J=8Hz), 7.12-7.33 (3H, m), 7.41 (1H, s)
(6) 3-(3,4-Dichlorophenoxymethyl)benzoic acid
NMR (CDCl3, δ) : 5.04 (2H, s), 7.17 (1H, dd,
J=2.5Hz, 8Hz), 7.28 (1H, dd, J=2.5Hz, 8Hz), 7.37 (1H, t, J=8Hz), 7.45 (1H, d, J=8Hz), 7.55 (1H, d, J=2.5Hz), 7.65 (1H, s), 7.70 (1H, d, J=8Hz)
(7) 3-(Methoxymethoxy)benzoic acid
NMR (CDCl3, δ) : 3.50 (3H, s), 5.25 (2H, s), 7.30 (1H, m), 7.40 (1H, t, J=6Hz), 7.65-7.75 (2H, m)
(8) 4- (Methoxymethoxy)benzoic acid
NMR (CDCl3, δ) : 3.52 (3H, s), 5.28 (2H, s),
7.10 (2H, d, J=10Hz), 8.10 (2H, d, J=10Hz) (9) 3-(3,4-Dichlorobenzyloxy)benzoic acid NMR (CDCl3-CD3OD, δ) : 5.04 (2H, s), 7.17 (1H, dd,
J=2.5Hz, 8Hz), 7.28 (1H, dd, J=2.5Hz, 8Hz), 7.37 (1H, t, J=8Hz), 7.45 (1H, d, J=8Hz), 7.55 (1H, d, J=2.5Hz), 7.65 (1H, broad s), 7.70 (1H, broad d, J=8Hz)
(10) 3-(3-Bromophenoxymethyl)benzoic acid
NMR (CDCl3-CD3OD, δ) : 5.10 (2H, s), 6.85-6.98 (1H, m), 7.02-7.20 (3H, m), 7.50 (1H, t, J=8Hz), 7.65 (1H, d, J=8Hz), 8.02 (1H, d, J=8Hz), 8.12 (1H, broad s)
(11) 3-[3-(Isopropoxyphenoxy)methyl]benzoic acid
NMR (CDCl3, δ) : 1.33 (6H, d, J=7.5Hz), 4.42-4.65 (1H, m), 5.10 (2H, s), 6.48-6.64 (3H, m),
7.10-7.25 (1H, m), 7.52 (1H, t, J=8Hz), 7.70 (1H, d, J=8Hz), 8.09 (1H, d, J=8Hz), 8.19 (1H, broad s) (12) 3-[N-(4-Isobutylbenzyl)-N-(4-isobutylphenyl)
carbamoyl]benzoic acid
mp : 142-143°C
NMR (CDCl3, δ) : 0.77 (6H, d, J=7Hz), 0.88 ( 6H, d, J=7Hz), 1.6-2.0 (2H, m), 2.34 (2H, d, J=7Hz), 2.45 (2H, d- J=7Hz), 5.09 (2H, s), 6.78 (2H, d,
J=8Hz), 6.90 (2H, d, J=8Hz), 7.07 (2H, d,
J=8Hz), 7.22 (2H, d, J=8Hz), 7.26 (1H, t,
J=7.5Hz), 7.58 (1H, dt, J=2Hz, 7.5Hz), 7.94 (1H, dt, J=2Hz, 7.5Hz), 8.03 (1H, t, J=2Hz)
(13) 3-[N-(4-Isobutylbenzoyl)-N-(4-isobutylphenyl)aminomethyl]benzoic acid
mp : : 126-127°C
NMR (CDCl3, δ) : 0.78 (12H, d, J=7Hz), 1.6-1.9 (2H, m), 2.34 (2H. d, J=7Hz), 2.36 (2H, d, J=7Hz), 5.18 (2H, s), 6.80 (2H, d, J=8Hz), 6.90 (2H, d, J=8Hz), 6.92 (2H, d, J=8Hz), 7.24 (2H, d,
J=8Hz), 7.42 (1H, t, J=7.5HZ), 7.66 (1H, d, J=7.5Hz), 7.9-8.1 (2H, m)
(14) 3-[N-(4-Isobutylbenzoyl)-N-(3-isobutylphenyl)- aminomethyl]benzoic acid
NMR (CDCl3, + CD3OD, δ) : 0.65 (6H, d, J=7Hz), 0.81 (6H, d, J=7Hz), 1.52 (1H, m), 1.76 (1H, m), 2.25 (2H, d, J=7Hz), 2.36 (2H, d, J=7Hz), 5.19 (2H, s), 6.58 (1H, br s), 6.8-7.0 (2H, m), 6.92 (2H, d, J=8Hz), 7.09 (1H, t, J=7.5Hz), 7.26 (2H, d, J=8Hz), 7.41 (1H, t, J=7.5Hz), 7.65 (1H, d, J=7.5Hz), 7.98 (1H, d, J=7.5Hz), 8.00 (1H, br s)
(15) 3-[N-Benzoyl-N-(4-isobutylphenyl)aminomethyl]benzoic acid
NMR (CDCl3, δ) : 0.79 (6H, d, J=7Hz), 1.74 (1H, m), 2.34 (2H, d, J=7Hz), 5.19 (2H, s), 6.80 (2H, d, J=8Hz), 6.91 (2H, d, J=8Hz), 7.1-7.3 (3H, m),
7.3-7.4 (2H, m), 7.42 (1H, t, J=8Hz), 7.66 (1H, d, J=8Hz), 7.98 (1H, s), 8.00 (1H, d, J=8Hz)
(16) 3-(4-Isobutylphenoxymethyl)benzoic acid
NMR (CDCl3, δ) : 0.90 (6H, d, J=7Hz), 1.70-1.84 (1H, m), 2.42 (2H, d, J=8Hz), 5.10 (2H, s), 6.90 (2H, d, J=8Hz), 7.06 (2H, d, J=8Hz), 7.50 (1H, t, J=8Hz), 7.72 (1H, dd, J=1Hz, 8Hz), 8.08 (1H, dd, J=1Hz, 8Hz), 8.18 (1H, t, J=1Hz)
(17) 4-(4-Propylphenoxymethyl)benzoic acid
NMR (CDCl3, δ) : 0.94 (3H, t, J=7.5Hz), 1.50-1.70 (2H, m), 2.52 (2H, t, J=7.5Hz), 5.12 (2H, s), 6.90 (2H, d, J=8Hz), 7.08 (2H, d, J=8Hz), 7.55 (2H, d, J=8Hz), 8.12 (2H, d, J=8Hz) (18) 3-(2-Isobutylphenoxymethyl)benzoic acid
NMR (CDCl3, δ) : 0.93 (6H, d, J=7.5Hz), 1.85-2.10 (1H, m), 2.59 (2H, d, J=7.5Hz), 5.12 (2H, s), 6.80-6.95 (2H, m), 7.08-7.22 (2H, m), 7.50 (1H, t, J=8Hz), 7.70 (1H, d, J=8Hz), 8.09 (1H, d,
J=8Hz), 8.21 (1H, s)
(19) 4-[2-(4-Isobutylphenyl)-1-propenyl]benzoic acid
NMR (CDCl3, δ) : 0.90 (6H, d, J=7.5Hz), 1.90 (1H, m), 2.30 (3H, d, J=0.4Hz), 2.50 (2H, d,
J=7.5Hz), 6.85 (1H, s), 7.18 (2H, d, J=10Hz), 7.45 (4H, d, J=10Hz), 8.12 (2H, d, J=10Hz)
Preparation 50
To a solution of 3-(3-isobutylphenoxymethyl)benzoic acid (1.75 g) in dichloromethane (20 ml) were added oxalyl chloride (0.644 ml) and dimethylformamide (2 drops) at 25°C. The reaction mixture was stirred at 25°C for 2 hours and evaporated in vacuo. The residue was dissolved in tetrahydrofuran (10 ml) and the solution was added to a solution of sodium phenolate, which was prepared with phenol (1.16 g) and sodium hydride (60% dispersion in mineral oil, 492 mg), in tetrahydrofuran (20 ml) at 25°C over 15 minutes. The mixture was quenched with 1N
hydrochloric acid, and was extracted with ether. The extract was washed with water and brine, and dried over magnesium sulfate. After evaporation at the solvent, the residue was chromatographed on silica gel (40 g) eluting with a mixture of dichloromethane and hexane (1:1) to give phenyl 3-(3-isobutylphenyloxymethyl)benzoate (2.15 g) as a colorless oil.
NMR (CDCl3, δ) : 1.88 (6H, d, J=4Hz), 1.86 (1H, m), 2.44 (2H, d, J=4Hz), 5.13 (2H, s), 6.72-6.87 (3H, m), 7.14-7.60 (7H, m), 7.72 (1H, dd, J=1Hz, 4Hz), 8.18 (1H, dd, J=1Hz, 4Hz), 8.28 (1H, t,
J=1Hz) Preparation 51
The following compounds were obtained according to a similar manner to that of Preparation 50. (1) Phenyl 3-(4-isopentylphenoxymethyl)benzoate
NMR (CDCl3, δ) : 0.92 (6H, d, J=4Hz), 1.4-1.7 (3H, m), 2.57 (2H, dd, J=4Hz, 5Hz), 5.12 (2H, s), 6.92 (2H, d, J=5Hz), 7.12 (2H, d, J=5Hz),
7.20-7.60 (5H, m), 7.73 (1H, dd, J=1Hz, 5Hz), 8.18 (1H, dd, J=1Hz, 5Hz), 8.29 (1H, t, J=1Hz)
(2) Phenyl 4-(4-isobutylbenzyloxy)benzoate
NMR (CDCl3, δ) : 0.90 (6H, d, J=7.5Hz), 1.7-2.0 (1H, m), 2.50 (2H, d, J=7.5Hz), 5.10 (2H, s), 7.05 (2H, d, J=10Hz), 7.1-7.5 (9H, m), 8.17 (2H, d,
J=10Hz)
(3) Phenyl 3-[bis(4-isobutylbenzyl)amino]benzoate
NMR (CDCl3, δ) : 0.90 (12H, d, J=7.5Hz), 1.7-2.0
(2H, m), 2.45 (4H, d, J=7.5Hz), 4.65 (4H, s),
6.9-7.0 (1H, m), 7.0-7.5 (14H, m), 7.52 (1H, d, J=7.5Hz), 7.62 (1H, s)
(4) Phenyl 2,3-dimethyl-4-[1-(4-isobutylphenyl)ethoxy]- benzoate
NMR (CDCl3, δ) : 0.89 (6H, d, J=7Hz), 1.67 (3H, d,
J=6Hz), 1.84 (1H, m), 2132 (3H, s), 2.44 (2H, d, J=7Hz), 2.58 (3H, s), 5.38 (1H, q, J=6Hz), 6.66 (1H, d, J=10Hz), 7.0-7.2 (4H, m), 7.2-7.3 (3H, m), 7.3-7.5 (2H, m), 7.86 (1H, d, J=10Hz)
(5) Phenyl 3-[1-(4-isobutylphenyl)ethoxy]benzoate
NMR (CDCl3, δ) : 0.88 (6H, d, J=4Hz), 1.64 (3H, d, J=4Hz), 1.82 (1H, m), 2.43 (2H, d, J=4Hz), 5.37 (3H, q, J=4Hz), 7.05-7.45 (11H, m), 7.30-7.40
(2H, m) (6) Phenyl 4,5-dimethyl-3-[1-(4-isobutylphenyl)ethoxy]- benzoate
NMR (CDCl3, δ) : 0.90 (6H, d, J=7.5Hz), 1.63 (3H, d, J=7.5Hz), 1.74-1.94 (1H, m), 2.30 (3H, s), 2.32 (3H, s), 2.43 (2H, d, J=7.5Hz), 5.40 (1H, q,
J=7.5Hz), 7.04-7.20 (4H, m), 7.20-7.34 (3H, m), 7.34-7.48 (3H, m), 7.60 (1H, s)
(7) Phenyl 3-(3,4-dichlorophenoxymethyl)benzoate
NMR (CDCl3, δ) : 5.11 (2H, s), 6.85 (1H, dd,
J=2.5Hz, 10Hz), 7.11 (1H, d, J=2.5Hz), 7.12-7.62 (7H, m), 7.70 (1H, d, J=8Hz), 8.20 (1H, d,
J=8Hz), 8.25 (1H, s) (8) Phenyl 3-(methoxymethoxy)benzoate
NMR (CDCl3, δ) : 3.51 (3H, s), 5.26 (2H, s), 7.2-7.5
(7H, m), 7.85-7.90 (2H, m)
(9) Phenyl 4-(methoxymethoxy)benzoate
NMR (CDCl3, δ ) : 3.50 (3H, s), 5.25 (2H, s), 7.12
(2H, d, J=10Hz), 7.15-7.30 (3H, m), 7.45 (2H, m), 8.15 (2H, d, J=10Hz)
(10) Phenyl 3-[bis(4-isobutylphenyl)methylthio]benzoate NMR (CDCl3, δ) : 0.92 (12H, d, J=6Hz), 1.86 (1H, m),
2.45 (4H, d, J=6Hz), 5.62 (1H, s), 7.11 (2H, d, J=8Hz), 7.15-7.50 (9H, m ), 7.95 (1H, broad d, J=6Hz), 8.10 (1H, broad s) (11) Phenyl 3-(3,4-dichlorophenylmethoxy)benzoate
NMR (CDCl3, δ) : 5.10 (2H, s), 7.15-7.39 (5H, m), 7.39-7.55 (4H, m), 7.59 (1H, d, J=2.5Hz), 7.80 (1H, broad s), 7.89 (1H, d, J=8Hz) (12) Phenyl 3-(3-bromophenoxymethyl)benzoate NMR (CDCl3, δ) : 5.12 (2H, s), 6.85-7.00 (1H, m),
7.05-7.35 (6H, m), 7.35-7.65 (3H, m), 7.70 (1H, d, J=8Hz), 8.18 (1H, d, J=8Hz), 8.25 (1H, broad s)
(13) Phenyl 3-[3-(isopropoxy)phenoxymethyl]benzoate
NMR (CDCl3, δ) : 1.33 (6H, d, J=8.5Hz), 4.42-4.62 (1H, m), 5.12 (1H, s), 6.43-6.62 (3H, m),
7.10-7.34 (4H, m), 7.34-7.60 (3H, m), 7.72 (1H, m), 8.16 (1H, d, J=8Hz), 8.25 (1H,- broad s)
(14) Phenyl 3-[2-(4-isobutylphenyl)-1-propenyl]benzoate NMR (CDCl3, δ) : 0.93 (6H, d, J=7Hz), 1.89 (1H, m),
2.30 (3H, d, J=1Hz), 2.50 (2H, d, J=7Hz), 6.87 (1H, d, J=1Hz), 7.1-7.6 (10H, m), 7.62 (1H, m),
8.08 (1H, m), 8.20 (1H, s)
(15) Phenyl 8-isobutyl-3,4,6,6-tetramethyl-6H-dibenzo- [b,d]pyrane-2-carboxylate
NMR (CDCl3, δ) : 0.93 (6H, d, J=7Hz), 1.67 (6H, s),
1.89 (1H, m), 2.28 (3H, s), 2.50 (2H, d, J=7Hz), 2.61 (3H, s), 7.02 (1H, d, J=1Hz), 7.15 (1H, dd, J=1Hz, 8Hz), 7.2-7.5 (3H, m), 7.46 (2H, m), 7.72 (1H, d, J=8Hz), 8.41 (1H, s)
(16) Phenyl 3-[2,2-bis(4-isobutylphenyl)ethyl]benzoate
NMR (CDCl3, δ) : 0.86 (12H, d, J=7Hz), 1.80 (2H, m),
2.40 (4H, d, J=7Hz), 3.41 (2H, d, J=7.5Hz), 4.17 (1H, t, J=7.5Hz), 7.02 (4H, d, J=8Hz), 7.12 (4H, d, J=8Hz), 7.0-7.3 (5H, m), 7.3-7.5 (2H, m),
7.88 (1H, br s), 7.95 (1H, d, J=7.5Hz)
(17) Phenyl 4-[2,2-bis(4-isobutylphenyl)ethyl]benzoate
mp : 97-98°C
NMR (CDCl3, δ) : 0.88 (12H, d, J=7Hz), 1.82 (2H, m), 2.41 (4H, d, J=7Hz), 3.41 (2H, d, J=7.5Hz), 4.18 (1H, t, J=7.5Hz), 7.3-7.0 (5H, m), 7.03 (4H, d, J=8Hz), 7.12 (4H, d, J=8Hz), 7.4-7.5 (2H, m), 8.00 (2H, d, J=9Hz)
(18) Phenyl 4-(4-isobutylphenoxy)benzoate
mp ; 78°C
NMR (CDCl3, δ) : 0.97 (6H, d, J=7Hz), 1.91 (1H, m), 2.53 (2H, d, J=7Hz), 7.04 (2H, d, J=8Hz), 7.06 (2H, d, J=8Hz), 7.2-7.4 (5H, m), 7.4-7.6 (2H, m), 8.18 (2H, d, J=8Hz)
(19) Benzyl phenyl 4,4'-biphenyldicarboxylate
Rf = 0.35 (CH2-Cl2:n-hexane (2:3))
(20) Phenyl 3-[N-(4-isobutylbenzyl)-N-(4-isobutylphenyl)- carbamoyl]benzoate
NMR (CDCl3, δ) : 0.81 (6H, d, J=7Hz), 0.90 (6H, d, J=7Hz), 1.7-2.0 (2H, m), 2.37 (2H, d, J=7Hz), 2.47 (2H, d, J=7Hz), 5.12 (2H, s), 6.84 (2H, d,
J=8Hz), 6.95 (2H, d, J=8Hz), 7.0-7.4 (8H, m), 7.4-7.5 (2H, m), 7.59 (1H, d, J=7.5Hz), 8.07 (1H, d, J=7.5Hz), 8.23 (1H, s) (21) Phenyl 3-[N-(4-isobutylbenzoyl)-N-(4-isobutylphenyl)- aminomethyl]benzoate
NMR (CDCl3, δ) : 0.7-0.9 (12H, m), 1.6-1.9 (2H, m), 2.3-2.5 (4H, m), 5.21 (2H, s), 6.7-7.0 (6H, m), 7.1-7.35 (5H, m), 7.35-7.6 (3H, m), 7.68 (1H, br s), 8.09 (2H, br s)
(22) Phenyl 3-[N-(4-isobutylbenzyl)-N-(4-isobutylphenyl)- aminomethyl]benzoate
NMR (CDCl3, δ) : 0.8-0.9 (12H, m), 1.80 (2H, m),
2.3-2.5 (4H, m), 4.6-4.7 (4H, m), 6.69 (2H, br s ) , 6. 9-7. 0 ( 2H, m) , 7. 0-7. 3 ( 7H, m) , 7. 4-7.7 ( 4H, m) , 8 . 07 ( 2H, br s )
(23) Phenyl 3-[N-(4-isobutylbenzoyl)-N-(3-isobutylphenyl)- aminomethyl]benzoate
NMR (CDCl3, δ) : 0.65 (6H, d, J=7Hz), 0.81 (6H, d,
J=7Hz), 1.52 (1H, m), 1.75 (1H, m), 2.25 (2H, d, J=7Hz), 2.35 (2H, d, J=7Hz), 5.22 (2H, s), 6.61 (1H, br s), 6.8-7.0 (4H, m), 7.0-7.3 (6H, m), 7.3-7.5 (3H, m), 7.68 (1H, d, J=7.5Hz), 8.0-8.2
(2H, m)
(24) Phenyl 3-[N-benzoyl-N-(4-isobutylphenyl)aminomethyl]- benzoate
NMR (CDCl3, δ) : 0.78 (6H, d, J=7Hz), 1.74 (1H, m),
2.35 (2H, d, J=7Hz), 5.21 (2H, s), 6.83 (2H, d,
J=8Hz), 6.92 (2H, d, J=8Hz), 7.1-7.6 (11H, m),
7.68 (1H, d, J=7.5Hz), 8.0-8.2 (2H, m) (25) Phenyl 3-(4-isobutylphenoxymethyl)benzoate
NMR (CDCl3, δ) : 0.88 (6H, d, J=7Hz ) , 1.70-1.94 (1H, m), 2.42 (2H, d, J=8Hz), 5.12 (2H, s), 6.90 (2H, d, J=8Hz), 7.08 (2H, d, J=8Hz), 7.18-7.50 (5H, m), 7.53 (1H, t, J=8Hz), 7.74 (1H, dd, J=1Hz, 8Hz), 8.18 (1H, dd, J=1Hz, 8Hz), 8.28 (1H, t,
J=1Hz)
(26) Phenyl 4-(4-propylphenoxymethyl)benzoate
NMR (CDCl3, δ) : 0.92 (3H, t, J=7.5Hz), 1.50-1.70 (2H, m), 2.52 (2H, t, J=7.5Hz), 5.15 (2H, s),
6.90 (2H, d, J=8Hz), 7.10 (2H, d, J=8Hz),
7.20-7.50 (5H, m), 7.58 (2H, d, J=8Hz), 8.20 (2H, d, J=8Hz) (27) Phenyl 2,3-dimethyl-5-(3-isobutylphenoxymethyl)- benzoate NMR (CDCl3, δ) : 0.93 ( 6H, d, J=7.5Hz), 1.80-2.00 (1H, m), 2.42 (3H, s), 2.48 (2H, d, J=7.5Hz), 2.58 (3H, s), 5.08 (2H, s), 6.78-6.90 (3H, m), 7.20-7.37 (4H, m), 7.45-7.52 (3H, m), 8.02 (1H, d, J=1Hz)
(28) Phenyl 2,3-dimethyl-5-(4-isobutylphenoxymethyl)- benzoate
NMR (CDCl3, δ) : 0.88 (6H, d, J=7.5Hz), 1.70-1.92 (1H, m), 2.38 (3H, s), 2.42 (2H, d, J=7.5Hz),
2.55 (3H, s), 5.04 (2H, s), 6.90 (2H, d, J=8Hz), 7.07 (2H, d, J=8Hz), 7.18-7.32 (3H, m), 7.40-7.50 (3H, m), 7.95 (1H, d, J=1Hz) (29) Phenyl 3-(2-isobutylphenoxymethyl)benzoate
NMR (CDCl3, δ) : 0.90 (6H, d, J=7.5Hz), 1.85-2.12 (1H, m), 2.58 (2H, d, J=7.5Hz), 5.18 (2H, s), 6.83-6.98 (2H, m), 7.08-7.35 (5H, m) , 7.35-7.63 (3H, m), 7.72 (1H, d, J=8Hz), 8.18 (1H, d,
J=8Hz), 8.30 (1H, s)
(30) Phenyl 4-(4-isobutylphenyl)benzoate
NMR (CDCl3, δ) : 0.95 (6H, d, J=7.5Hz), 1.80-2.04 (1H, m), 2.53 (2H, d, J=7.5Hz), 7.20-7.35 (5H, m), 7.42 (2H, d, J=8Hz), 7.59 (2H, d, J=8Hz),
7.72 (2H, d, J=8Hz), 8.25 (2H, d, J=8Hz)
(31) Phenyl 4'-isobutylstilbene-3-carboxylate
NMR (CDCl3, δ) : 0.95 (6H, d, J=7.5Hz), 1.92 (1H, m), 2.52 (2H, d, J=7.5Hz), 7.10-7.40 (5H, m),
7.40-7.60 (5H, m), 7.78 (1H, m), 8.10 (1H, m), 8.38 (1H, m)
(32) Phenyl 4-[2-(4-isobutylphenyl)-1-propenyl]benzoate NMR (CDCl3, δ) : 0.90 (6H, d, J=0.75Hz), 1.90 (1H, m), 2.30 (3H, d, J=0.4Hz), 2.50 (2H, d,
J=7.5Hz), 6.90 (1H, s), 7.15-7.35 (5H, m),
7.40-7.55 (6H, m), 8.20 (2H, d, J=10Hz) Preparation 52
A mixture of methyl 3-(chloroformyl)propionate (5.4 ml) and aluminum chloride (11.7 g) in dichloromethane was stirred at 25°C for 1 hour, and then a solution of
6-chloroindole (3.0 g) in dichloromethane (20 ml) at 25°C. The reaction mixture was stirred at 25°C for.1 hour, and poured into a mixture of ice and 1N hydrochloric acid.
The organic layer was separated, washed with water, and dried over magnesium sulfate. After evaporation of the solvents the crystalline residue was recrystallized from ethyl acetate to give methyl 4-(6-chloroindol-3-yl)-4- oxobutyrate (2.54 g) as colorless crystals.
NMR (CDCl3-CD3OD, δ) : 2.80 (2H, t, J=7.5Hz), 3.19 (2H, t, J=7.5Hz), 3.70 (3H, s), 7.21 (1H, dd, J=2.5Hz, 8Hz), 7.39 (1H, d, J=2.5Hz), 7.85 (1H, s), 8.24 (1H, d, J=8Hz)
Preparation 53
IM solution of borane in tetrahydroffran (4.6 ml) was added to a solution of methyl 4-(6-chloroindol-3-yl)-4- oxobutyrate (1.20 g) in tetrahydrofuran (40 ml) at 25°C over 5 minutes. The mixture was stirred at 25°C for 30 minutes, and IM solution of borane" in tetrahydrofuran 2.3 ml) was added at 25°C. The mixture was stirred at 25°C for 30 minutes, and then another IM solution of borane in tetrahydrofuran (2.3 ml) was added at 25°C. The reaction mixture was stirred at 25°C for 15 minutes and poured into a mixture of ethyl acetate and 1N hydrochloric acid. The organic layer was separated, washed with water and brine, and dried over magnesium sulfate. After evaporation of the solvent, the residue was purified by column chromatography on silica gel (50 g) eluting with
chloroform and by recrystallization from a mixture of ethyl acetate and hexane to give methyl 4-(6-chloroindol- 3-yl)butyrate (669 mg) as pale yellow crystals.
NMR (CDCl3, δ) : 1.92-2.15 (2H, m), 2.40 (2H, t,
J=7.5Hz), 2.80 (2H, t, J=7.5Hz), 3.70 (3H, s), 7.00 (1H, d, J=2.5Hz), 7.10 (1H, dd, J=2.5Hz, 8Hz), 7.35 (1H, d, J=2.5Hz), 7.52 (1H, d,
J=8Hz), 7.97 (1H, broad s)
Preparation 54
Methyl 4-(6-chloroindol-3-yl)butyrate (1.2 g) was hydrolyzed with 1N aqueous solution of sodium hydroxide (12 ml) and the crude product was recrystallized from a mixture of ethyl acetate and hexane to give 4-(6- chloroindol-3-yl)butyric acid (1.09 g) as colorless crystals.
NMR (CDCl3-CD3OD, δ) : 1.90-2.10 (2H, m), 2.38 (2H, t, J=7.5Hz), 2.79 (2H, t, J=7.5Hz), 6.98 (1H, s), 7.05 (1H, dd, J=2.5Hz, 8Hz), 7.35 (1H, d,
J=2.5Hz), 7.50 (1H, d, J=8Hz)
Preparation 55
A solution of 3-indolebutyric acid (2.42 g) in
N,N-dimethylformamide (20 ml) was added to a suspension of sodium hydride (60% dispersion in mineral oil, 1.05 g) in N,N-dimethylformamide (30 ml) at 25°C over 15 minutes. The mixture was stirred at 25°C for 1.5 hours and cooled to -40°C. A solution of phenyl 3-(methoxymethoxy)benzoate (3.07 g) in tetrahydrofuran (40 ml) was added at -40°C over 30 minutes, and the mixture was stirred at the same temperature for 30 minutes. The mixture was worked up in an usual manner, and the crude product was purified by column chromatography on silica gel (50 g) eluting with chloroform and recrystallization from a mixture of ethyl acetate and hexane to give 4-[1-[3-(methoxymethoxy)- benzoyl]indol-3-yl]butyric acid (2.96 g) as colorless crystals.
NMR (CDCl3, δ) : 2.03 (2H, tt, J=6Hz, 6Hz), 2.42
(2H, t , J=6Hz), 2.66 (2H, t, J=6Hz ), 3.50 (3H, s), 5.36 (2H, s), 7.10 (1H, s), 7.2-7.6 (7H, m), 8.40 (1H, d, J=8Hz)
Preparation 56
The following compound was obtained according to a similar manner to that of Preparation 55.
4-[1-[4-(Methoxymethoxy)benzoyl]indol-3-yl]butyric acid
NMR (CDCl3, δ) : 2.05 ( 2H, m), 2.45 ( 2H, t, J=8Hz),
2.75 (2H, t, J=8Hz), 3.52 (3H, s), 5.25 (2H, s), 6.7-7.4 (5H, m), 7.55 (1H, m), 7.70 (2H, d, J=8Hz), 8.45 (1H, m) Preparation 57
A mixture of 4-[1-[4-(methoxymethoxy)benzoyl]- indol-3-yl]butyrate (2.50 g), benzyl bromide (1.81 g) and potassium carbonate (2.82 g) in N,N-dimethylformamide (30 ml) was stirred at 25°C for 6 hours. The mixture was diluted with ethyl acetate, washed with 1N hydrochloric acid, water, aqueous sodium bicarbonate solution and brine, dried over magnesium sulfate, and evaporated. The residue was chromatographed on silica gel (100 g) with dichloromethane to give benzyl 4-[1-[4-(methoxymethoxy)- benzoyl]indol-3-yl]butyrate (3.02 g) as a pale yellow oil.
NMR (CDCl3, δ) : 2.05 (2H, m), 2.50 (2H, t, J=8Hz), 2.75 (2H, t, J=8Hz), 3.50 (3H, s), 5.10 (2H, s), 5.28 (2H, s), 7.1-7.2 (3H, m), 7.25-7.4 (7H, m), 7.55 (1H, m), 7.70 (2H, d, J=8Hz), 8.85 (1H, m) Preparation 58
To a solution of 4-[1-[3-(methoxymethoxy)benzoyl]- indol-3-ylIbutyric acid (1.4 g) in 1,4-dioxane (10 ml) was added 4N solution of hydrogen chloride in 1,4-dioxane (4 ml) at 25°C. The mixture was stirred at 25°C for 6 hours, and poured into a mixture of ether and 1N hydrochloric acid. The organic layer was separated, washed with water and brine, and dried over magnesium sulfate. After evaporation of the solvent, the crystalline residue was washed with isopropyl ether to give
4-[1-(3-hydroxybenzoyl)indol-3-yl]butyric acid (1.00 g) as colorless crystals.
NMR (CDCl3-CD3OD, δ) : 2.02 (2H, tt, J=6Hz, 6Hz), 2.40 (2H, t, J=6Hz), 2.75 (2H, t, J=6Hz),
7.05-7.2 (3H, m), 7.30-7.45 (4H, m), 7.6-7.7 (1H, m), 8.38 (1H, dd, J=2Hz, 8Hz)
Preparation 59
Benzyl 4-[1-[4-(methoxymethoxy)benzoyl]indol-3-yl]- butyrate (572 mg) was dissolved in trifluoroacetic acid (12 ml) at 25°C and the mixture was stirred at the same temperature for 15 minutes. After evaporation of the solvent, the residue was dissolved with ethyl acetate, washed with aqueous sodium bicarbonate solution and brine, dried over magnesium sulfate, and evaporated. The residue was chromatographed on silica gel (30 g) eluting with a mixture of hexane and ethyl acetate (2:1) to give benzyl 4-[1-(4-hydroxybenzoyl)indol-3-yl]butyrate (350 mg) as a yellow oil.
NMR (CDCl3, δ) : 2.10 (2H, m), 2.50 (2H, t, J=8Hz),
2.80 (2H, t, J=8Hz), 5.15 (2H, s), 6.98 (2H, d, J=10Hz), 7.2-7.6 (7H, m), 7.60 (1H, m), 7.65 (2H, d, J=10Hz), 8.40 (1H, m) Example 1
A solution of 4-(indol-3-yl)butyric acid (1.25 g) in N,N-dimethylformamide (10 ml) was added to a suspension of sodium hydride (60% dispersion in mineral oil, 541 mg) in N,N-dimethylformamide (20 ml) at 25°C over 15 minutes. The mixture was stirred at 25°C for 1 hour, and then a solution of phenyl 3-(3-isobutylphenoxymethyl)benzoate (2.22 g) in tetrahydrofuran (10 ml) was added at -40°C. The reaction mixture was stirred at -40°C for 30 minutes and poured into a mixture of ether and 1N hydrochloric acid. The organic layer was separated, washed with water and brine, and dried over magnesium sulfate. The residue was purified by column chromatography on silica gel (40 g) eluting with chloroform and by recrystallization from a mixture of ethyl acetate and hexane to give 4-[1-[3-(3- isobutylphenoxymethyl)benzoyl]indol-3-yl]butyric acid (1.45 g) as colorless crystals,
mp : 81-83ºC
NMR (CDCl3, δ) : 0.88 (6H, d, J=4Hz), 1.88 (1H, m), 2.06 (2H, quintet, J=4Hz), 2.45 (2H, t, J=4Hz),
2.47 (2H, d, J=4Hz), 2.76 (2H, t, J=4Hz),
5.16 (2H, s), 6.75-6.87 (3H, m), 7.09 (1H, s), 7.20-7.77 (7H, m), 7.83 (1H, s), 8.40 (1H, dd, J=1Hz, 4Hz)
Example 2
The following compounds were obtained according to a similar manner to that of Example 1. (1) 4-[1-[3-(4-Isopentylphenoxymethyl)benzoyl]indol-3- yl]butyric acid
mp : 114-116°C
NMR (CDCl3, δ) : 0.92 (6H, d, J=4Hz), 1.4-1.7 (3H, m), 2.01 (2H, m), 2.42 (2H, t, J=4Hz), 2.54 (2H, dd, J=4Hz, 5Hz), 2.72 (2H, t, J=4Hz), 5.10 (2H, s), 6.90 (2H, d, J=5Hz), 7.05-7.70 (9H, m), 7.80 (1H, t, J=1Hz), 8.38 (1H, dd, J=1Hz, 5Hz)
(2) 4-[1-[4-(4-Isobutylbenzyloxy)benzoyl]indol-3-yl]- butyric acid
mp : 156°C
NMR (CDCl3, δ) : 0.95 (6H, d, J=7.5Hz), 1.8-2.2 (3H, m), 2.4-2.6 (4H, m), 2.78 (2H, t, J=7.5Hz), 5.15 (2H, s), 7.12 (2H, d, J=10Hz), 7.2-7.5 (7H, m), 7.60 (1H, m), 7.75 (2H, d, J=10Hz), 8.35 (1H, m)
(3) 4-[1-[3-[Bis(4-isobutylbenzyl)amino]benzoyl]indol-3- yl]butyric acid
NMR (CDCl3, δ) : 0.92 (12H, d, J=7.5Hz), 1.65-2.0 (2H, m), 2.0-2.1 (2H, m), 2.42 (2H, t, J=7.5Hz),
2.48 (4H, d, J=7.5Hz), 2.70 (2H, t, J=7.5Hz), 4.70 (4H, s), 6.9-7.1 (2H, m), 7.1-7.2 (8H, m), 7.25-7.5 (5H, m), 7.5-7.6 (1H, m), 8.40 (1H, d, J=7.5Hz)
(4) 4-[1-[2,3-Dimethyl-4-[1-(4-isobutylphenyl)ethoxy]- benzoyl]indol-3-yl]butyric acid
mp : 98-99°C
NMR (CDCl3, δ) : 0.88 (6H, d, J=7Hz), 1.67 (3H, d, J=6Hz), 1.85 (1H, m), 1.97 (2H, m), 2.22 (3H, s), 2.31 (3H, s), 2.3-2.5 (5H, m), 2.69 (2H, t, J=7.5Hz), 5.36 (1H, q, J=6Hz), 6.66 (1H, d, J=9Hz), 6.86 (1H, s), 7.04 (1H, d, J=9Hz), 7.11 (2H, d, J=8Hz), 7.2-7.4 (4H, m), 7.5-7.6 (1H, m), 8.23 (1H, d, J=7.5Hz)
(5) 4-[1-[3-[1-(4-Isobutylphenyl)ethoxy]benzoyl]indol-3- yl]butyric acid
NMR (CDCl3, δ) : 0.87 (6H, d, J=4Hz), 1.64 (3H, d, J=4Hz), 1.80 (1H, m), 1.98 (2H, quintet, J=4Hz), 2.40 (2H, t, J=4Hz), 2.41 (2H, d, J=4Hz), 2.72 (2H, t, J=4Hz), 5.32 (1H, g, J=4Hz), 6.8-7.4 (11H, m), 7.53 (1H, dd, J=2Hz, 5Hz), 8.35 (1H, dd, J=2Hz, 5Hz)
6) 4-[1-[4,5-Dimethyl-3-[1-(4-isobutylphenyl)ethoxy]- benzoyl]indol-3-yl]butyric acid
NMR (CDCl3, δ) : 0.88 (6H, d, J=7.5Hz), 1.62 (3H, d, J=7.5Hz), 1.68-2.08 (3H, m), 2.22-2.49 (10H, m), 2.58-2.80 (2H, m), 6.78-6.88 (1H, m), 6.92-7.02
(2H, m), 7.02-7.16 (3H, m), 7.20-7.40 (3H, m), 7.48-7.60 (1H, m), 8.28-8.38 (1H, m)
(7) 4-[1-[3-(3,4-Dichlorophenoxymethyl)benzoyl]indol-3- yl]butyric acid
NMR (CDCl3, δ) : 1.90-2.10 (2H, m), 2.40 (2H, t,
J=7.5Hz), 2.73 (2H, t, J=7.5Hz), 5.14 (2H, s), 6.84 (1H, dd, J=2.5Hz, 10Hz), 7.05 (1H, s), 7.09 (1H, d, J=2.5Hz), 7.20-7.45 (3H, m), 7.50-7.75 (4H, m), 7.78 (1H, s), 8.38 (1H, d, J=8Hz)
(8) 4-[1-[3-[Bis(4-isobutylphenyl)methylthio]benzoyl]- indol-3-yl]butyric acid
NMR (CDCl3, δ) : 0.85 (12H, d, J=6Hz), 1.80 (2H, m), 2.02 (2H, m), 2.36-2.50 (4H, m), 2.72 (2H, t,
J=6Hz), 5.55 (1H, s), 6.95 (1H, s), 7.05 (4H, d, J=8Hz), 7.2-7.5 (9H, m), 7.5-7.6 (2H, m), 8.26 (1H, d, J=8Hz) (9) 4-[5-Chloro-1-[3-(3-isobutylphenoxymethyl)benzoyl]- indol-3-yl]butyric acid
mp : 96-97°C
NMR (CDCl3, δ) : 0.88 (6H, d, J=7.5Hz), 1.70-2.10 (3H, m), 2.30-2.50 (4H, m), 2.69 (2H, t, J=7.5Hz), 5.10 (2H, s), 6.70-6.85 (3H, m), 7.10 (1H, s), 7.20 (1H, t, J=8Hz), 7.32 (1H, dd, J=2.5Hz, 8Hz), 7.45-7.75 (4H, m), 7.80 (1H, s), 8.30 (1H, d, J=8Hz) (10) 4-[6-Chloro-1-[3-(3-isobutylphenoxymethyl)benzoyl]- indol-3-yl]butyric acid
mp : 126-127°C
NMR (CDCl3, δ) : 0.89 (6H, d, J=7.5Hz), 1.72-2.10 (3H, m), 2.35-2.50 (4H, m), 2.70 (2H, t,
J=9.5Hz), 5.5 (2H, s), 6.70-6.85 (3H, m), 7.05 (1H, s), 7.12-7.38 (2H, m), 7.40-7.75 (4H, m), 7.80 (1H, s), 8.49 (1H, d, J=2.5Hz)
(11) 4-[1-[3-(3,4-Dichlorobenzyloxy)benzoyl]indol-3-yl]- butyric acid
NMR (CDCl3, δ) : 1.90-2.15 (2H, m), 2.41 (2H, t,
J=7.5Hz), 2.71 (2H, t, J=7.5Hz), 5.02 (2H, s), 7.02 (1H, s), 7.12-7.65 (10H, m), 8.35 (1H, d, J=8Hz)
(12) 4-[1-[3-(3-Bromophenoxymethyl)benzoyl]indol-3-yl]- butyric acid
NMR (CDCl3, δ) : 1.85-2.15 (2H, m), 2.42 (2H, t,
J=7.5Hz), 2.70 (2H, t, J=7.5Hz), 5.10 (2H, s), 6.83-6.95 (1H, m), 7.00-7.20 (4H, m), 7.20-7.50
(2H, m), 7.50-7.75 (4H, m), 7.80 (1H, broad s), 8.38 (1H, d, J=8Hz)
(13) 4-[1-[3-[3-(Isopropoxy)phenoxymethyl]benzoyl]- indol-3-yl]butyric acid
mp : 80-82°C
NMR (CDCl3, δ) : 1.33 (6H, d, J=7.5Hz), 1.90-2.13 (2H, m), 2.42 (2H, t, J=7.5Hz), 2.75 (2H, t, J=7.5Hz), 4.40-4.62 (1H, m), 5.11 (2H, s), 6.45-6.60 (3H, m), 7.08 (1H, s), 7.10-7.25 (1H, m), 7.28-7.48 (2H, m), 7.48-7.63 (2H, m),
7.63-7.74 (2H, m), 7.81 (1H, broad s), 8.38 (1H, m) (14) 4-[1-[3-[2-(4-Isobutylphenyl)-1-propenyl]benzoyl]- indol-3-yl]butyric acid
mp : 109-110°C
NMR (CDCl3, δ) : 0.92 (6H, 7H), 1.87 (1H, m),
2.02 (2H, m), 2.30 (3H, d, J=1Hz), 2.4-2.6 (4H, m), 2.76 (2H, t, J=7.5Hz), 6.87 (1H, d, J=1Hz),
7.1-7.2 (3H, m), 7.3-7.6 (8H, m), 7.70 (1H, s), 8.40 (1H, m)
(15) 4-[1-[8-Isobutyl-3,4,6,6-tetramethyl-6H-dibenzo[b,d]- pyran-2-ylcarbonyl]indol-3-yl]butyric acid
NMR (CDCl3, δ) : 0.95 (3H, d, J=7Hz), 1.70 (6H, s), 1.90 (1H, m), 2.03 (2H, m), 2.44 (2H, t,
J=7.5Hz), 2.52 (2H, d, J=7Hz), 2.74 (2H, t, J=7.5Hz), 7.0-7.2 (3H, m), 7.2-7.5 (2H, m), 7.5-7.7 ( 3H, m) , 8.33 ( 1H, m)
(16) 4-[1-[3-[2,2-Bis(4-isobutylphenyl)ethyl]benzoyl]- indol-3-yl]butyric acid
NMR (CDCl3, δ) : 0.80 (12H, d, J=7Hz), 1.75 (2H, m), 2.01 (2H, m), 2.3-2.5 (2H, m), 2.36 (4H, d,
J=7Hz), 2.73 (2H, t, J=7.5Hz), 3.39 (2H, d, J=7.5Hz), 4.16 (1H, t, J=7.5Hz), 7.0-7.4 (6H, m), 7.00 (4H, d, J=8Hz), 7.10 (4H, d, J=8Hz), 7.4-7.5 (1H, m), 7.55 (1H, m), 8.25 (1H, m)
(17) 4-[1-[4-[2,2-Bis(4-isobutylphenyl)ethyl]benzoyl]- indol-3-yl]butyric acid
mp : 152°C
NMR (CDCl3, δ) : 0.87 (12H, d, J=7Hz), 1.82 (2H, m), 1.9-2.1 (2H, m), 2.3-2.5 (2H, m), 2.42 (4H, d, J=7Hz), 2.74 (2H, t, J=7.5Hz), 3.42 (2H, d, J=7.5Hz), 4.20 (1H, t, J=7.5Hz), 7.0-7.2 (1H, m), 7.03 (4H, d, J=8Hz), 7.12 (4H, d, J=8Hz), 7.2-7.4 (2H, m), 7.5-7.6 (1H, m), 7.10 (2H, d,
J=8Hz), 7.52 (2H, d, J=8Hz), 8.28 (1H, m)
(18) 4-[1-[4-(4-Isobutylphenoxy)benzoyl]indol-3-yl]butyric acid
NMR (CDCl3, δ) : 0.93 (6H, d, J=7Hz), 1.87 (1H, m),
2.04 (2H, quint, J=7.5Hz), 2.4-2.6 (4H, m), 2.76 (2H, t, J=7.5Hz), 7.01 (2H, d, J=8Hz), 7.05 (2H, d, J=8Hz), 7.16 (1H, s), 7.18 (2H, d, J=8Hz), 7.2-7.5 (2H, m), 7.57 (1H, d, J=7.5Hz), 7.71 (2H, d, J=8Hz), 8.35 (1H, d, J=7.5Hz)
(19) 4-[1-[4-(4'-Benzyloxycarbonyl)biphenylcarbonyl]- indol-3-yl]butyric acid
NMR (CDCl3, δ) : 2.03 (2H, m), 2.43 (2H, t,
J=7.5Hz), 2.75 (2H, t, J=7.5Hz), 5.41 (2H, s),
7.13 (1H, s), 7.2-7.5 (7H, m), 7.58 (1H, d, J=7.5Hz), 7.72 (2H, d, J=8Hz), 7.76 (2H, d, J=8Hz), 7.83 (2H, d, J=8Hz), 8.18 (2H, d,
J=8Hz), 8.41 (1H, d, J=7.5Hz)
(20) 4-[1-[3-[N-(4-Isobutylbenzoyl)-N-methylamino3- benzoyl]indol-3-yl]butyric acid
NMR (CDCl3, δ) : 0.81 ( 6H, d, J=6Hz), 1.7-1.9 (1H, m), 2.00 (2H, t, J=7Hz), 2.3-2.5 (4H, m), 2.71 (2H, t, J=7Hz), 3.52 (3H, s), 6.8-7.1 (4H, m),
7.2-7.6 (8H, m), 8.29 (1H, m)
(21) 4-[1-[3-[N-(4-Isobutylbenzyl)-N-(4-isobutylphenyl)- carbamoyl]benzoyl]indol-3-yl]butyric acid
NMR (CDCl3, δ) : 0.78 (6H, d, J=7Hz), 0.86 (6H, d, J=7Hz), 1.6-1.9 (2H, m), 2.06 (2H, quint,
J=7Hz), 2.3-2.5 (6H, m), 2.80 (2H, t, J=7Hz), 5.08 (2H, s), 6.76 (2H, d, J=8Hz), 6.91 (2H, d, J=8Hz), 6.94 (1H, s), 7.04 (2H, d, J=8Hz), 7.16 (2H, d, J=8Hz), 7.1-7.5 (4H, m), 7.5-7.7 (2H, m), 7.84 (1H, br s), 8.37 (1H, d, J=7.5Hz)
(22) 4-[1-[3-[N-(4-Isobutylbenzoyl)-N-(4-isobutylphenyl)- aminomethyl]benzoyl]indol-3-yl]butyric acid
NMR (CDCl3, δ) : 0.80 (12H, d, J=7Hz), 1.75 (2H, m),
2.05 (2H, quint, J=7Hz), 2.38 (4H, d, J=7Hz), 2.43 (2H, t, J=7.5Hz), 2.77 (2H, t, J=7Hz), 5.23 (2H, s), 6.83 (2H, d, J=8Hz), 6.90 (2H, d,
J=8Hz), 6.94 (2H, d, J=8Hz), 7.11 (1H, s), 7.20 (2H, d, J=8Hz), 7.3-7.5 (4H, m), 7.59 (1H, d,
J=7.5Hz), 7.6-7.8 (1H, m), 7.77 (1H, br s), 8.45 (1H, d, J=7.5Hz)
(23) 4-[1-[3-[N-(4-Isobutylbenzoyl)-(3-isobutylphenyl)- aminomethyl]benzoyl]indol-3-yl]butyric acid
NMR (CDCl3, δ) : 0.64 (6H, d, J=7Hz), 0.80 (6H, d, J=7Hz), 1.51 (1H, m), 1.74 (1H, m), 2.25 (2H, d, J=7Hz), 2.33 (2H, d, J=7Hz), 2.42 (2H, t, J=7Hz), 2.74 (2H, t, J=7Hz), 5.21 (2H, s), 6.59 (1H, br s), 6.8-7.0 (4H, m), 7.0-7.3 (4H, m),
7.5-7.3 (4H, m), 7.57 (1H, d, J=7.5Hz), 7.6-7.8 (1H, m), 7.75 (1H, br s), 8.42 (1H, d, J=7.5Hz)
(24) 4-[1-[3-[N-(4-Isobutylbenzyl)-N-(4-isobutylphenyl)- aminomethyl]benzoyl]indol-3-yl]butyric acid
NMR (CDCl3, δ) : 0.86 (6H, d, J=7Hz), 0.88 (6H, d,
J=7Hz), 1.78 (2H, m), 1.98 (2H, quint, J=7.5Hz), 2.3-2.5 (6H, m), 2.70 (2H, t, J=7.5Hz), 4.6-4.7 (4H, m), 6.70 (1H, br s), 6.8-7.7 (15H, m), 8.35 (1H, d, J=7.5Hz) (25) 4-[1-[3-[N-Benzoyl-N-(4-isobutylphenyl)aminomethyl]- benzoyl]indol-3-yl]butyric acid
NMR (CDCl3, δ) : 0.78 (6H, d, J=7Hz), 1.74 (1H, m), 2.35 (2H, d, J=7Hz), 5.21 (2H, s), 6.83 (2H, d, J=8Hz), 6.92 (2H, d, J=8Hz), 7.1-7.6 (11H, m),
7.68 (1H, d, J=7.5Hz), 8.0-8.2 (2H, m)
(26) 4-[1-[3-(4-Isobutylphenoxymethyl)benzoyl]indol-3- yl]butyric acid
NMR (CDCl3, δ) : 0.89 (6H, d, J=7Hz), 1.70-1.92 (1H, m), 1.95-2.12 (2H, m), 2.36-2.50 (4H, m), 2.75 (2H, t), 5.12 (2H, s), 6.88 (2H, d, J=8Hz), 7.07 (2H, d, J=8Hz), 7.08 (1H, s), 7.20-7.72 (6H, m), 7.80 (1H, s), 8.38 (1H, dd, J=1Hz, 8Hz)
(27) 4-[1-[4-(4-Propylbenzyloxy)benzoyl]indol-3-yl]- butyric acid
mp : 93-94°C
NMR (CDCl3, δ) : 0.92 (3H, t, J=7.5Hz), 1.52-1.72 (2H, m), 1.95-2.22 (2H, m), 2.43 (2H, t,
J=7.5Hz), 2.55 (2H, t, J=7.5Hz), 2.76 (2H, t, J=7.5Hz), 5.15 (2H, s), 6.92 (2H, d, J=8Hz), 7.08 (1H, s), 7.12 (2H, d, J=8Hz), 7.30-7.62 (5H, m), 7.75 (2H, d, J=8Hz), 8.38 (1H, dd, J=1Hz, 8Hz)
(28) 4-[1-[2,3-Dimethyl-5-(3-isobutylphenoxymethyl]- benzoyl]indol-3-yl]butyric acid
NMR (CDCl3, δ) : 0.90 (6H, d, J=7.5Hz), 1.75-2.10 (3H, m), 2.23 (3H, s), 2.38 (3H, s), 2.43-2.52
(4H, m), 2.72 (2H, t, J=7.5Hz), 5.07 (2H, s), 6.75-6.90 (4H, m), 7.20 (1H, dd, J=6Hz, 8Hz), 7.30-7.50 (5H, m), 7.58 (1H, dd, J=1Hz, 8Hz) (29) 4-[1-[2,3-Dimethyl-5-(4-isobutylphenoxymethyl)- benzoyl]indol-3-yl]butyric acid
NRM (CDCl3, δ) : 0.90 (6H, d, J=7.5Hz), 1.7-2.1 (3H, m), 2.24 (3H, s), 2.40 (3H, s), 2.41-2.48 (4H, m), 2.72 (2H, t, J=7.5Hz), 5.06 (2H, s), 6.84 (1H, broad s), 6.90 (2H, d, J=8Hz), 7.08 (2H, d,
J=8Hz), 7.28-7.46 (5H, m), 7.48 (1H, dd, J=1Hz,
8Hz)
(30) 4-[1-[3-(2-Isobutylphenoxymethyl)benzoyl]indol-3-yl]- butyric acid
NMR (CDCl3, δ) : 0.89 (6H, d, J=7.5Hz), 1.81-2.15 (3H, m), 2.44 (2H, t, J=7.5Hz), 2.58 (2H, d, J=7.5Hz), 2.75 (2H, t, J=7.5Hz), 5.18 (2H, s), 6.83-7.02 (2H, m), 7.02-7.25 (3H, m), 7.25-7.50 (2H, m), 7.50-7.90 (5H, m), 8.40 (1H, m)
(31) 4-[1-[4-(4-Isobutylphenyl)benzoyl]indol-3-yl]butyric acid
NMR (CDCl3, δ) : 0.92 (6H, d, J=7.5Hz), 1.78-2.14 (4H, m), 2.42 (2H, t, J=7.5Hz), 2.54 (2H, d,
J=7.5Hz), 2.76 (2H, t, J=7.5Hz) 7.17 (1H, s), 7.20-7.45 (4H, m), 7.58 (3H, d, J=8Hz), 7.77 (4H, A2B2, J=8Hz), 8.40 (1H, d, J=8Hz) (32) 4-[1-[3-[2-(4-Isobutylphenyl)vinyl]benzoyl]indol-3- yl]butyric acid
NMR (CDCl3, δ) : 0.90 (6H, d, J=7.5Hz), 1.88 (1H, m), 2.01 (2H, m), 2.35-2.50 (4H, m), 2.75 (2H, t, J=7.5Hz), 7.0-7.6 (12H, m), 7.77 (1H, m), 7.87 (1H, m), 8.40 (1H, m)
(33) 4-[1-[4-[2-(4-Isobutylphenyl)-1-propenyl]benzoyl]- indol-3-yl]butyric acid
NMR (CDCl3, δ) : 0.90 (6H, d, J=0.75Hz), 1.90 (1H, m), 2.02 (2H, m), 2.35 (3H, t, J=0.5Hz), 2.45-2.55 (4H, m), 2.75 (2H, t, J=5Hz), 6.88 (1H, s), 7.12-7.20 (3H, m), 7.30-7.60 (7H, m), 7.75 (2H, d, J=7.5Hz), 8.40 (1H, m) Example 3
A solution of 4-[1-(3-hydroxybenzoyl)indol-3-yl]- butyric acid (480 mg) in N,N-dimethylformamide (10 ml) was added to a suspension of sodium hydride (60% dispersion in mineral oil, 131 mg) in N,N-dimethylformamide at 25°C over 15 minutes. The mixture was stirred at 25°C- for 30 minutes, and then a solution of bis(4-isobutylphenyl)- bromomethane (640 mg) in tetrahydrofuran (10 ml) was added at 25°C. The reaction mixture was stirred at 25°C for 4 hours and allowed to stand at 25°C for 2 days. The mixture was worked up in an usual manner and the crude product was purified by column chromatography on silica gel (40 g) eluting with chloroform to give 4-[1-[3-[bis- (4-isobutylphenyl)methoxy3benzoyl]indol-3-yl]butyric acid (0.37 g) as a colorless oil.
NMR (CDCl3, δ) : 0.88 (12H, d, J=6Hz), 1.86 (2H, m),
2.02 (2H, m), 2.37-2.50 (4H, m), 2.62 (2H, t, J=6Hz), 6.23 (1H, s), 7.00 (1H, s), 7.10 (4H, d, J=8Hz), 7.15-7.40 (10H, m), 7.58 (1H, m) . 8.47 (1H, dd, J=2Hz, 8Hz)
Example 4
The following compounds were obtained according to a similar manner to that of Example 3. (1) Benzyl 4-[1-[4-[bis(4-isobutylphenyl)methoxy3- benzoyl]indol-3-yl]butyrate
NMR (CDCl3, δ) : 0.90 (12H, d, J=5Hz), 1.85 (2H, m), 2.05 (2H, m), 2.35-2.80 (6H, m), 2.70 (2H, t, J=8Hz), 5.10 (2H, s), 6.28 (1H, s), 7.00-7.40 (18H, m), 7.50 (1H, m), 7.65 (1H, m), 8.30 (1H, m) (2) Benzyl 4-[1-[4-[1-(4-isobutylphenyl)ethoxy]benzoyl]- indol-3-yl]butyrate
NMR (CDCl3, δ) : 0.85 (6H, d, J=5Hz), 1.62 (3H, d, J=7Hz), 1.80 (1H, m), 2.00 (2H, m), 2.8-2.95 (4H, m), 2.65 (2H, t, J=8Hz), 5.02 (2H, s), 5.32 (1H, q, J=7Hz), 6.90 (2H, d, J=10Hz), 7.00-7.10 (3H, m), 7.15-7.45 (9H, m), 7.42 (1H, m), 7.55 (2H, d, J=10Hz), 8.23 (1H, m) Example 5
A mixture of benzyl 4-[1-[4-[bis(4-isobutylphenyl)- methoxy3benzoyl]indol-3-yl]butyrate (500 mg) and 10% palladium on activated carbon (50 mg) in 1,4-dioxane (10 ml) was stirred under hydrogen atmosphere (1 atm) at 25°C for 8 hours. The catalyst was filtered off and the filtrate was evaporated. The residue was treated with isopropyl ether and the solid was filtered to give
4-[1-[4-[bis(4-isobutylphenyl)methoxy]benzoyl]indol-3- yl]butyric acid (162 mg) as white powder.
NMR (CDCl3, δ) : 0.90 (12H, d, J=5Hz), 1.80 (2H, m),
2.05 (2H, m), 2.35-2.50 (6H, m), 2.72 (2H, t, J=8Hz), 6.25 (1H, s), 7.00-7.20 (7H, m),
7.25-7.40 (6H, m), 7.55 (1H, m), 7.65 (2H, d, J=10Hz), 8.30 (1H, m)
Example 6
The following compound was obtained according to a similar manner to that of Example 5. 4-[1-[4-[1-(4-Isobutylphenyl)ethoxy]benzoyl]- indol-3-yl]butyric acid
NMR (CDCl3, δ) : 0.85 (6H, d, J=6Hz), 1.65 (3H, d, J=7Hz), 1.85 (1H, m), 2.00 (2H, m), 2.35-2.50 (4H, m), 2.72 (2H, t, J=8Hz), 5.40 (1H, g,
J=7Hz), 6.95 (2H, d, J=10Hz), 7.05-7.20 (3H, m), 7.20-7. 40 ( 4H, m) , 7.50-7. 70 ( 3H, m) , 8.30 ( 1H, m)
Example 7
4N-Hydrogen chloride in 1,4-dioxane (1 ml) was added to a solution of methoxymethyl 4-[1-[4-(4'-tert- butylcarbamoyl)biphenylcarbonyl]indol-3-yl]butyrate (30 mg) in 1,4-dioxane (0.5 ml). The mixture was stirred at room temperature for 20 minutes and partitioned between ethyl acetate and water. The organic layer was washed with water, dried over magnesium sulfate and evaporated. The residue was washed with diisopropyl ether to give 4-[1-[4-(4'-tert-butylcarbamoyl)biphenylcarbonyl]indol- 3-yl]butyric acid as a white powder (12.1 mg) .
mp : 174-175°C
NMR (CDCl3, δ) : 1.51 (9H, s), 2.03 (2H, m), 2.44 (2H, -t, J=7.5Hz), 2.76 (2H, t, J=7.5Hz), 6.04 (1H, br s), 7.14 (1H, s), 7.3-7.5 (2H, m), 7.59 (1H, d, J=7.5Hz), 7.6-7.9 (8H, m), 8.41 (1H, d, J=7.5Hz)
Example 8
1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (30 mg) and 1-hydroxybenzotriazole (20 mg) was added to a mixture of methoxymethyl 4-[1-[4-(4'- carboxy)biphenylcarbonyl]indol-3-yl]butyrate (40 mg) and tert-butylamine (15 mg) in dichloromethane (3 ml). The mixture was stirred at room temperature for 5 hours and poured into ice water. The organic layer was washed with water, dried over magnesium sulfate and evaporated. The residue was purified by thin-layer chromatography on silica gel using a mixture of n-hexane and ethyl acetate (1:1) as the eluent. Appropriate fractions were combined, extracted with ethyl acetate and evaporated to give methoxymethyl 4-[1-[4-[4'-tert-butylcarbamoyl)biphenyl- carbonyl]indol-3-yl]butyrate (26 mg) as a colorless foam. NMR (CDCl3, δ) : 1.52 (9H, s), 2.05 (2H, m), 2.45 (2H, t, J=7.5Hz), 2.76 (2H, t, J=7.5Hz), 3.44 (3H, s), 5.21 (2H, s), 6.02 (1H, br s), 7.15 (1H, s), 7.3-7.5 (2H, m), 7.61 (1H, d, J=7.5Hz),
7.3-7.4 (8H, m), 8.42 (1H, d, J=7.5Hz)
Example 9
A mixture of methoxymethyl 4-[1-[4-(4'-benzyloxy- carbonyl)biphenylcarbonyl]indol-3-yl]butyrate (0.70 g) and 10% palladium on carbon (0.26 g) in ethyl acetate (30 ml) was shaken under hydrogen atmosphere (3.5 atm) at room temperature for 2 hours. The catalyst was filtered off and the filtrate was evaporated. The residue was washed with diisopropyl ether to give methoxymethyl 4-[1-[4-(4'- carboxy)biphenylcarbonyl]indol-3-yl]butyrate (0.21 g) as a white powder.
mp : 188-189°C
NMR (CDCl3, δ) : 2.06 (2H, m), 2.46 (2H, t,
J=7.5Hz), 2.77 (2H, t, J=7.5Hz), 3.43 (3H, s),
5.22 (2H, s), 7.14 (1H, s), 7.3-7.5 (2H, m), 7.61 (1H, d, J=7.5Hz), 7.7-8.0 (6H, m), 8.26 (2H, d, J=8Hz), 8.42 (1H, d, J=7.5Hz) Example 10
Chloromethyl methyl ether (0.17 ml) was added to a mixture of 4-[1-[4-(4'-benzyloxycarbonyl)biphenylcarbonyl]indol-3-yl]butyric acid (0.55 g) and potassium carbonate (0.21 g) in dimethylformamide (10 ml). The mixture was stirred at room temperature for 5 hours and partitioned between ethyl acetate and water. The organic layer was washed with water, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (40 g) using a mixture of n-hexane and ethyl acetate (5:1) as an eluent. Appropriate fractions were combined and evaporated to give methoxymethyl 4-[1-[4-(4'-benzyloxycarbonyl)biphenylcarbonyl]indol-3-yl]butyrate (0.51 g) as a colorless foam.
NMR (CDCl3, δ) : 2.05 (2H, m), 2.45 (2H, t,
J=7.5Hz), 2.76 (2H, t, J=7.5Hz), 3.44 (3H, s),
5.21 (2H, s), 5.41 (2H, s), 7.14 (1H, s),
7.3-7.6 (7H, m), 7.61 (1H, d, J=7.5Hz), 7.74 (2H, d, J=8Hz), 7.78 (2H, d, J=8Hz), 7.84 (2H, d, J=8Hz), 8.21 (2H, d, J=8Hz), 8.41 (1H, d, J=7.5Hz)
Example 11
A mixture of 4-[1-[4-[2-(4-isobutylphenyl)-1- propenyl]benzoyl]indol-3-yl]butyric acid (200 mg) and 10% palladium on activated carbon (60 mg) in 1,4-dioxane (10 ml) was shaken under hydrogen atmosphere (2 atm) at 25°C for 3 hours. The catalyst was filtered off, and the filtrate was evaporated. The crystalline residue was washed with isopropyl ether to give 4-[1-[4-[2-(4- isobutylphenyl)propyl]benzoyl]indol-3-yl]butyric acid (151 mg) as yellow crystals.
NMR (CDCl3, δ) : 0.90 (6H, d, J=7.5Hz), 1.30 (3H, d, J=5Hz), 1.85 (1H, m), 2.00 (2H, m), 2.40 (4H, m), 2.75 (2H, t, J=5Hz), 2.85-3.10 (3H, m), 7.00-7.10 (5H, m), 7.18 (2H, d, J=6Hz),
7.25-7.40 (2H, m), 7.55-7.65 (3H, m), 8.32 (1H, m)
Example 12
The following compounds were obtained according to a similar manner to that of Example 11.
(1) 4-[1-[3-[2-(4-Isobutylphenyl)propyl]benzoyl]- indol-3-yl]butyric acid
mp : 77-78°C NMR (CDCl3, δ) : 0.85 (6H, d, J=7Hz), 1.27 (3H, d,
J=6Hz), 1.79 (1H, m), 2.03 (2H, m), 2.41 (2H, d, J=7Hz), 2.43 (2H, t, J=7.5Hz), 2.75 (2H, t, J=7.5Hz), 2.7-3.1 (3H, m) , 7.0-7.1 (5H), 7.2-7.6 (7H, m), 8.31 (1H, m) (2) 4-[1-[3-(4-Isobutylphenethyl)benzoyl]indol-3-yl]- butyric acid
NMR (CDCl3, δ) : 0.89 (6H, d, J=7.5Hz), 1.80 (1H, m), 2.00 (2H, m), 2.35-2.50 (4H, m), 2.74 (2H, t, J=7.5Hz), 2.80-3.10 (4H, m), 7.00-7.15 (5H, m), 7.30-7.45 (4H, m), 7.45-7.60 (3H, m), 8.35 (1H, m)

Claims

CLAIMS 1. A compound of the formula :
Figure imgf000090_0001
wherein R1 is carboxy or protected carboxy,
R2 is hydrogen, lower alkyl or halogen, R3 is aryl or ar(lower) alkyl, each of which may have suitable substituent(s), or a group of the formula :
Figure imgf000090_0002
in which is heterocyclic group
Figure imgf000090_0004
containing nitrogen atom, and
n is 0 or 1,
A is lower alkylene which may be substituted by oxo or lower alkenylene,
Q is carbonyl, sulfonyl or lower alkylene.
Figure imgf000090_0003
in which R4 is hydrogen or lower alkyl, and
R5 is hydrogen, lower alkyl or
Y-Z-R3, Y is bond or lower alkylene,
Z is bond, lower alkylene, lower alkenylene,
Figure imgf000091_0001
-O-, -S- or -N- ,
in which R is lower alkyl,
ar( lower)alkyl which may have suitable
substituent( s) or
amino protective group; or X-Y-Z-R3 is 6H-dibenzo[b,d]pyranyl
which may have suitable substituent(s), and pharmaceutically acceptable salts thereof.
2. A compound of claim 1, wherein
R1 is carboxy or esterified carboxy,
R3 is aryl which may be substituted by one to three substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, halogen and lower alkylcarbamoyl, ar(lower)alkyl which may be substituted by one to three
substituent(s) selected from lower alkyl, halogen, cyano, carboxy, esterified carboxy, amidated carboxy and oxo, and
R6 is lower alkyl, ar(lower)alkyl which may be
substituted by lower alkyl..
3. A compound of claim 2, wherein
R1 is carboxy, lower alkoxycarbonyl or mono- or di- or triphenyl(lower)alkoxycarbonyl,
R3 is phenyl substituted by one to three
substituent( s) selected from the group consisting of lower alkyl, lower alkoxy, halogen and lower alkylcarbamoyl, mono- or di- or triphenyl(lower)alkyl which may be
substituted by one to three substituents selected from lower alkyl, halogen, cyano, carboxy, mono- or di- or tri
phenyl(lower)alkoxycarbonyl, mono- or di(lower)alkylcarbamoyl, phenylcarbamoyl, lower alkylphenylcarbamoyl and oxo
R6 is lower alkyl, mono- or di- or triphenyl(lower)- alkyl which may be substituted by lower alkyl.
4. A process for preparing a compound of the formula
Figure imgf000092_0001
wherein R1 is carboxy or protected carboxy,
R2 is hydrogen, lower alkyl or halogen, R3 is aryl or ar(lower)alkyl, each of which may have suitable substituent(s), or a group of the formula :
Figure imgf000092_0002
in which is heterocyclic group
Figure imgf000092_0004
containing nitrogen atom, and
n is 0 or 1,
A is lower alkylene which may be substituted by oxo or lower alkenylene,
Q is carbonyl, sulfonyl or lower alkylene.
Figure imgf000092_0003
in which R4 is hydrogen or lower alkyl, and
R 5 is hydrogen, lower alkyl or
Y-Z-R3,
Y is bond or lower alkylene,
Z is bond, lower alkylene, lower alkenylene,
Figure imgf000093_0001
-O-, -S- or -N- ,
in which R6 is lower alkyl,
ar(lower) alkyl which may have suitable
substituent(s) or
amino protective group; or X-Y-Z-R3 is 6H-dibenzo[b,d]pyranyl which
may have suitable substituents(s), or a salt thereof,
which comprises,
(1) reacting a compound of the formula
Figure imgf000093_0002
wherein R 1, R2, A, Q, X, and Y are each as defined above, and
Figure imgf000093_0003
Z 1 is -O-, -S- or -N- in which is lower alkyl or
Figure imgf000093_0005
amino protective group, or a salt thereof, with a compound of the formula :
Figure imgf000093_0004
wherein is ar(lower) alkyl which may have suitable
Figure imgf000094_0004
substituent(s) or a group of the
formula :
Figure imgf000094_0001
in which and n are each as defined
Figure imgf000094_0005
above, and
W1 is acid residue,
or a salt thereof, to give a compound of the formula:
Figure imgf000094_0002
wherein R 1, R2, A, Q, X, Y and Z1 are each as
Figure imgf000094_0006
defined above,
or a salt thereof, or
(2) reacting a compound of the formula
Figure imgf000094_0003
wherein R 1, R2 and A are each as defined above, or a salt thereof, with a compound of the formula
W2-Q-X-Y-Z-R3 wherein R 1, R3 , Q, X, Y, Z and A are each as defined above, and W2 is acid residue,
or a salt thereof, to give a compound of the formula:
Figure imgf000095_0001
wherein R 1, R2, R3, A, Q, X, Y and Z are each as
defined above,
or a salt thereof, or
(3) reacting a compound of the formula
Figure imgf000095_0002
wherein R 1, R2, A, Q and X are each as defined above,
W3 is acid residue, and
Y is lower alkylene,
or a salt thereof, with a compound of the formula :
H-Z 2-R3 wherein R3 is as defined above, and
Figure imgf000095_0003
Z 2 is -O- or -N- in which R6 is as defined above, ori a salt thereof, to give a compound of the formula:
Figure imgf000096_0001
wherein R 1, R2, R3, A, Q, X, Y1 and Z2 are each as defined above,
or a salt thereof, or
(4) reacting a compound of the formula :
Figure imgf000096_0002
wherein R1, R2,
Figure imgf000096_0006
A, Q, X and Y are each as defined above,
or a salt thereof, with a compound of the formula :
Figure imgf000096_0003
wherein and W1 are each as defined above,
Figure imgf000096_0005
or a salt thereof, to give a compound of the formula:
Figure imgf000096_0004
wherein R1, R2,
Figure imgf000097_0003
3 A, Q, X and Y are each as defined above,
or a salt thereof, or
(5) subjecting a compound of the formula
Figure imgf000097_0001
wherein R 2, R3, A, Q, X, Y and Z are each as
defined above, and
is protected carboxy,
Figure imgf000097_0004
or a salt thereof, to elimination reaction of the carboxy protective group, to give a compound of the formula :
Figure imgf000097_0002
wherein R 2, R3, A, Q, X, Y and Z are each as defined above,
or a salt thereof, or
(6) subjecting a compound of the formula
Figure imgf000098_0001
wherein R 1, R2, A, Q, X, Y and Z are each as defined above,
R7 is aryl which may have suitable
substituent(s), and
R8 is carboxy protective group, or a salt thereof, to elimination reaction of the carboxy protective group, to give a compound of the formula :
Figure imgf000098_0002
wherein R 1, R2, R7, A, Q, X, Y and Z are each as
defined above,
or a salt thereof, or
(7) reacting a compound of the formula :
Figure imgf000099_0001
wherein R 1, R2, R7, A, Q, X, Y and Z are each as
defined above,
or its reactive derivative at the carboxy group or a salt thereof, with a compound of the formula :
H-R9 wherein R9 is amino which may have suitable
substituent(s),
or its reactive derivative at the amino group
or a salt thereof, to give a compound of the formula:
Figure imgf000099_0002
wherein R1, R2, R7, R9, A, Q, X, Y and Z are each
as defined above,
or a salt thereof, or
(8) reacting a compound of the formula :
Figure imgf000100_0001
wherein R 1, R2, R3, A, Q, X and Y are each as defined above,
or a salt thereof, with a compound of the formula :
Figure imgf000100_0003
wherein is lower alkyl, ar( lower)alkyl which may
Figure imgf000100_0005
have suitable substituent(s) or amino protective group, and
W4 is acid residue,
or a salt thereof, to give a compound of the formula:
Figure imgf000100_0002
wherein R1, R2, R3, A, Q, X and Y are each as
Figure imgf000100_0004
defined above,
or a salt thereof, or
(9) subjecting a compound of the formula :
Figure imgf000101_0001
wherein R 2, R3, A, Q, X, Y and Z are each as defined above,
or a salt thereof, to introduction of the carboxy protective group, to give a compound of the formula :
Figure imgf000101_0002
wherein R2, R3, A, Q, X, Y and Z are each as
Figure imgf000101_0003
defined above,
or a salt thereof.
5. A pharmaceutical composition comprising a compound of claim 1 or pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.
6. A method for treating or preventing testosteron
5α-reductase-mediated diseases, which comprises administering a compound of claim 1 or
pharmaceutically acceptable salt thereof to human being or animals.
7. Use of a compound of claim 1 or pharmaceutically
acceptable salt thereof as a medicament.
8. Use of compound of claim 1 or pharmaceutically acceptable salt thereof as a testosteron 5α-reductase inhibitor.
9. A process for preparing a pharmaceutical composition which comprises admixing a compound of claim 1 or pharmaceutically acceptable salt thereof with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.
PCT/JP1992/000981 1991-08-02 1992-08-03 Indole derivatives WO1993003012A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP92916519A EP0600084A1 (en) 1991-08-02 1992-08-03 Indole derivatives
JP5503471A JPH06511238A (en) 1991-08-02 1992-08-03 indole derivative

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9116732.0 1991-08-02
GB919116732A GB9116732D0 (en) 1991-08-02 1991-08-02 Indole derivatives

Publications (1)

Publication Number Publication Date
WO1993003012A1 true WO1993003012A1 (en) 1993-02-18

Family

ID=10699428

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1992/000981 WO1993003012A1 (en) 1991-08-02 1992-08-03 Indole derivatives

Country Status (4)

Country Link
EP (1) EP0600084A1 (en)
JP (1) JPH06511238A (en)
GB (1) GB9116732D0 (en)
WO (1) WO1993003012A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0757982A1 (en) * 1995-08-08 1997-02-12 Roussel Uclaf Biphenylic compounds, process for their preparations and intermediates for this process, their use as 5-alpha-reductase inhibitors and pharmaceutical compositions containing them
EP0967195A1 (en) * 1998-03-30 1999-12-29 Quest International B.V. Aldehydic ketones and their use in perfumes
US6448220B1 (en) 1998-03-30 2002-09-10 Quest International B.V. Fragrance compound
US7022708B2 (en) 2002-10-18 2006-04-04 Roche Palo Alto Llc 4-piperazinyl benzenesulfonyl indoles and uses thereof
US7196089B2 (en) 2003-01-29 2007-03-27 Asterand Uk Limited EP4 receptor antagonists
US7417068B2 (en) 2003-10-16 2008-08-26 Asterand Uk Limited EP4 receptor antagonists
US7855225B2 (en) 2006-03-02 2010-12-21 Astellas Pharma Inc. 17βHSD type 5 inhibitor
US8513422B2 (en) 2007-08-31 2013-08-20 Astellas Pharma Inc. Piperidine derivative
WO2018154118A3 (en) * 2017-02-24 2018-12-06 Xeniopro GmbH Aromatic compounds which enhance notch signaling, for use in therapy
JP2019513703A (en) * 2016-03-17 2019-05-30 ゼニオプロ ゲーエムベーハー Enhancers of Notch signaling and its use in the treatment of cancers and malignancies treatable by upregulation of Notch
US11591289B2 (en) 2017-02-24 2023-02-28 Xeniopro GmbH Aromatic compounds

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (en) * 1997-10-10 2004-07-15 Пфайзер, Інк. Prostaglandin agonists and use thereof for the treatment of bone disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013060A1 (en) * 1990-02-26 1991-09-05 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013060A1 (en) * 1990-02-26 1991-09-05 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0757982A1 (en) * 1995-08-08 1997-02-12 Roussel Uclaf Biphenylic compounds, process for their preparations and intermediates for this process, their use as 5-alpha-reductase inhibitors and pharmaceutical compositions containing them
FR2737721A1 (en) * 1995-08-08 1997-02-14 Roussel Uclaf NOVEL BIPHENYL COMPOUNDS, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US5827887A (en) * 1995-08-08 1998-10-27 Roussel Uclaf Biphenyl compounds
EP0967195A1 (en) * 1998-03-30 1999-12-29 Quest International B.V. Aldehydic ketones and their use in perfumes
US6448220B1 (en) 1998-03-30 2002-09-10 Quest International B.V. Fragrance compound
US7022708B2 (en) 2002-10-18 2006-04-04 Roche Palo Alto Llc 4-piperazinyl benzenesulfonyl indoles and uses thereof
US7196089B2 (en) 2003-01-29 2007-03-27 Asterand Uk Limited EP4 receptor antagonists
US7858644B2 (en) 2003-01-29 2010-12-28 Asterand Uk Limited EP4 receptor antagonists
US7507754B2 (en) 2003-01-29 2009-03-24 Asterand Uk Limited EP4 receptor antagonists
US7528157B2 (en) 2003-01-29 2009-05-05 Asterand Uk Limited EP4 receptor antagonists
US7569602B2 (en) 2003-10-16 2009-08-04 Asterand Uk Limited Furan derivatives as EP4 receptor antagonists
US7417068B2 (en) 2003-10-16 2008-08-26 Asterand Uk Limited EP4 receptor antagonists
US7855225B2 (en) 2006-03-02 2010-12-21 Astellas Pharma Inc. 17βHSD type 5 inhibitor
US8513422B2 (en) 2007-08-31 2013-08-20 Astellas Pharma Inc. Piperidine derivative
JP2019513703A (en) * 2016-03-17 2019-05-30 ゼニオプロ ゲーエムベーハー Enhancers of Notch signaling and its use in the treatment of cancers and malignancies treatable by upregulation of Notch
JP2023002688A (en) * 2016-03-17 2023-01-10 ゼニオプロ ゲーエムベーハー Enhancers of notch signaling and their use in the treatment of cancers and malignancies medicable by upregulation of notch
JP2023027160A (en) * 2016-03-17 2023-03-01 ゼニオプロ ゲーエムベーハー Enhancers of Notch signaling and their use in the treatment of cancers and malignancies treatable by upregulation of Notch
JP7402300B2 (en) 2016-03-17 2023-12-20 ゼニオプロ ゲーエムベーハー Enhancers of Notch signaling and its use in the treatment of cancers and malignancies treatable by upregulation of Notch
WO2018154118A3 (en) * 2017-02-24 2018-12-06 Xeniopro GmbH Aromatic compounds which enhance notch signaling, for use in therapy
US11591289B2 (en) 2017-02-24 2023-02-28 Xeniopro GmbH Aromatic compounds

Also Published As

Publication number Publication date
JPH06511238A (en) 1994-12-15
GB9116732D0 (en) 1991-09-18
EP0600084A1 (en) 1994-06-08

Similar Documents

Publication Publication Date Title
US5863918A (en) Naphthalene derivatives
EP0458207A2 (en) Indole derivatives
US5155101A (en) Tricyclic compounds
EP0757682A1 (en) Benzofuran derivatives useful as inhibitors of bone resorption
WO1993003012A1 (en) Indole derivatives
US5530019A (en) Indole derivatives useful as testosterone 5α-reductase inhibitors
EP0516849B1 (en) Indole derivatives
US5264438A (en) Quinazoline derivatives
US5334716A (en) Heterocyclic derivatives
US5312829A (en) Indole derivatives
US5212320A (en) Indole derivatives and their use for testosterone 5-alpha-reductase-mediated diseases
US5461048A (en) Tricyclic compounds having cholecystokinin antagonist activity
WO1993018030A1 (en) Benzimidazole derivatives as angiotensin ii antagonists
US5780633A (en) Process for the preparation of indolizine derivatives
EP0603278A1 (en) Indole derivatives as 5-alpha-reductase inhibitor
US5283251A (en) Indole derivatives
RU2120942C1 (en) INDOLIZINE DERIVATIVES, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION, METHOD OF INHIBITION OF ACTIVITY OF TESTOSTERONE-5α-REDUCTASE
GB2287706A (en) Indolizine derivatives
WO1994026710A1 (en) INDOLE DERIVATIVES AS TESTOSTERONE 5α-REDUCTASE INHIBITORS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1992916519

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1994 182118

Date of ref document: 19940511

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1992916519

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992916519

Country of ref document: EP